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Abstract
INTRODUCTION: Chronic myeloid leukaemia (CIVIL) is a clonal myeloproliferative 
disorder of the haemopoietic stem cell (HSC). It results from acquisition of the 
Philadelphia (Ph) chromosome and expression of the oncogenic fusion protein 
BCR-ABL. Imatinib mesylate (IM) is a tyrosine kinase inhibitor (TKI) which 
competitively inhibits ATP binding to BCR-ABL, resulting in inhibition of 
downstream signal transduction pathways. Despite inducing a complete 
cytogenetic response in the majority of CIVIL patients in chronic phase (CP), nearly 
all patients treated with IM have detectable disease at the molecular level by 
quantitative RT-PCR and, therefore, are unlikely to be cured. It has been 
demonstrated that this molecular persistence results from a population of 
quiescent CIVIL stem cells which are not effectively targeted by IM. In addition, a 
minority of CML patients harbour BCR-ABL kinase domain mutations, rendering 
them IM-resistant. We set out to investigate different therapeutic strategies for 
targeting the quiescent CML stem cell population in vitro. These strategies were 
treating with continuous or interrupted IM in combination with recombinant human 
granulocyte-colony stimulating factor (rHu-G-CSF), comparing the efficacy of IM 
with the novel, dual SRC/BCR-ABL TKI, dasatinib, and combining either IM or 
dasatinib with the cytotoxic farnesyltransferase inhibitor (FTI), BMS-214662.
METHODS: CD34^ CML cells isolated from newly diagnosed CP CML patients, 
normal CD34^ cells, total mononuclear cells (MNC) from blast crisis (BC) CML 
patients and acute myeloid leukaemia (AML) patients, and wild-type and mutant 
BCR-ABL-expressing Ba/F3 cells were cultured in the described conditions. To 
assess efficacy against the primitive progenitor population, carboxy-fluorescein 
diacetate succinimidyl diester (CFSE) was used to track cell division and caspase- 
3 activity to assess apoptosis in primary cell samples. To determine the inhibitory
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effect of different agents on BCR-ABL kinase activity a flow-cytometry based CrKL 
phosphorylation assay was developed and used. The relevance of SRC kinases in 
the different phases of CML was assessed by measuring expression of 
phosphorylated SRC (p-SRC) and BCL-2 at baseline and again following 
treatment with different TKIs (IM, dasatinib and PP2). Previous studies have 
indicated that alterations in BCL-2 expression may be linked to SRC family kinase 
activity in CML cells in vitro. Long-term culture-initiating cell (LTC-IC) assays were 
used to determine the efficacy of BMS-214662 against CML and normal HSC. 
Tritiated thymidine proliferation assays were employed to assess concentration- 
response curves and determine the efficacy of BMS-214662 in Ba/F3 cell lines 
with BCR-ABL kinase mutations. Fluorescence in-situ hybridisation (FISH) 
confirmed the proportion of BCR-ABL^ CD34^ cells at baseline and again after 
culture in the different treatment conditions.
RESULTS; Interrupted IM therapy did not enhance the eradication of total viable 
cells or non-proliferating CFSE"^^  ^ CD34^ CML cells compared to continuous IM. 
The combination of continuous IM with intermittent rHu-G-CSF more effectively 
reduced total viable cells than other IM/rHu-G-CSF combinations. Imatinib 
mesylate had no significant effect on non-proliferating CFSE*^®^  CD34^ CML cells. 
Intermittent rHu-G-CSF significantly reduced non-proliferating CFSE*^ ®^  CD34"" 
CML cells compared to either no rHu-G-CSF or continuous rHu-G-CSF by 
increasing the number of cells which left the quiescent fraction by cell division. The 
addition of IM did not enhance this effect.
At therapeutically achievable concentrations (5pM and 150nM, respectively) IM 
and dasatinib had equivalent cytotoxicity on primary CD34^ CML cells. Compared 
to no drug control, neither IM nor dasatinib reduced the non-proliferating CFSE"^ ®^  
CD34^ CML cell population. Caspase-3 activity was not significantly increased in
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the treatment arms, indicating that the cells exiting the undivided gate did so by 
cell division and not apoptosis. Using the CrKL phosphorylation assay, dasatinib 
was shown to be a more effective BCR-ABL kinase inhibitor than IM. Activated 
SRC expression, measured by p-SRC and BCL-2 levels, was significantly 
increased in CD34^ CML cells compared to normal CD34^ cells. There was a trend 
for higher p-SRC, but not BCL-2 expression, in BC compared to CP CML. Further 
results suggested that p-SRC expression was mediated by BCR-ABL, as IM or 
dasatinib, but not the SRC-specific kinase inhibitor PP2, reduced p-SRC 
expression; albeit only temporarily with IM.
BMS-214662 was very potent against CD34^ CML cells at clinically achievable 
concentrations (250nM). When used in combination with IM or dasatinib, BMS- 
214662 significantly enhanced overall cytotoxicity compared to either IM or 
dasatinib alone. BMS-214662 targeted non-proliferating CFSE"^^  ^ CD34^ cells in 
short-term culture experiments, and had minimal anti-proliferative effect. Apoptosis 
studies demonstrated that BMS-214662 increased caspase-3 activity in 
proliferating and non-proliferating CFSE^^^ CD34^ CML cells. BMS-214662 
overcame the anti-proliferative effects of IM or dasatinib to significantly reduce 
non-proliferating CFSE"^®  ^CD34^ cells present after treatment. The LTC-IC assays 
confirmed that BMS-214662 was targeting primitive CML stem cells and provided 
evidence of selectivity for CML versus normal HSCs. In 2 of 3 patients, FISH 
confirmed that more than 90% of the cells surviving LTC-IC were Ph ; further 
evidence for the selectivity of BMS-214662 for Ph^ cells. Preliminary experiments 
presented here indicate that BMS-214662 is likely to be effective in BC CML, 
patients with BCR-ABL kinase mutations resistant to TKIs and also AML.
CONCLUSIONS: Intermittent exposure to rHu-G-CSF can enhance the effect of 
IM on CML cells by specifically targeting the non-proliferating CD34^ sub­
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population. A pilot study to treat CP CML patients with IM and intermittent rHu-G- 
CSF is currently underway to determine if this strategy will reduce molecular 
persistence in vivo, Dasatinib was more effective than IM within the CML stem cell 
compartment, however the most primitive quiescent CML cells appear to be 
inherently resistant to both drugs, indicating that BCR-ABL and SRC kinases may 
not be relevant targets in the most primitive quiescent CML stem cell population. 
BMS-214662 is the first agent assessed using the CFSE method to show a 
significant reduction in non-proliferating CFSE"^^  ^CD34^ cells compared to the no 
drug control in CML. LTC-IC confirmed that BMS-214662 was targeting CML stem 
cells and highlighted specificity for Ph^ versus Ph' cells. Further studies are 
ongoing to elucidate the mode of action of BMS-214662 which may have utility not 
only in CML but also other malignancies in which cancer stem cells have been 
identified.
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7-AAD
17AAG
ABGG2
ABL
ALL
ailoSCT
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AP
APC
Ara-G
ATP
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BCA
BCR
BCR-ABL
BCR-ABL
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CCR
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CML
CMoIR
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CXCR-4
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DNAse
EDTA
EGF
EGF-R
ELISA
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FAK
FCS
FGF-R
FISH
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FL
Tritiated
7-Aminoactinomycin D
17-(Allylamino)-17-demethoxygetdanamycin
ATP binding cassette subfamily member 2
Abelson proto-oncogene
Acute lymphoblastic leukaemia
Allogeneic stem cell transplant
Acute myeloid leukaemia
Accelerated phase
Allophycocyanin
Cytosine arabinoside
Adenosine triphosphate
Blast crisis
Bicinchoninic acid
Breakpoint cluster region gene
BCR-ABL fusion gene
BCR-ABL protein tyrosine kinase
Bovine serum albumin/insulin/transferrin serum substitute 
Bovine serum albumin 
Complete cytogenetic response
Cluster of differentiation; cell surface molecules recognised by 
specific sets of antibodies 
Centromere protein 
Colony-forming cell assay
Carboxy-fluorescein diacetate succinimidyl diester 
Granulocyte macrophage-colony forming unit 
Complete haematologic response 
Cytokine-induced SH2~containing family of proteins 
Chronic lymphocytic leukaemia 
Chronic myeloid leukaemia 
Complete molecular response 
Chronic phase
v-Crk avian sarcoma virus CT10 oncogene homolog-like
Chemokine (C-X-C motif) receptor 4
Donor lymphocyte infusion
Dulbecco's modified eagle medium
Dimethyl sulphoxide
Deoxyribonucleic acid
Deoxyribonuclease
Ethylenediaminetetraacetic acid
Epidermal growth factor
Epidermal growth factor receptor
Enzyme-linked immunosorbent assay
Fluorescence activated cell sorting
Focal adhesion kinase
Foetal calf serum
Fibroblast growth factor receptor
Fluorescence in-situ hybridisation
Fluorescein isothiocyanate
Fluorescence channel
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FSC Forward scatter
FT Farnesyltransferase
FTI Farnesyltransferase inhibitor
Go Gap phase 0 (of cell cycle; quiescent)
Gi Gap phase 1 (of cell cycle)
G2 Gap phase 2 (of cell cycle)
G-CSF Granulocyte-colony stimulating factor
G-CSF-R Granulocyte-colony stimulating factor receptor gene
G-CSF-R Granulocyte-colony stimulating factor receptor protein
G-proteins Guanine nucleotide binding proteins
GIMI G-CSF with Imatinib Mesylate Intermittently
GM-CSF Granulocyte macrophage-colony stimulating factor
GGT Geranylgeranyltransferase
GvHD Graft versus host disease
GvL Graft versus leukaemia
GSK-3P Glycogen synthase kinase-3p
HBSS-CMF Hank’s buffered salt solution -  calcium and magnesium free
HLA Human leukocyte antigen
HSC Haemopoietic stem cell
lAP Inhibitor of apoptosis protein
IC50 Inhibitory concentrationso
IFN-a Interferon-a
ig ImmunoglobulinIkK IkB kinase
IL Interleukin
IM Imatinib mesylate
IMDM Iscove’s Modified Dulbecco’s Medium
iNOS Inducible nitric oxide synthase
IRIS International study of Interferon versus STI571
JAK Janus kinase
K562-R IM-resistant K562 cell line
kbp Kilobase pairs
kD KiloDalton
LAMA-R IM-resistant LAMA cell line
LDAC Low dose cytosine arabinoside
LSC Leukaemic stem cell
LTBMC Long term bone marrow culture
LTC-IC Long term culture-intitiating cell assay
M Mitosis phase (of cell cycle)
MARK Mitogen-activated protein kinase
MCR Major cytogenetic response
mCR Minor cytogenetic response
MDR Multidrug resistance protein
MFI Mean fluorescence intensity
mg Milligrams
mL Millilitres
MMoIR Major molecular response
MNC Mononuclear cell
MRC Medical Research Council
MRD Minimal residual disease
mRNA Messenger ribonucleic acid
mTOR Mammalian target of rapamycin
MW Molecular weight
M9 Micrograms
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mm Micromolar
NA Not applicable/not available
NCI National Cancer Institute
NCRN National Cancer Research Network
ND Not determined
NF-KB Nuclear factor- kB
ng Nanograms
nM Nanomolar
NK cells Natural killer cells
NO Nitric oxide
NOD Non-obese diabetic
P PhosphorylatedPAGE Polyacrylamide gel electrophoresis
PBS Phosphate buffered saline
PCR Partial cytogentic response
PDGF-R Platelet-derived growth factor receptor
PE Phycoerythrin
PFS Progression free survival
Ph Philadelphia chromosome
PI Propidium iodide
PI3K Phosphatîdylinositol-3-kinase
PMSF Phenoxymethylsulphonylfluoride
PTEN Phosphatase and tensin homolog
PTPases Protein tyrosine phosphatases
qRT-PCR Quantitative real-time RT-PCR
Ras-GAP Ras-GTPase activating protein
Ras-GDP Ras-guanidine diphosphate
Ras-GTP Ras-guanidine triphosphate
rHu-G-CSF Recombinant human G-CSF
RISCT Reduced intensity stem cell transplant
ROS Reactive oxygen species
RPM Revolutions per minute
RT-PCR Reverse transcriptase polymerase chain reaction
S Synthesis phase (DNA; of cell cycle)
SCF Stem cell factor
SCID Severe combined immunodeficiency
SCT Stem cell transplant
SDF-1 Stromal-derived factor-1
SDS Sodium dodecyl sulphate
SEM Standard error of the mean
SFM Serum free medium
SFM + 5GF Serum free medium supplemented with a 5 growth factor 
cocktail (IL-3, IL-6, Flt-3 ligand, G-CSF, SCF)
SH SRC homology domain
sIRNA Short interfering RNA
SKI SRC kinase inhibitor
SOCS Suppressors of cytokine signalling family of proteins
SOS Son of sevenless
SSC Side scatter
STAT Signal transducers and activators of transcription
STI Signal transduction inhibitor 571
t Translocation
TDZD-8 4-benzyl, 2-methyl, 1,2,4-thiadiazolidine 3,5-dione
TG buffer Tris/glycine buffer
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TGS buffer 
TKI
VEGF-R
WCC
WHO
WT
Y
Tris/glycine/SDS buffer
Tyrosine kinase inhibitor
Vascular endothelial growth factor receptor
White cell count
World Health Organisation
Wild type
Tyrosine
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1 Introduction
1.1 Haemopoietic stem cells and normal haemopoiesis
Stem cells are defined as cells that can differentiate into multiple different cell 
types and have the ability to self-renew. There are two broad categories of stem 
cells: (1) the pluripotent stem cell which can differentiate into endoderm, 
mesoderm and ectoderm, e.g. embryonic stem cells; and (2) multi potent stem cells 
which are lineage-specific and include haemopoietic stem cells (HSC). The HSC is 
a relatively rare cell within the bone marrow, and it is estimated that there are 
between 3x10^ and 4x10® HSC in the human, based on studies using limiting 
dilution analysis in NOD-SCID mice (Wang et al., 1997) and long-term culture- 
initiating cell (LTC-IC) assays (Pettengell et al., 1994). Further studies indicate that 
each HSC divides approximately 70 times during its lifetime (Vickers et al., 2000) 
so its self-renewal capacity is finite. By this process of cellular amplification, it is 
estimated that if one stem cell divides 20 times then 1x10® mature cells are 
produced.
Haemopoiesis is the process of blood cell production. As the majority of mature 
blood cells only live for a short time in the circulation (a few hours in the case of 
granulocytes) before destruction by the spleen, it is necessary for the bone 
marrow to produce up to 10^ ® cells per day to maintain the haemopoietic system. 
The process of haemopoiesis begins with the multipotent HSC which has self­
renewal capacity and the ability to differentiate into all types of mature blood cell 
(myeloid, erythroid, lymphoid etc) through a range of lineage-committed progenitor 
cells (Figure 1-1).
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Figure 1-1. Diagrammatic representation of the HSC and the cell lines produced from it. Only 
long-term and short-term stem cells undergo self-renewal. The multi potent progenitors do 
not undergo self-renewal, but give rise to common myeloid and common lymphoid 
progenitors, which through several proliferation and differentiation steps, give rise to the 
mature cells of the haemopoletic system.
The ability of HSCs to self-renew is heterogeneous and studies on mouse bone 
marrow cells indicate that 0.05% of bone marrow cells are multipotent progenitors. 
This HSC population can be divided into three distinct maturational sub­
populations: long-term self-renewing HSCs that produce mature haemopoietic 
cells for the lifetime of the mouse; short-term self-renewing HSCs; and multipotent 
progenitors which have lost the ability to self-renew, reconstitute lethally irradiated 
mice for less than eight weeks and have increased mitotic activity (Morrison et al., 
1997).
Mhairi Copland, 2007 Chapter 1, 24
It is believed that, in steady state, only a minority of HSCs reconstitute the
haemopoietic system, with the vast majority of HSCs existing in a quiescent state
(i.e.in Go; out of the cell cycle). This extended period in Go allows the resting HSCs
time to repair any DMA damage and maintain their genetic integrity (Lajtha, 1979).
Evidence for the existence of HSCs in a quiescent state came from culture studies
in which primitive human progenitor cells remained as single cells for as long as
two weeks and only began proliferation after stimulation with a cytokine cocktail
(Leary et al., 1989; Leary et al., 1992).
Potential human HSCs are characterised as CD34^lin"CD38' (Miller et al., 1999) 
and these cells have the ability to repopulate SCID mice. However, for clinical and 
the majority of research purposes, HSCs tend to be isolated on the basis of CD34 
expression only, resulting in a heterogeneous population of which only a small 
proportion are multipotent HSCs. The CD34 antigen is a transmembrane 
glycoprotein and member of the sialomucin family (Simmons et al., 2001). 
Although its precise function is unknown, CD34 is believed to be involved in cell 
adhesion.
The in vitro study of HSCs is difficult for a number of reasons. Firstly, these are 
rare cells with only relatively small numbers present in any individual. Secondly, in 
vitro culture results in varying degrees of expansion and differentiation of these 
cells depending on the culture conditions. This results in the loss of stem cell 
phenotype as the cells mature and acquire lineage-specific markers, and the stem 
cells become diluted by their more mature progeny. Thirdly, despite extensive 
studies into the functional and phenotypic properties of HSCs (Weissman, 2000), 
the mechanisms which control self-renewal versus proliferation and differentiation 
remain unexplained. The HSC achieves both these functions via asymmetric cell 
division in which one new HSC is produced along with one daughter which then
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undergoes symmetrical division and differentiates. However, HSCs can also
undergo symmetrical cell division to produce two daughter cells. It is believed that
stem cell fate is decided by, as yet unidentified, factors in the stem cell niche.
Following the identification and characterisation of the HSC, comparisons were 
drawn with the behaviour of cancer cells, in particular leukaemias, with the first 
evidence for the ‘cancer stem cell’ being described in acute myeloid leukaemia 
(AML), (Bonnet and Dick, 1997). The leukaemic stem cell (LSC) shares a number 
of properties with normal HSC including self-renewal capacity, similar phenotype 
(i.e. CD34^38 ) and the ability to reconstitute NOD-SCID mice, with the recipient 
mice developing leukaemias of the same phenotype as the transplanted cells. It is 
now believed that the LSC is derived from an HSC following one or more 
leukaemogenic events (Figure 1-2). Chronic myeloid leukaemia (CML) and acute 
lymphoblastic leukaemia (ALL) have also been described as HSC disorders 
(Eaves et al., 1998; Cobaleda et al., 2000).
Leukaemogenic
event(s)
Self-renewal
m
Self-renewalr
HSC LSC
Clonogenic
leukaemic
progenitors
Non-clonogenic 
leukaemic blast cells
Figure 1-2. Schematic diagram of the transformation of an HSC to a LSC which also retains 
the capacity to self-renew. Following a number of intermediate progenitor stages, the 
leukaemic blast cells are produced and these blast cells form the vast majority of leukaemic 
cells present.
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1.2 Chronic myeloid leukaemia (CML)
Chronic myeloid leukaemia develops when a single, multipotent HSC acquires the 
Philadelphia (Ph) chromosome (Figure 1-3) which is an abnormal, shortened 
chromosome 22 that results from a reciprocal translocation between the long arms 
of chromosomes 9 and 22 and is designated t(9;22)(q34;q11) (Rowley, 1973). In 
the 1980s, it was shown that this translocation resulted in the ABL proto­
oncogene, normally on chromosome 9, becoming juxtaposed with the breakpoint 
cluster region (BCR) on chromosome 22 (Bartram et al., 1983; Groffen et al., 
1984), resulting in production of the unique fusion gene product BCR-ABL, a 
210kD oncoprotein, often referred to as which is a constitutively
active tyrosine kinase (Lugo et al., 1990). The Ph chromosome appears in the 
myeloid, erythroid, megakaryocytic and lymphoid cells of CML patients.
Normal chromosome 9 
Chromosome 9 with derivative from 22
Philadelphia chromosome 
Q j 5 3 0 *0  Normal chromosome 22
Figure 1-3. The Philadelphia (Ph) chromosome results from a reciprocal translocation 
between the long arms of chromosome 9 and 22, t(9;22)(qS4;q11). The Ph chromosome Is 
the shortened chromosome 22 and results In production of the fusion gene product BCR- 
ABL which has unregulated tyrosine kinase activity. A reciprocal fusion, ABL-BCR, Is 
formed on the long arm of chromosome 9; however, this is not thought to play a role In the 
pathogenesis of CML. In addition to the Ph chromosome, a minority of patients (~15%) have 
deletions on the long arm of chromosome 9 which occur at the time of the reciprocal 
translocation, Involve the derivative chromosome 22 and are associated with a poor 
prognosis (Huntly et al., 2001).
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Chronic myeloid leukaemia is a myeloproliferative disorder and accounts for 15-
20% of all leukaemias in adults (Faderl et al., 1999). The incidence of CML is
constant worldwide at 1.0 to 1.5 per 100,000 of the population. The median age of
onset is 40-60 years; however, it may occur in children and the very old. There is a
slight male predominance (1.4:1). The risk of CML is slightly increased by
exposure to high doses of irradiation as seen in atomic bomb survivors and
patients irradiated for ankylosing spondylitis. Most cases of CML are sporadic and
no predisposing factors or familial predispositions have been identified.
Chronic myeloid leukaemia has three stages: chronic phase (CP); accelerated 
phase (AP); and blast crisis (BC). It is usually diagnosed in CP, which is 
characterised by a leucocytosis due to increased granulopoiesis with 
hepatosplenomegaly as a result of leukaemic infiltration and can last from several 
months to several years. In 50% of patients, the disease evolves gradually, 
through an intermediate stage, AP, which may last for months or occasionally 
years before frank BC. In the remaining 50%, the CP transforms unpredictably and 
abruptly to BC. In AP there is an increase in the number of immature cells in the 
bone marrow or peripheral blood and it may be associated with additional 
cytogenetic abnormalities (i.e. clonal evolution). Blast crisis may be of myeloid or 
lymphoid lineage and behaves like an acute leukaemia; it carries a very poor 
prognosis. The WHO criteria for the diagnosis of AP and BC CML are shown in 
Table 1-1 (Vardiman et al., 2002).
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AP CML
Diagnosis if one or more of the following present:
Blasts 10-19% of peripheral white cell count (WCC) or bone marrow cells; 
Peripheral blood basophils ^ 20%;
Persistent thrombocytopenia (< 100x10^/L) unrelated to therapy, or persistent 
thrombocytosis > 1000x10^/L unresponsive to therapy;
Increasing spleen size or WCC unresponsive to therapy;
Cytogenetic evidence of clonal evolution.
BC CML
Diagnosis if one or more of the following present:
Blasts ^ 20% of peripheral WCC or bone marrow cells; 
Extramedullary blast proliferation;
Large clusters or foci of blasts in bone marrow trephine.
Table 1-1. Criteria for the diagnosis of AP and BC CML.
The peripheral blood and bone marrow in CP CML usually have a distinct 
morphological appearance. There is a leucocytosis, usually > 50x10®/L, but 
occasionally > 500x10®/L with a complete spectrum of myeloid cells present in the 
peripheral blood. The white cell differential count is characteristic with myelocytes 
and mature neutrophils predominating. Blast cells and promyelocytes are 
increased to a lesser extent. Nearly all patients have a basophilia and the majority 
also have an eosinophilia. There is often an associated normochromic normocytic 
anaemia. The platelet count may be normal, increased or decreased. The bone 
marrow is usually very hypercellular with marked granulocytic hyperplasia and the 
myeloid:erythoid ratio often exceeds 10:1. Occasionally there may be associated 
megakaryocyte hyperplasia or marrow fibrosis at presentation.
1.2.1 BCR-ABL and its mechanisms of action
The fusion gene product, BCR-ABL, has a central role in the pathogenesis of CML 
and this makes it an attractive target for drug therapy. A number of features of 
BCR-ABL are essential for cellular transformation. In BCR these include the
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coiled-coil motif present in amino acids 1-63, the tyrosine at position 177 (Y177),
and phosphoserine-threonine-rich sequences between amino acids 192-242 and
298-413; and in ABL, the SHI, SH2, and actin-binding domains (Pendergast et al.,
1991; McWhirter et al., 1993; Pendergast et al., 1993). The most important
functional domains of BCR and ABL proteins are shown in Figure 1-4.
Autophosphorylated BCR-ABL tyrosine kinase phosphorylates a range of
substrates and activates a range of intracellular signalling pathways which alter
the behaviour of CML stem cells in a number of ways. Substrates of BCR-ABL can
be grouped into three broad categories (1) adaptor molecules such as CrKL and
p6 2 °0 Cj (2) proteins associated with the cell membrane and cytoskeleton such as
talin and paxillin and (3) proteins with catalytic function such as Ras-GAP and
phospholipase Cy (Deininger et al., 2000). Figure 1-5 shows the main pathways
activated by BCR-ABL in CML cells.
NH, C-C '^moUf Y177 Ser/Thr kinase GAP COOH
BCR protein
NH, SH2 SHI NLS DNAbinding m COOH
ABL protein
Figure 1-4. The important functional domains of BCR and ABL proteins. In BCR, the colled- 
coll (C-C) motif Is at the amino (NH2) terminus. This Is followed by the tyrosine at position 
177, and phosphoserlne-threonlne-rlch sequences between amino acids 192-242 and 298- 
413. The serlne-threonlne rich kinase domain of BCR contains an SH2 binding domain and 
can bind the SH2 domain of ABL In a non-phosphotyroslne-dependent manner. BCR also 
has a GTPase-actlvatIng protein (GAP)-homology domain and a pleckstrin (PH) domain at 
the carboxy (COOH) terminus. In ABL, there are SH3, SH2 and SHI domains towards the 
amino terminus followed by a nuclear localisation site (NLS). At the carboxy terminus there 
are DNA and actin binding domains. C-C, colled coll; Y177, tyrosine 177; Ser/Thr kinase, 
serlne-threonlne rich kinase domain; GAP, GTPase-actlvatIng protein; PH, pleckstrin
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homology; SH, Src homology domain; NLS, nuclear localisation site. Adapted from 
Holyoake (Holyoake, 2001).
BCR-ABL
Ras JAKPI3K
RafAKT
STAT
mTOR NFkB MEK
BADMDM2
ERK 1
Mitochondrionp53
Nucleus
Figure 1-5. Schematic diagram of the three main signal transduction pathways (PI3K-AKT, 
Ras-Raf-MEK-ERK and JAK-STAT) activated by BCR-ABL in CML cells. In normal HSC, 
these pathways are activated by the cytokine interleukin-3 (IL-3) and promote survival, 
growth and differentiation. However, BCR-ABL activates these pathways in the absence of 
IL-3, resulting in increased proliferation and prolonged survival by inhibiting apoptosis 
(Steelman et ai., 2004).
BCR-ABL has transforming activity both in vitro and in vivo which was originally 
demonstrated in a mouse model (Daley et a!., 1990). Briefly, in these studies, 
murine bone marrow was infected with a retrovirus encoding and
transplanted into irradiated syngeneic recipients. The transplant recipients 
developed haematological malignancies, including a CML-like myeloproliferative 
disorder in the majority.
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In vitro cell culture studies (Eaves et al., 1986; Eaves et al., 1987) have shown that
BCR-ABL results in marked clonal expansion (i.e. proliferation) in association with
increasing differentiation. However, this is heterogeneous, with proliferation rates
varying between patients. In addition, in CML, the mechanisms which normally
maintain the majority of HSCs in a quiescent state are deregulated, contributing to
the increased proliferation, although a deeply quiescent population of CML stem
cells has been identified (Holyoake et al., 1999). Further evidence for an increased
proliferation rate in CML versus normal progenitor cells comes from studies of
telomere dynamics which showed that there was accelerated replication-
dependent telomere shortening in Ph^ versus Ph' leucocytes (Brummendorf et al.,
2000). In addition, very short telomeres predicted early progression to BC,
suggesting a link between the CML stem cell, genetic instability and disease
progression. An alternative hypothesis for the cell expansion seen in CML called
the ‘discordant maturation hypothesis’ has also been proposed in which the most
mature proliferating cells in CP CML are responsible for expansion of the Ph^
population (Strife et al., 1988). However, further studies have demonstrated that
the myeloid expansion observed in CML is far more likely to be a result of
increased numbers of primitive CML progenitor cells (Marley et al., 1996).
The increased proliferation and abnormal circulation of primitive CML progenitors 
can, in part, be explained by abnormal adhesive interactions between the bone 
marrow microenvironment and the CML cells. Studies have shown that CML 
progenitors fail to adhere to normal stromal layers (Gordon et al., 1987; Verfaillie 
et al., 1992) and that this may be related to abnormal function of adhesion 
molecules. Further studies using LTC-IC and colony forming cell (CFC) assays 
have demonstrated that treatment with interferon-a (IFN-a) restores normal 
adhesive interactions between CML cells and the bone marrow stroma in a 
concentration-dependent manner (Dowding et al., 1991; Bhatia et al., 1994). In
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addition, in CML cells, restoration of normal adhesive properties in the presence of
IFN-a was inhibited by antibodies to 0 4 , as and (3i integrins. These integrins are
present at normal levels on CML progenitors and the levels are unchanged by
IFN-a treatment (Bhatia et al., 1994). This indicates that abnormal adhesion
between CML progenitors and bone marrow stroma may result from defective a4(3 i
and aspi integrin receptor function which results in a failure in the transmission of
signals that inhibit proliferation from the bone marrow microenvironment to the
primitive CML progenitors. Normalisation of progenitor-stromal interactions by IFN-
a in CML may result in normal progenitor proliferation and partly explain the
therapeutic efficacy of IFN-a in CML.
In addition to the deregulation of cell proliferation in CML, there is an imbalance 
between the rate of cell production and cell death. As shown in Figure 1-5, BCR- 
ABL triggers multiple signal transduction pathways including the PI3K-AKT, Ras- 
Raf-MEK-ERK and JAK-STAT pathways (Steelman et al., 2004) which inhibit 
apoptosis and prolong growth factor-independent survival of CML cells (Bed! et al.,
1994). Inhibition of BCR-ABL by antisense oligonucleotides reversed this anti- 
apoptotic effect resulting in increased cell death in response to serum deprivation 
or treatment with cytotoxic agents (Bedi et ai., 1994; McGahon et al., 1994). 
Further studies have shown that the anti-apoptotic effect of BCR-ABL is 
associated with prolongation of cell cycle arrest at the G2M checkpoint (Bedi et al.,
1995). In this study, BCR-ABL"" Ba/F3 cells were exposed to ionising radiation and 
cell cycle distribution was assessed. The irradiated Ba/F3 cells remained viable 
and had a prolonged G2 arrest compared to non-irradiated cells. It was 
hypothesised that this transient delay at the G2 checkpoint promoted cell survival 
by permitting repair of otherwise lethal DNA damage caused by cytotoxic agents, 
thus allowing successful completion of DNA replication and explaining, at least in
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part, the resistance to chemotherapeutic agents seen in CML. These repaired
CML cells were then capable of proliferating through subsequent cell divisions.
1.2.1.1 Phosphatidylinositol-3 kinase-AKT pathway
Phosphatidylinositol-3 kinase (PI3K) activity is associated with cell division, 
glucose transport/metabolism, cytoskeletal organisation and inhibition of 
apoptosis. In CML, BCR-ABL forms a complex with PI3K, Cbl and the adaptor 
molecules Crk and CrKL via which PI3K is activated (Battler and Salgia, 1998). 
AKT exerts it anti-apoptotic effects through phosphorylation of downstream target 
molecules. The first downstream target of AKT to be identified was the BCL-2 
family member protein BAD (Datta et al., 1997; Andreeff et al., 1999). The 
phosphorylation of BAD by AKT resulted in the association of BAD with 14-3-3 
proteins, which enhanced cell survival by inhibiting the binding of BAD to BCL-2 
and BCLxl, thus allowing BCLxl to bind pro-apoptotic BAX molecules and 
preventing the formation of pro-apoptotic BAX homodimers. Studies have shown 
that BAD-dependent and independent anti-apoptotic pathways are active in CML 
(Neshat et al., 2000).
AKT also phosphorylates IkB kinase (IkK), which induces degradation of the 
nuclear factor-xB (N F -kB ) inhibitor IkB. NF-kB is a transcription factor that inhibits 
apoptosis and may also regulate cellular transformation (Romashkova and 
Makarov, 1999). Expression of BCR-ABL, via up-regulation of AKT, leads to 
activation of NF-xB-dependent transcription by causing nuclear translocation of 
NF-KB and increasing the trans-activation function of the RelA/p65 subunit of NF- 
kB (Figure 1-6). This activation is dependent on the tyrosine kinase activity of 
BCR-ABL and partially requires Ras (Reuther et al., 1998). The mechanism by 
which Ras activates N F-kB  is not known, but may be through AKT which is
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downstream of Ras as well as BCR-ABL. However, inhibition of Ras blocks NF-kB
activation.
BCR-ABL
Ras
IkK ^  Activation of IkK via AKT
Phosphorylation of IkB
NF-kB '^Degradation of IkB by 26S proteasomeIkB
Proliferation 
Inhibition of apoptosis 
Invasion
Control of differentiation
Nucleus NF-kB
Figure 1-6. Schematic diagram of the upregulation of NF-kB by BCR-ABL. AKT 
phosphorylates IkK, resulting in the subsequent phosphorylation and degradation of IkB. 
Without the inhibitory effect of IkB, NF-kB is activated and translocated to the nucleus 
where it exerts effects on proliferation, inhibition of apoptosis, tumour invasion and control 
of differentiation. The mechanism of activation of NF-kB by Ras is unknown.
Further downstream targets of AKT include MDM2 and mammalian target of 
rapamycin (mTOR). MDM2 is a negative regulator of the function of the tumour 
suppressor gene p53 that targets p53 for degradation by the proteasome (Mayo 
and Donner, 2001). Studies have shown that BCR-ABL activates MDM2 resulting 
in increased MDM2 expression and enhanced resistance to apoptosis (Trotta et 
al., 2003). The serine threonine kinase mTOR is a central regulator of cell growth 
and recent studies have shown that BCR-ABL induces expression of vascular 
endothelial growth factor via the PI3K pathway and mTOR, contributing to the
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increased angiogenesis seen in CML (Mayerhofer et al., 2002; Mayerhofer et al.,
2005).
1.2.1.2 Ras-Raf-MEK-ERK pathway
The Ras proteins are a group of guanine nucleotide binding proteins (G-protelns) 
that, following isoprenylation in the cytosol, associate with the inner plasma 
membrane of the cell and transduce external signals to the interior of the cell. 
They belong to the protein group termed the ‘Ras superfamily of monomeric 
GTPases’ which also contains the Rho and Rab protein families which are 
involved in the signal transduction between cell-surface receptors and the actin 
cytoskeleton and regulation of intracellular transport vesicles, respectively. The 
Ras protein superfamily are substrates for post-translational modification and 
undergo prénylation via farnesyItransferase (FT) and geranylgeranyltransferase 
(GGT). Ras proteins exist in specific isoforms (H-Ras, K-Ras and N-ras) that differ 
in their affinity for specific isoprenyl groups and are either in an active form (Ras- 
GTP) or inactive form (Ras-GDP) which is tightly regulated (Figure 1-7). The Ras- 
Raf-MEK-ERK pathway, which is often referred to as the mitogen-activated protein 
kinase (MAPK) pathway, transmits signals from cell surface receptors to 
transcription factors in the nucleus and is able to interact with other signal 
transduction pathways including PI3K-AKT and JAK-STAT. Activation of Ras by 
cytokines such as IL-3 leads to recruitment of the serine-threonine kinase Raf to 
the cell membrane which results in a signalling cascade through MEK1/2 and ERK 
culminating in the activation of gene transcription (Marais et al., 1995; Cahill et ai.,
1996). It is believed that when mutated, Ras is no longer under the control of its 
regulators such as the positive regulator Son of sevenless (SOS; a guanine 
nucleotide exchange factor) (Figure 1-7), resulting in constitutive activation of 
Ras-GTP (Lowy and Willumsen, 1993).
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Figure 1-7. Schematic diagram of Ras-medlated signalling. Ras Is farnesylated In the 
cytoplasm by fa rn esy Itra nsfe rase (FT) and this process can be Inhlbted by 
farnesyltransferase Inhibitors (FTIs). Farnesylated Ras (Ras-F) then translocates to the cell 
membrane where It Interacts with the regulatory proteins GAP and SOS. Farnesylated Ras 
cycles between active GTP-bound and Inactive GDP-bound forms. Activated farnesylated 
Ras-GTP stimulates the Raf-MEK-ERK effector pathway resulting In alterations In the 
transcriptional control of cell growth, proliferation and differentiation. The association of 
BCR-ABL with the Grb-2/SOS complex stabilises Ras In Its activated GTP-bound form 
resulting In Increased cell growth and proliferation.
A number of associations between BCR-ABL and Ras have been identified. 
Autophosphorylation of BCR-ABL on Y177 allows direct interaction with the 
adaptor molecule Grb-2 (Pendergast et al., 1993). This enables Grb-2 to bind SOS 
and stabilise Ras in its activated GTP-bound form. The adaptor molecules She 
and CrKL can also activate Ras (Oda et al., 1994; Pelicci et al., 1995; Senechal et 
al., 1996). In CML, BCR-ABL activates Ras, and inhibition of Ras results in arrest 
of cell growth. This was demonstrated in cell line models in which the introduction 
of a dominant-negative Ras into BCR-ABL-transfected cells inhibited malignant 
transformation (Sawyers et al., 1995). Further studies have shown that disrupting 
the Grb-2/SOS complex inhibits Ras-mediated cell proliferation in BCR-ABL
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expressing cell lines and primary CML cells (Kardinal et al., 2001). Therefore, the
Ras-Raf-MEK-ERK axis appears to be important in the pathogenesis of BCR-ABL^
leukaemias and inhibition of this pathway may represent a valuable treatment
option for patients with CML (Section 1.3.3.1).
1.2.1.3 JAK-STAT pathway
The JAK-STAT pathway is activated by cytokines such as IL-3, IFN-a and 
granulocyte macrophage-colony stimulating factor (GM-CSF). The Janus kinases 
(JAKs) are a class of tyrosine kinases which phosphorylate and activate a group of 
transcription factors called the signal transducers and activators of transcription 
(STATs). The STATs are then translocated to the nucleus where they up regulate 
the transcription of specific genes which are predominantly associated with the 
regulation of cell survival, proliferation and differentiation. The JAK-STAT pathway 
is regulated by the suppressors of cytokine signalling (SOCS) and cytokine- 
induced SH2-containing (CIS) family of proteins. To date, four different JAK (JAK 
1-3 and TYK1), seven different STAT (STAT 1, 2, 3, 4, 5a, 5b, and 6) and six 
different SOGS/CIS (SOCS 1-5 and CIS1) molecules have been described 
(Kisseleva et al., 2002). The STATs are constitutively phosphorylated in CML cells 
and appear to contribute to the malignant transformation seen in CML (Chai et al., 
1997; de G root et al., 1999). The constitutive activation of STAT5 is not always 
associated with the activation of JAK, indicating that BCR-ABL may be able to 
directly activate STAT5 (Chai et al., 1997). The effect of STAT activation on BCR- 
ABL-transformed cells is predominantly anti-apoptotic and involves the 
transcriptional activation of BC Lxl (Horita et al., 2000; Siliaber et al., 2000).
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1.2.2 Growth factor independence in CML
1.2.2.1 Interleukin-3 (IL-3)
Interleukin-3 is a highly glycosylated 26kD cytokine. It binds to the IL-3 receptor 
which is a member of the cytokine receptor gene family. Activation of the IL-3 
receptor induces the activity of the JAK-STAT, PI3K-AKT and Ras signalling 
pathways promoting survival, growth and differentiation of HSCs (Steelman et al., 
2004).
1.2.2.2 Granulocyte-colony stimulating factor (G-CSF)
Like IL-3, granulocyte-colony stimulating factor (G-CSF) is a 25kD glycoprotein 
that acts as a cytokine. It binds to the G-CSF receptor (G-CSF-R), another 
member of the cytokine receptor gene family, resulting in ligation of the 
extracellular domain of the G-CSF-R. The G-CSF-R is expressed by all cells in the 
granulocyte series, including HSCs (McKinstry et al., 1997). In addition, the G- 
CSF-R is also expressed on endothelial cells, placental cells, activated T 
lymphocytes and many non-haemopoietic tumour cell lines (Roberts, 2005). 
Granulocyte-colony stimulating factor affects survival, proliferation and 
differentiation of all cells of myeloid lineage, from HSCs to mature neutrophils 
through activation of downstream signal transduction pathways including JAK- 
STAT, PI3K-AKT and Ras as well as the SRC family of proteins. Stimulation with 
G-CSF alone is sufficient for committed myeloid progenitors to proliferate and 
differentiate. However, for normal HSC proliferation, additional stimulation with 
other cytokines is also required. Further functional roles for G-CSF include 
speeding up the maturation of metamyelocytes, enhancing the function of mature 
neutrophils by increasing superoxide production, bacteriocidal killing and 
phagocytosis, mobilisation of HSCs from the bone marrow into the peripheral
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blood and, possibly regulation of immune responses (Roberts, 2005). All tissues in
the body are capable of producing G-CSF after stimulation, in particular,
macrophages, endothelial cells, fibroblasts, other mesenchymal cells and bone
marrow stroma.
In humans, the serum concentration of G-CSF is very low (1.4±0.7 pg/mL) in 
healthy subjects (Jorgensen et al., 2003). However, levels significantly increase in 
response to infection or inflammation and fall again with recovery (Kawakami et 
al., 1990; Jorgensen et al., 2003). Inflammatory stimuli such as IL-1, 
lipopolysaccharide and tumour necrosis factor-a increase the production of G-CSF 
by macrophages, fibroblasts and endothelial cells (Roberts, 2005). Interleukin-17 
is thought to be a major upstream regulator of G-CSF production, particularly by 
bone marrow cells and, in vitro, results in a concentration-dependent increase in 
G-CSF expression (Fossiez et al., 1996). In vivo, in a murine model deficient in 
leucocyte adhesion molecules which resulted in abnormal haemopoiesis and 
neutrophilia, inhibition of IL-17 reduced serum G-CSF concentrations and 
neutrophil count, thereby providing evidence for a feedback loop between IL-17 
and G-CSF (Forlow et al., 2001).
Recently, SOCS-3 was shown to be rapidly up-regulated in response to G-CSF in 
mature neutrophils and the myeloid cell line U937 (Hortner et al., 2002). SOCS-3 
negatively regulates STAT activation. In addition, this study showed that 
recruitment of SOCS-3 to the G-CSF-R was phosphorylation dependent and 
pY729 was the major recruitment site on the G-CSF-R for SOCS-3. An in vivo 
mouse model in which the haemopoietic cells had a SOCS-3 deletion confirmed 
that SOCS-3 was an important negative regulator of G-CSF signalling in myeloid 
cells (Croker et al., 2004). When given exogenous G-CSF, these mice developed 
neutrophilia, splenomegaly and inflammatory disorders.
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1.2.2.3 The roles of autocrine IL-3 and G-CSF production in CIVIL
Research in the late 1980s first demonstrated that the production of autocrine 
growth factors in myeloid malignancies resulted in autonomous growth (Young et 
al., 1987; Oster et al., 1989). Studies in murine bone marrow transplantation 
models showed that in mice, in whom the bone marrow cells had either been 
retrovirally transduced or transgenically engineered to produce IL-3, there was 
development of a myeloproliferative disorder with leukaemic transformation of 
primitive progenitors (Chang et al., 1989; Wong et al., 1989; Just et al., 1993). 
Further in vitro studies have demonstrated that continuous expression of BCR- 
ABL in cytokine-dependent cell lines resulted in growth factor-independent 
proliferation in association with autocrine production of IL-3 and GM-CSF (Li et al., 
1999; Li et al., 2001; Peters et al., 2001b). In addition, in one of these studies, 
transplant of these cells into a mouse model induced a fatal leukaemia (Peters et 
al., 2001b). However, the other study showed that IL-3 and GM-CSF were not 
required for induction of a CML-like myeloproliferative disorder in mice by BCR- 
ABL (Li et al., 2001), but may be required for disease maintenance. Research has 
also shown that primitive CD34^ CML stem cells produce IL-3 and G-CSF via an 
autocrine mechanism which results in increased STAT5 phosphorylation that is 
highly dependent on IL-3 but not G-CSF (Jiang et al., 1999; Jiang et al., 2000b). It 
is believed that this contributes to their resistance to apoptosis by prolonging the 
growth factor independent survival of CML progenitors. This hypothesis was 
further corroborated by in vitro studies which showed that, after prolonged culture, 
IL-3""" mouse bone marrow cells transduced with BCR-ABL required rescue with 
an IL-3 transgene to maintain growth factor-independence and STATS activation, 
in addition, these BCR-ABL-transduced cells lacked in vivo leukaemogenic activity 
(Jiang et al., 2002). These data are also supported by results from an in vivo 
mouse model which used a murine retroviral stem cell vector to transduce the
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BCR-ABL oncogene into mouse bone marrow cells (Zhang and Ren, 1998). A
myeloproliferative disorder resembling human CP CML was induced in 100% of
transplanted mice in association with excess production of IL-3. Overall, these
studies suggest that the combined expression of BCR-ABL and IL-3 may be vital
to leukaemia stem cell survival in CML. However, the role of G-CSF is less clear.
It was first demonstrated in 1990 that G-CSF transcripts were increased in CML 
(Klein et al., 1990). This study also showed that the G-CSF produced from these 
cells was functional, as supernatants taken from cultures of these cells were 
capable of stimulating growth of granulocyte-forming colonies from normal bone 
marrow cells. Additionally, the growth of colonies obtained from these CML cells 
could be inhibited by neutralising G-CSF antibodies. Therefore, this study 
concluded that CML-derived progenitors secrete autocrine G-CSF which drives 
terminal cell divisions. Further studies have confirmed that purified populations of 
CD34^ CML cells can survive and proliferate in vitro in the absence of exogenous 
growth factors, however, normal CD34^ cells rapidly die under the same culture 
conditions (Bedi et al., 1994; Maguer-Satta et al., 1998). Jiang et al have also 
shown that when CD34^ cells differentiate and become CD34’, IL-3 and G-CSF 
production decrease, and the cells lose their growth factor independence in vitro, 
despite the continued expression of BCR-ABL (Jiang et al., 1999). In addition, 
these autonomously proliferating CD34^ CML cells are capable of producing 
clonogenic progenitors in vitro for all the lineages (erythroid, granulocyte- 
macrophage and megakaryocyte) that normal CD34^ cells generate in vivo in the 
presence of haemopoietic growth factors (Jiang et al., 2000b). These findings 
highlight the role of autocrine growth factor production in the multi-lineage 
expansion of CD34'*' CML cells that occurs in vivo.
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1.2.3 Quiescent LSCs in CML
Cells with a mechanism of autocrine IL-3 production would be expected to have 
Increased cell cycle activity which would make them susceptible to eradication by 
conventional chemotherapy agents. However, CML is incurable using repeated 
AML-type chemotherapy (Kantarjian et al., 1991) suggesting that there is a pool of 
quiescent CML stem cells which are resistant to treatment. Studies have now 
confirmed the existence of a highly quiescent population of LSC in CML (Holyoake 
et al., 1999). Viable BCR-ABL^ Go cells were isolated using Hoescht 33342 and 
Pyronin Y staining from total CD34^ CML cells by fluorescence activated cell 
sorting (FACS) and were demonstrated to have in vitro progenitor activity by LTC- 
IC assay and the capability of engrafting immunodeficient mice. The ability of 
these quiescent CML stem cells to produce leukaemic progeny also illustrates the 
reversibility of this quiescent state. Further research showed that the entry of BCR- 
ABL^ progenitors into a quiescent state in vivo was greatest in the most primitive 
leukaemia cell populations. This was associated with down-regulation of IL-3 and 
G-CSF gene expression, and spontaneously reversed in association with up­
regulation of IL-3 expression and entry of cells into a continuously cycling state 
(Holyoake et al., 2001). The phenomenon of quiescence in CML is important 
because it would be predicted that the growth factor-independent quiescent CML 
stem cells would have a proliferative advantage over normal quiescent HSCs 
when the concentration of cytokines is low.
1.2.4 The historicai treatment of CML
There have been great advances in the management of CML over the past half 
century. Prior to this, a range of therapies including arsenic, benzene, radiotherapy 
and splenectomy were used as palliative treatment in small numbers of patients 
with limited success (Geary, 2000). From the 1950s to the 1980s, patients with CP
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CML were treated with the oral alkylating agent busulphan as this was relatively
specific for haemopoietic tissue (Galton, 1953). However, this frequently resulted
in permanent sterility and bone marrow failure, and was later reserved for
progressive disease.
In the 1980s, IFN-a, and the ribonucleotide reductase inhibitor hydroxycarbamide 
(formerly hydroxyurea), were introduced for the management of CML. Interferon-a 
is given by subcutaneous injection and is effective at reducing the leukocyte count 
and reversing the clinical and laboratory features of CML. In addition, it has been 
observed that 5-15% of patients receiving IFN-a sustain a very significant 
reduction in Ph^ marrow metaphases (cytogenetic response) with restoration of 
Ph' 'normal' haemopoiesis (Talpaz et al., 1986). However, IFN-a is not without 
side effects; almost all patients experience rigors, fevers, muscle aches and 
general 'flu-like' symptoms on commencing therapy. These symptoms usually last 
1-2 weeks and can be relieved by paracetamol, but they recur whenever the dose 
is increased. A significant proportion of patients are unable to tolerate IFN-a as a 
result of lethargy, malaise, weight loss, depression and other psychological 
disorders.
Hydroxycarbamide targets relatively mature myeloid progenitors. It is given orally 
and the leukocyte count begins to fall within a few days of commencing therapy. 
Hydroxycarbamide therapy can be continued indefinitely, but does not induce a 
cytogenetic response and has no effect on the natural history of the disease, with 
patients eventually progressing to more advanced phases of CML (Kantarjian et 
al., 1993). Hydroxycarbamide has relatively few side effects.
The 1980s also saw the introduction of allogeneic stem cell transplantation 
(alloSCT) which, for the first time, offered the possibility of cure for younger CML
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patients (<50-55 years of age) with HLA-matched donors (Goldman et at., 1986).
This accounts for approximately 20% of CML patients’; however, the procedure is
associated with significant morbidity and a mortality of between 20 and 40%, most
commonly resulting from opportunistic infections and graft-versus-host disease
(GvHD) (Sawyers, 1999; Silver et al., 1999). For those patients’ who receive an
alloSCT, a leukaemia-free survival rate of up to 70% is achieved (Clift and
Anasetti, 1997). The success of alloSCT in CML is related to the power of the
“graft-versus-leukaemia” (GvL) effect in addition to myeloablation. The GvL effect
is greatest in those patients who have post-transplant GvHD, with GvL and GvHD
being driven by major and minor HLA mismatches between donor and recipient
(Spierings et al., 2004), although donor T lymphocytes may also recognise and
destroy as yet unidentified leukaemia-specific antigens (Barrett and van Rhee,
1997). Donor T cell responses to minor histocompatibility antigen differences may
contribute up to 35% of the total GvL response in leukaemic patients (Kloosterboer
et al., 2004).
For patients that relapse after alloSCT, donor lymphocyte infusions (DLI) are given 
in incremental doses with the aim of harnessing the GvL effect. A response to DLI 
can be expected between 3 and 12 months post-infusion. The success rate of DLI 
for relapse of CML post-transplant is at least 70% for patients with haematologic 
relapse and as high as 90% in patients with molecular relapse only (Kolb et al.,
1995).
With the success of alloSCT/DL! in curing CML by exploiting the GvL effect, 
interest in the late 1990s focused on reduced intensity “mini” stem cell transplant 
regimens (RISCT). These less intensive transplant conditioning regimens allow 
transplantation of older patients (up to age 70) and reduce regimen-related 
toxicities compared to standard alloSCT (Slavin et al., 1998; Champlin et al.,
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2000). A recent study (Or et ai., 2003) showed that of 24 patients with CML who
received a RISCT in first CP, 21 remained alive and disease free after a median of
42 months follow up. The GvL effects of donor immunocompetent lymphocytes
eradicated all host haemopoietic cells, as evidenced by molecular testing.
Because only a minority of patients are suitable for alloSCT, interest in the 1990s 
focused on autologous SCT. It was hoped that autografting would result in durable 
Ph' haemopoiesis and, in 2000, the Medical Research Council (MRC) in the UK 
initiated one study comparing autografting with IFN-a therapy (The MRC CML 
2000 trial), and another trial (the CML IV trial) to define the relative roles of IFN-a, 
autologous and alloSCT in the younger patient. However, with the introduction of 
the BCR-ABL tyrosine kinase inhibitor (TKI) imatinib mesylate (IM; Glivec™; 
Gleevec™, formerly STI571, Novartis Pharmaceuticals, Basel, Switzerland), these 
trials were abandoned as patients opted to commence IM treatment rather than 
start or continue on IFN-a therapy or undergo autologous SCT. Even the role of a 
potentially curative alloSCT has been called into question in the IM era.
1,2.5 The development of IM
1.2.5.1 Early studies of protein TKls
The first step towards development of a useful TKI was synthesis of compounds 
called tyrphostins which were low molecular weight TKls that blocked epidermal 
growth factor (EGF)-dependent cell proliferation (Yaish et al., 1988). It was later 
reported that two tyrphostins, AG568 and AG1112, which inhibited the ABL protein 
tyrosine kinase, inhibited p210^^^'^^^ tyrosine kinase activity in the BC-derived 
CML cell line, K562, in association with erythroid differentiation (Anafi et al., 1993). 
Following this, it was suggested that these compounds would be useful for purging 
Ph'*' cells in preparation for autologous SCT. Another tyrphostin, AG957, was
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reported to restore (3i integrin-mediated adhesion and inhibitory signalling in
primary CML (CD34^) stem cell cultures (Bhatia et al., 1998), suppress Ph^ colony
growth in a concentration-dependent manner and induce apoptosis in combination
with an anti-Fas receptor antibody (Carlo-Stella et al., 1999).
Parallel studies showed that the benzoquinonoid ansamycin antibiotic herbimycin 
A also had inhibitory activity against v-ABL and the SRC family of protein tyrosine 
kinases and reversed the transformation of susceptible cell lines with a reduction 
in phosphotyrosine content (Uehara et al., 1988). Herbimycin A was also reported 
to inhibit the growth and tyrosine phosphorylation of K562 cells and induce 
erythroid differentiation (Honma et al., 1989). In addition, herbamycin A induced 
growth inhibition in a variety of p210^ *^ '^ '^ '^ transformed cell lines but did not inhibit 
the growth of a broad spectrum of Ph" haemopoietic cell lines (Okabe et al., 1992) 
and prolonged survival in a SCID mouse model with a disease resembling human 
Ph"*” ALL (Honma et al., 1995). Taken together, these studies using tyrphostins and 
herbimycin A suggested that the development of an agent with the potential to 
specifically inhibit BCR-ABL would be of therapeutic benefit in Ph^ leukaemias.
1.2.5.2 The pre-clinical development of IM
The studies leading to the development of IM began in the early 1990s. A large 
number of adenosine triphosphate (ATP)-competitive 2-phenylaminopyrimidine 
compounds were synthesized and screened for protein tyrosine kinase inhibitory 
activity. One of these compounds, CGP57148 (CG = Ciba-Geigy), was found to be 
a potent inhibitor of ABL, c-KIT and platelet-derived growth factor receptor (PDGF- 
R) acting via competitive inhibition of the protein kinases with respect to ATP 
(Druker et al., 1996). The structure of this molecule is shown in Figure 1-8. 
CGP57148 was evaluated for its effects on cells containing the BCR-ABL fusion
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protein. Cellular proliferation and tumour formation by BCR-ABL-expressing cells
were specifically inhibited by this compound. In the CFC assays of peripheral
blood or bone marrow from patients with CML and non-CML controls, there was a
92-98% decrease in the number of BCR-ABL"*" colonies formed from CML cells,
but only 15-20% inhibition of normal colony formation, and it was concluded that
this compound might be useful in the treatment of BCR-ABL^ leukaemias. In
addition, a mouse model demonstrated a concentration-dependent inhibition of
tumour growth in BCR-ABL-inoculated animals treated with CGP57148, with no
effects on animals inoculated with a non-BCR-ABL-expressing cell line.
CGP57148 later became known as STI571 (Signal Transduction Inhibitor 571) or
imatinib mesylate and is now marketed as Glivec™ in Europe and Gleevec™ in
the USA by Novartis Pharmaceuticals, a company formed in 1996 by the merger
of the Swiss life sciences companies Ciba-Geigy and Sandoz.
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Figure 1-8. Structure of IM (Glivec™, Gleevec™; formerly CGP57148 and STI571).
The selective inhibition of BCR-ABL tyrosine kinase is mediated via interaction 
between IM and the amino acids that constitute the ATP binding cleft of BCR-ABL. 
IM is a competitive inhibitor of ATP at its specific binding site in the kinase domain 
of the BCR-ABL protein (Deininger et al., 2000). When ATP binds to its specific 
binding site in the kinase domain, tyrosine phosphorylation of downstream target 
proteins occurs. However, when the synthetic ATP mimic IM is bound, it blocks the
Mhairi Copland, 2007 Chapter 1, 48
tyrosine phosphorylation of target proteins downstream of BCR-ABL, inhibiting
effector pathways. IM has an inhibitory concentrationso ( I C 5 0 )  of 0.25 pM on BCR-
ABL kinase activity (Druker et a!., 1996). The IC50 can be measured as either
inhibition of biochemical kinase activity or cellular proliferation. The IC 5 0  i s  the
concentration of drug which results in 50% inhibition of either kinase activity
(biochemical IC50) or cellular proliferation (cellular IC50) compared to a no drug
control. These initial results were swiftly confirmed in a number of other studies
(Carroll et al., 1997; Deininger et al., 1997; le Coutre et al., 1999). Importantly, le
Coutre et al compared dosing nude mice previously injected with BCR-ABL""
human leukaemia cells once, twice and three times daily with IM over an 11-day
period (le Coutre et al., 1999). In the mice dosed three times daily, there was an
87-100% cure rate; however, mice dosed once or twice daily were not cured of
their Ph"" leukaemia. This study supported the hypothesis that continuous therapy
was likely to be necessary for IM to be effective in patients with Ph"" leukaemias.
Preliminary toxicity testing of the oral IM compound revealed occasional renal 
calcification and mild bladder mucosal hyperplasia in rats at a dose of 6  mg/kg, 
and liver toxicity, vomiting, diarrhoea, anaemia and pancytopenia in dogs at the 
highest dose of 100 mg/kg (Druker and Lydon, 2000).
1.2.6 The introduction of IM into ciinical trials
Phase 1 dose escalating trials of IM were undertaken in patients with CP CML who 
had failed IFN-a and patients with BC CML or Ph"" ALL (Druker et al., 2001a; 
Druker et al., 2001b). Serious adverse events were minimal; the most common 
side effects seen were nausea, myalgia, oedema and diarrhoea. Doses of up to 
lOOOmg/day were given; however, a maximum tolerated dose was not reached. In 
patients with CP CML who had failed IFN-a, complete haematologic responses 
(CHR) were seen in 53 of 54 patients treated with daily doses greater than SOOmg
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(Druker et al., 2001b). See Table 1-2 for definitions of response. In addition,
cytogenetic responses were seen in 29 of the 54 treated with more than SOOmg
per day and, of these, 7 patients achieved a complete cytogenetic response
(CCR). In patients with myeloid BC CML responses were seen in 21 of 38 patients
of which 4 had a CHR and, in patients with lymphoid BC or Ph"" ALL, 14 of 20
patients responded , including a further 4 patients who had a CHR (Druker et al.,
2001a). However, in more advanced disease, responses were not durable, with
the majority of patients relapsing within 6 months of commencing therapy. These
studies concluded that IM was well tolerated and had significant anti-leukaemic
activity in all phases of CML. In addition, these studies demonstrated the essential
role of BCR-ABL tyrosine kinase activity in CML and highlighted the potential for
the development of anti-cancer drugs based on a specific molecular abnormality.
Response Definition
Complete haematologic 
response (CHR)
Reduction of the WCC to less than 10 x 10®/L and 
platelet count to less than 450 x 10®/L, with no immature 
cells in the peripheral blood and disappearance of all 
symptoms and signs related to leukaemia including 
splenomegaly, maintained for at least 4 weeks
Complete cytogenetic 
response (CCR)
No Ph"" cells detectable by cytogenetics in the bone 
marrow
Partial cytogenetic 
response (PCR)
1-34% of bone marrow cells have a detectable Ph 
chromosome
Major cytogenetic 
response (MCR)
Includes those that have achieved a CCR or PCR (i.e < 
35% cells Ph"*
Minor cytogenetic 
response (mCR)
35-90% of bone marrow cells have a detectable Ph 
chromosome
Complete molecular 
response (CMoIR)
Either BCR-ABL undetectable by qRT-PCR or > 4.5 log 
reduction in BCR-ABL transcript levels compared to 
starting value
Major molecular 
response (MMoIR)
Either > 3 log reduction in BCR-ABL transcript levels or 
a BCR-ABL transcript level < 0.1% by qRT-PCR 
compared to starting value
Table 1-2. Definitions of response to IM therapy In CML
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Imatinib mesylate progressed rapidly through Phase 2 clinical trials in which the
efficacy and good toxicity profile of the drug were confirmed (Kantarjian et al.,
2002; Ottmann et al., 2002; Sawyers et al,, 2002; Talpaz et al., 2002). In these
studies, the standard dose of IM was established as 400mg/daily for CP CML, but
its favourable toxicity profile allowed IM to be used at higher doses (600-800mg
daily) with the standard dose in AP and BC CML increasing to 600mg/daily and
the possibility of combining IM with other chemotherapeutic interventions
emerged. However, the appearance of the clinical phenomenon of IM resistance,
particularly in lymphoid BC and Ph"" ALL was concerning (Ottmann et al., 2002).
Following the success of the Phase 1 and 2 trials of IM in all phases of CML, a 
prospective, multicentre, open-label, Phase 3, randomised study was designed 
called the IRIS trial (International Randomised Study of Interferon versus STI571). 
This study set out to compare the efficacy of IM with that of IFN-a combined with 
low dose cytosine arabinoside (LDAC) in newly diagnosed CP CML patients and 
determine the haematologic and cytogenetic response rates, toxicity and rates of 
progression. Crossover between the two arms was allowed for lack of response, 
loss of response or intolerance to treatment. Interferon-a in combination with 
LDAC was chosen for the control arm because this combination was shown to 
result in superior rates of cytogenetic response (Guilhot et al., 1997; Baccarani et 
al., 2002) and possibly survival compared to IFN-a alone (Guilhot et al., 1997). 
However, the combination of IFN-a plus LDAC required daily subcutaneous 
injection of both drugs with frequent and troublesome side effects.
The rate of MCR at 18 months was 87.1% in the IM group compared with 34.7% in 
the IFN-a plus LDAC group (P<0.001) (O'Brien et al., 2003). The rates of CCR 
were 76.2% and 14.7% respectively (P<0.001). In addition, at 18 months, 
progression free survival (PFS) in the IM arm was 96.7% compared to 91.5% in
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the control arm. IM was also better tolerated than IFN-a plus LDAC (Hahn et al.,
2003). At the most recent update of this study, the CCR and MCR rates in the IM
arm were 87% and 92%, respectively, with a PFS of 93% at 60 months (Druker et
al., 2006). Only 3% of patients commenced on IFN-a plus LDAC continued on this
arm compared to 69% of patients who initially commenced IM. Therefore, this trial
demonstrated the superiority of IM to IFN-a plus LDAC in terms of disease
response, PFS and tolerability. During the course of this study, molecular
responses were assessed at regular intervals by qRT-PCR of peripheral blood
leucocytes for BCR-ABL transcripts (Hughes et al., 2003). Patients responding to
IM had a 3-4 log reduction in transcript levels compared to their starting value.
Therefore, other than alloSCT, IM induced a much higher rate of CCR than any
other licensed therapy and, indeed, has brought the role of alloSCT in CML into
question. However, alloSCT remains the only proven curative option for CML as,
after successful alloSCT, the majority of patients are BCR-ABL" by qRT-PCR.
Conversely, even patients who have an optimal response to IM, i.e. achieve CCR,
continue to have low levels of BCR-ABL transcripts detectable by qRT-PCR. In
addition, there is increasing evidence for disease resistance at the stem cell level
(Graham et al., 2002); a phenomenon termed molecular persistence, and the
emergence of IM resistance, particularly in advanced disease.
7.2.7 Imatinib mesylate resistance
Although more common in AP and BC, resistance to IM may also be seen in CP 
CML. This phenomenon has resulted in IM being less successful in advanced 
disease (Druker et al., 2001a; Ottmann et al., 2002; Sawyers et al., 2002; Talpaz 
et al., 2002). Some patients in AP do respond well, and although many patients 
treated in BC achieve some haematological improvement, these benefits are not 
maintained, with the majority of patients in the advanced stages of CML
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developing resistance to IM. Resistance can be primary, i.e. no response to IM
after initial therapy, and is defined as failure to achieve CHR within 3 months and
failure to achieve MCR by 6 months or CCR by 12 months, or acquired, i.e. loss of
established haematological, cytogenetic or molecular response to IM or
progression to AP or BC.
There are 2 broad categories of IM resistance: BCR-ABL-independent and BCR- 
ABL-dependent. In BCR-ABL-independent resistance, the leukaemia cells are no 
longer reliant on BCR-ABL to drive proliferation; their growth being dependent on 
additional oncogenic mutations (Donato et al., 2004) and this represents clonal 
evolution. Thus, in these cells, BCR-ABL is no longer a relevant target for IM and 
any specific BCR-ABL inhibitor would be ineffective in this situation. This may 
occur in primary or acquired resistance.
Acquired resistance in Ph"' leukaemias is usually BCR-ABL-dependent and is the 
result of restoration of BCR-ABL kinase activity. This can occur via three different 
mechanisms. The first of these is BCR-ABL amplification which was first described 
in a landmark publication by Gorre et al in 2001 (Gorre et al., 2001). In this study, 
dual-colour fluorescence In-situ hybridisation (FISH) was performed to determine if 
BCR-ABL gene amplification could be implicated in IM resistance in primary CML 
samples. In a number of patients with advanced phase disease, multiple copies of 
the BCR-ABL gene were detected. It is presumed that, in the presence of BCR- 
ABL amplification, there is insufficient IM present in the leukaemic cell to inhibit the 
increased level of BCR-ABL protein.
In addition, this study by Gorre et al (Gorre et al., 2001) was one of the first to 
consider the possibility that mutations in BCR-ABL might result in IM resistance. 
Indeed, this was the first study to report the single nucleotide substitution (C to T)
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at position 315 of ABL, resulting in replacement of a threonine residue with
isoleucine (T315I). To date, more than 40 different BCR-ABL kinase domain
mutations which result in intrinsic changes in the kinase that can affect drug
binding or kinase activity have been reported (Branford et al., 2002; Shah et al.,
2002; von Bubnoff et al., 2002; Branford et al., 2003). These mutations may
involve the ATP-binding site (P-loop), the activation loop or the carboxy terminus
of the BCR-ABL molecule. However, the T315I mutation remains the most
clinically significant as it is resistant to high concentrations of IM and also the
second generation inhibitors described later (Section 1.3.2).
Recent studies suggest that BCR-ABL protein conformation is absolutely critical 
for IM binding and function (Shah et al., 2002). Active BCR-ABL exists in an open 
(non-accessible) conformation and inactive BCR-ABL in a closed (accessible) 
conformation; thus sensitivity to IM in CML is presumed to result from a dynamic 
switch between open and closed conformations possibly linked to cell cycle 
progression. Indeed, IM has been shown to bind to the closed conformation of 
BCR-ABL and results in a number of structural changes to the protein after binding 
(Schindler et al., 2000). Therefore, in the presence of BCR-ABL kinase domain 
mutations, it is thought that IM is unable to bind due to either interruption of critical 
contact points between IM and BCR-ABL or induction of an inaccessible BCR-ABL 
conformation (Shah et al., 2002). The clinical significance of BCR-ABL kinase 
domain mutations is variable. Apart from the T315I mutation, those affecting the P- 
loop are associated with the poorest outcomes (Branford et al., 2003). In addition, 
studies have shown that some mutations confer only a moderate degree of IM 
resistance which can be overcome by increasing the dose of IM (Corbin et al., 
2003).
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The ciinical significance of the T315I mutation is related to its position in the BCR-
ABL molecule and it is described as a ‘gatekeeper’ of the ATP binding site. This is
because it separates the ATP binding site from an internal cavity and the nature of
the gatekeeper molecule is a vital determinant of inhibitor specificity (Liu et al.,
1999; Schindler et al., 1999). Threonine^^^ forms critical hydrogen bonds with IM,
and the absence of the oxygen molecule provided by the side chain of threonine^^^
prevents the formation of a vital hydrogen bond with IM (Gorre et al., 2001). In
addition, compared to threonine, isoleucine contains an extra hydrocarbon group,
resulting in a steric clash with IM and preventing IM binding to BCR-ABL.
The third proposed mechanism of BCR-ABL-dependent IM resistance is that 
intracellular levels of IM are reduced. This may occur via multidrug resistance 
proteins, e.g. MDR1 overexpression which increases drug efflux (Mahon et al., 
2003; Thomas et al., 2004) and alpha-1-acid glycoprotein which reduces the 
availability of the drug in vivo (Gambacorti-Passerini et al., 2002). Further studies 
have shown that expression levels of the cellular transporter OCT-1 are low in 
some patients with CML on IM, resulting in low intracellular concentrations of IM 
(Thomas et al., 2004; White et al., 2005). The role of other transporter molecules 
is more contentious, in particular the role of ABCG2 with some groups showing IM 
to be a substrate of ABCG2 (Burger et al., 2004) and others an inhibitor (Houghton 
et al., 2004; Jordanides et al., 2006); although there is now increasing evidence 
that IM is an ABCG2 inhibitor.
In clinical practice, the most common mechanism of IM resistance is mutation of 
the BCR-ABL kinase domain that interferes with IM binding (P-loop mutations) 
and, in some patients, these mutations have been shown to be present prior to 
commencing treatment with IM (Roche-Lestienne et al., 2002; Kreuzer et al.,
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2003). A major focus of current research interest is overcoming IM resistance and
inducing CML stem cell apoptosis.
1.2.8 Molecular persistence
Despite an impressive rate of CCR in CP CML, the majority of patients have 
persistent detectable disease at the molecular level by qRT-PCR (Hughes et al., 
2003; Branford et al., 2004). It is hypothesised that this minimal residual disease 
(MRD) is due to a dual population of primitive leukaemic cells. The first is a subset 
of CML cells which undergo cell cycle arrest and accumulate in G0/G1 in vitro in 
the presence of IM or other anti-proliferative agents, including conventional 
chemotherapy agents (Jorgensen et al., 2005a). Theoretically, these cells can be 
eradicated by giving pulsed sequential therapies to encourage the cells back into 
cycle. The second, and more significant population, postulated to contribute to 
MRD is the quiescent stem cell population (Holyoake et al., 1999) as, in vitro, 
quiescent CML stem cells were shown to be completely insensitive to IM at 
concentrations up to 10 times higher than those achievable in vivo (Graham et al.,
2002), while proliferating cells remained exquisitely sensitive. In addition, an in 
vivo study to assess presence of BCR-ABL"" cells by FISH and levels of BCR-ABL 
mRNA by qRT-PCR demonstrated that samples from different CML patients 
collected at different time points displayed persistence of BCR-ABL"" progenitors 
despite continued IM therapy (Bhatia et al., 2003). This was further indication that 
IM did not eliminate malignant primitive progenitors in CML patients. Further 
clinical studies have shown that, over time, in patients who have achieved a CCR, 
BCR-ABL transcript levels slowly continue to decrease (Goldman et al., 2005). 
This finding supports the hypothesis that CML stem cells are less sensitive than 
more mature CML progenitors to IM in vivo. The quiescent CML stem cell 
population is gradually reduced as these cells enter the cell cycle and proliferate.
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becoming IM-sensitive and undergoing apoptosis. As the quiescent CML stem cell
population diminishes, the BCR-ABL transcript level falls. Therefore, despite its
impressive clinical efficacy in CML, particularly CP, due to the quiescent CML
stem cell population, IM does not cure CML.
One possible explanation for the relative insensitivity of quiescent CML stem cells 
to IM is the conformation of the BCR-ABL kinase domain in the quiescent versus 
proliferating stem cells (Shah et al., 2002). The switch between open (non- 
accessible) and closed (accessible) conformations may not be triggered in 
quiescent CML stem cells; hence IM may not be the optimal choice of agent to 
eradicate this population. Other proposed explanations for insensitivity of CML 
stem cells to IM include BCR-ABL amplification or increased BCR-ABL transcripts 
within the stem cell compartment and altered levels of drug influx and efflux pumps 
on the cell membrane of CML stem cells.
In some patients, no residual BCR-ABL transcripts were detected after prolonged 
treatment with IM (Kantarjian et al., 2004; Rosti et al., 2004; Cortes et al., 2005b). 
However, the reported frequency of this was very variable (4% to 34%), probably 
due to the different sensitivities of the test methods used and available technical 
skills (Baccarani et al., 2006). In a few patients who stopped IM after achieving a 
CMoIR, disease rapidly recurred further highlighting the clinical importance of 
quiescent CML stem cells (Cortes et al., 2004b; Mauro et al., 2004). Despite this, 
IM has altered the natural history of the condition by increasing PFS in those 
patients who respond to it and therefore the overall median survival (Druker et al., 
2006). However, the long term efficacy of IM remains unknown and the side 
effects of long term IM exposure remain to be assessed. A recent study brought 
attention to an Increased risk of cardiac morbidity and mortality in patients treated 
with IM (Kerkela et al., 2006). It was reported that ten patients presented with
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congestive cardiac failure while on IM therapy and, in addition, mice treated with
IM developed left ventricular contractile dysfunction. This was found to be related
to the endoplasmic reticulum stress response in cardiac myocytes which can be
mediated by ABL. Therefore, cardiotoxicity may be an unexpected side effect of IM
inhibition of ABL. However, this finding is controversial as there was no significant
increase in cardiac morbidity or mortality reported in the IRIS trial (Druker et al.,
2006).
Thus, in view of the potential for long term side effects and also the potential for 
molecular relapse, which may be due to the emergence of BCR-ABL kinase 
mutations, all CP CML patients, and particularly those with molecular persistence 
need to be clinically assessed regularly and monitored for signs of molecular 
relapse by qRT-PCR for BCR-ABL.
1.2.9 Assessment of BCR-ABL kinase activity
While measurement of BCR-ABL transcripts by qRT-PCR provides a valuable 
estimation of disease burden and how a patient is responding to treatment 
(Branford et al., 1999; Hughes et al., 2003; Hughes et al., 2006), it does not 
provide a direct assessment of the efficacy of a treatment against BCR-ABL 
kinase activity. In addition, there may be a discrepancy between BCR-ABL 
transcript and protein expression levels. Therefore it is important to be able to 
directly measure BCR-ABL kinase activity both in vitro and in vivo. The most direct 
measure of this would be determination of phosphorylated BCR-ABL protein 
expression which, although measurable in cell lines (Konopka et al., 1985; Clark et 
al., 1987), is difficult to measure in clinical specimens because BCR-ABL is 
subject to rapid degradation when conventional lysis buffer is used (Maxwell et al., 
1987). This is because lysis of mature CML MNCs releases an enzyme, which is 
now thought to be an acid-dependent hydrolase (Patel et al., 2006), that
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selectively destroys BCR-ABL and ABL, but not other proteins. Therefore, it is now
accepted that measurement of phosphorylated CrKL, an adaptor molecule which
is phosphorylated by BCR-ABL is an adequate surrogate (Nichols et al., 1994;
Oda et al., 1994; ten Hoeve et al., 1994; Hochhaus et al., 2001). CrKL directly
binds BCR-ABL and links BCR-ABL with downstream effector pathways (Senechal
et al., 1996), playing a functional role in transformation. Phosphorylated CrKL can
be measured reproducibly and quantitatively in clinical samples by Western
blotting. In addition, it has been shown that CrKL phosphorylation is inhibited in a
concentration-dependent fashion when CML cells were treated with IM, and this
strongly correlated with inhibition of BCR-ABL phosphorylation (Gorre et al., 2001).
Therefore assessment of CrKL phosphorylation status can be used to assess the
degree and concentration-dependence of inhibition of BCR-ABL kinase activity by
different TKIs in both cell lines and clinical samples.
1.3 Potential strategies to overcome IM resistance and 
molecuiar persistence
A number of potential strategies exist to overcome IM resistance and molecular 
persistence seen in CML both in vitro and in vivo. The three which I will 
concentrate on for the remainder of this thesis are (1) attempting to reverse the 
quiescent state and Gq/Gi cell cycle arrest seen in primitive CML cells after 
treatment with IM; (2) the use of potent dual SRC/BCR-ABL TKIs; and (3) 
combining IM with other chemotherapeutic agents.
1.3.1 The rationale for reversing quiescence in CML stem cells
Studies have already shown that increasing the dose of IM does not eliminate 
CML cells in vitro (Graham et al., 2002) or in vivo. In fact, while IM effectively 
reduced dividing CML cells in vitro, it resulted in an increase in the number of non-
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dividing (quiescent) CML cells due to a marked anti-proliferative effect (Graham et
al., 2002) which was not anticipated and the mechanism behind it remains to be
elucidated. In addition, many drug combinations do not eliminate quiescent CML
cells in vitro (Holtz et al., 2005; Jorgensen et al., 2005a) resulting in the molecular
persistence seen in vivo. Thus, reversal of the quiescent state may restore IM
sensitivity in CML stem cells.
Cytokines, including G-CSF can trigger normal quiescent primitive progenitors to 
enter the cell cycle (Ogawa, 1993). In addition, exogenous G-CSF has been 
shown to promote rapid progression into S-phase of initially quiescent, primitive (c- 
kit"", Sca-1^, lin") progenitors in a murine model (van Pelt et al., 2003). Further 
studies have shown that G-CSF-R transcript levels are two-fold higher in cycling 
(G1/S/G2/M phases) normal human bone marrow cells in comparison to quiescent 
(Go) cells (Jorgensen et al., 2006) . Of specific relevance, haemopoietic growth 
factors have been shown to stimulate AML cells in vitro, and the simultaneous 
administration of chemotherapy with growth factors resulted in increased 
cytotoxicity in AML, in particular with the cell cycle-specific agent cytosine 
arabinoside (Ara-C) (Cannistra et al., 1989; Bhalla et al., 1991; te Boekhorst et al., 
1993). In addition, there are case reports of occasional patients with leukaemia 
achieving remission when treated with recombinant human G-CSF (rHu-G-CSF) 
alone (Nimubona et al., 2002).
A recent clinical trial examined the effect of priming with rHu-G-CSF in 
combination with conventional chemotherapy including Ara-C in the induction 
therapy phase on the outcome of AML (Lowenberg et al., 2003). The results 
demonstrated that although there was no significant difference in response rate 
after induction therapy, after a median follow-up of 55 months, the disease-free 
survival rate was higher in those patients receiving rHu-G-CSF with their
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chemotherapy compared to those who did not receive rHu-G-CSF (42% versus
33%: P=0.02). In addition, chemotherapy including rHu-G-CSF showed a trend
towards improved overall survival (P=0.016). However, in the subgroup of patients
with poor risk AML, the administration of rHu-G-CSF did not improve outcome.
Therefore, induction therapy including rHu-G-CSF with Ara-C improved overall and
disease-free survival in standard risk AML (Lowenberg et al., 2003). Importantly,
this study provided proof of the principle that combining haemopoietic growth
factors to sensitise leukaemia cells with conventional chemotherapy was a valid
potential therapeutic strategy for improving the response to therapy.
Recombinant human G-CSF has also been safely and successfully used for 
peripheral blood stem cell mobilisation in healthy donors (Goldman et al., 2006) 
and CML patients treated with IM with no significant rise in BCR-ABL transcript 
levels by qRT-PCR (Drummond et al., 2003; Hui et al., 2003). Furthermore, it is 
current practice to use rHu-G-CSF in combination with IM in CML patients with IM- 
induced neutropenia because myelosuppression during IM therapy is associated 
with a poorer cytogenetic response (Marin et al., 2003a; Sneed et al., 2004). It has 
been suggested that the improved cytogenetic responses observed in these 
patients result from an increased exposure to IM (Heim et al., 2003; Marin et al., 
2003b; Quintas-Cardama et al., 2004). However, another possible action of G- 
CSF in this situation may be to promote re-entry of quiescent CML stem cells into 
the cell cycle and hence increase their sensitivity to IM (Jorgensen et al., 2005b).
Previous studies had shown that, in vitro, Ph"" CML cells lost LTC-IC activity when 
cultured regardless of the presence of growth factors (Udomsakdi et al., 1992; 
Petzer et al., 1997). However, at the same time, CFC numbers were amplified and 
there was accumulation of increasingly differentiated cells of mixed lineages 
(Maguer-Satta et al., 1998; Jiang et al., 1999). These results indicate that the rapid
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loss of LTC-IC activity seen in CML cells in vitro may be due to an enhanced
propensity for primitive CML progenitors to differentiate into more mature cells
which no longer have multipotent stem cell potential. Therefore, it may be possible
to increase the differentiation of CML progenitor cells by the addition of rHu-G-
CSF in vitro or in vivo to force quiescent cells to enter the cell cycle. In effect, is it
possible to eradicate CML by forcing all the quiescent CML stem cells to
proliferate, differentiate and lose their stem cell properties?
If this hypothesis is correct, it may be possible to induce cell cycle activation in 
quiescent CML stem cells with rHu-G-CSF, thereby escaping the IM-insensitive 
quiescent state. Additionally, continuous IM resulted in accumulation of IM- 
insensitive quiescent CML stem cells in Go (Graham et al., 2002), so it may be 
possible to bring the cells back into cycle by interrupting IM therapy, a so called 
'IM holiday’. It is possible that combining these two approaches may be synergistic 
in eradicating quiescent CML stem cells. Thus, by inducing cell cycle activation 
with rHu-G-CSF and/or interruption of IM therapy, the aim is to reverse quiescence 
and sensitise cells to IM, thereby eliminating disease.
1.3.2 The rationale for using potent dual SRC/BCR-ABL TKIs
A significant minority of patients, particularly those with advanced disease become 
resistant to IM through the development of BCR-ABL kinase domain mutations 
which interfere with the binding of IM to the ATP binding pocket of BCR-ABL 
(Gorre et al., 2001; Branford et al., 2002; Shah et al., 2002; von Bubnoff et al., 
2002; Branford et al., 2003). In addition, the mechanisms which contribute to the 
molecular persistence present in CML patients after treatment with IM are unclear 
(Hughes et al., 2003; Branford et al., 2004). Therefore, there is a requirement for 
the development of new agents which are more powerful inhibitors of BCR-ABL 
and bind to BCR-ABL regardless of conformational status, reducing the likelihood
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of developing resistance. A new generation of combined SRC/BCR-ABL kinase
inhibitors that do not appear to be conformation sensitive and are at least 10-20-
fold more potent than IM are now available (Nagar et al., 2002). These novel
agents are active against many of the frequently observed kinase domain
mutations that cause resistance towards IM (von Bubnoff et al., 2003). Dasatinib
(Sprycel™; formerly BMS-354825, manufactured by Bristol-Myers Squibb,
Princeton, NJ, USA) is one such agent and was the first of these compounds to
enter clinical trials in Ph"" leukaemias. The structure of dasatinib is shown in
Figure 1-9.
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Figure 1-9. Structure of dasatinib (SpryceF"; formerly BMS-354825).
1.3.2.1 Dasatinib
Dasatinib was selected from a panel of substituted 2-(aminopyridyl) and 2- 
(aminopyrimidinyl) thiazole-5-carboxamides which were all shown to have 
substantial anti-proliferative activity against haematological and solid tumour cell 
lines, including the BC CML cell line K562 (Lombardo et al., 2004). Dasatinib was 
chosen on the basis of broad-spectrum anti-proliferative activity and suitable 
circulating plasma levels following oral dosing in a mouse screening assay with 
only moderate plasma protein interactions and maintained blood levels. Three- 
dimensional X-ray crystallography studies showed that ABL kinase complexed 
with dasatinib in an active conformation with the presence of three hydrogen 
bonds between dasatinib and ABL (Lombardo et al., 2004). These specific 
hydrogen bonds between dasatinib and ABL may account for the activity of
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dasatinib against mutant BCR-ABL kinases (except T315I). A similar pattern of
binding was observed between dasatinib and SRC kinases.
A kinase selectivity panel showed that dasatinib was a potent competitive inhibitor 
of ATP binding to SRC (IC50 ~0.5nM) and BCR-ABL (IC50 < lOnM) as well as 
PDGF-R-p (IC50 28nM) and c-KIT (IC50 6nM)(Lombardo et al., 2004). (n vivo 
activity against wild-type BCR-ABL was evaluated using a K562 xenograft assay in 
nude mice (Lombardo et al., 2004). After the establishment of detectable tumour 
burden, daily treatment with dasatinib resulted in complete disappearance of 
tumour cells with no observed toxicity in the animals, showing, for the first time the 
potency of dasatinib in vivo and the favourable toxicity profile, at least in animal 
models of CML.
Further in vitro and in vivo experiments were undertaken to determine the efficacy 
of dasatinib in overcoming IM resistance caused by BCR-ABL kinase domain 
mutations (Shah et al., 2004). Firstly, using a cell-based assay, this study 
confirmed that dasatinib was more effective than IM at inhibiting wild-type BCR- 
ABL. Further cell-based assays using the murine pro-B cell line Ba/F3 which had 
been engineered to express different clinically significant mutant BCR-ABL 
kinases showed BCR-ABL inhibition and suppression of growth when dasatinib 
was used in the low nM range. Interestingly, even within this very low 
concentration range, there were differences in the sensitivities of selected BCR- 
ABL mutants (Shah et al., 2004; O'Hare et al., 2005). However, the T315I 
expressing Ba/F3 cell line was resistant to dasatinib, even in the pM range.
To assess therapeutic potential of dasatinib in IM-resistant Ph"^  leukaemias, SCID 
mice were inoculated with Ba/F3 cells expressing different BCR-ABL kinase 
mutations (Shah et al., 2004). Assessment of BCR-ABL activity by determination
Mhairi Copland, 2007 Chapter 1, 64
of CrKL phosphorylation status on splenocyte lysates from the affected mice
showed inhibition of CrKL phosphorylation for up to seven hours after
administration of dasatinib. Another cohort of mice were treated with dasatinib for
two weeks beginning three days after inoculation with Ba/F3 cells. The untreated
control mice developed progressive disease as did those treated with dasatinib but
inoculated with cells containing the T315I mutation. However, mice inoculated with
cells expressing wild-type BCR-ABL or the IM-resistant mutant M351T remained
healthy. Further in vitro studies using human bone marrow progenitor cells were
undertaken to further assess the efficacy and safety of dasatinib. Dasatinib at a
concentration of 5nM failed to inhibit the growth of CFCs from healthy donors.
However, CFCs were inhibited by 60-80% in bone marrow progenitor cells taken
from patients with either wild-type or mutant BCR-ABL (Shah et al., 2004). Based
on the results of these studies, it was hypothesised that a significant number of
patients with IM-resistant Ph"" leukaemias would benefit from dasatinib if it could
be given safely in the low nM range. Thereafter, dasatinib progressed rapidly to
clinical trial.
Other dual SRC/BCR-ABL kinase inhibitors including PD173955, PD166326 and 
SKI-606 have been shown to be potent at picomolar concentrations in both cell 
line (Nagar et al., 2002; Golas et al., 2003; Huron et al., 2003; von Bubnoff et al., 
2003; Konig et al., 2006) and animal models (Golas et al., 2003; Wolff et al.,
2003). In addition, newer agents such as INNO-406, a BCR-ABL/LYN TKI are 
currently under evaluation (Kimura et al., 2005; Yokota et al., 2006). However, as 
yet, only SKI-606 and INNO-406 have entered phase 1 clinical trials (Cortes et al., 
2006).
The results of a Phase 1 dose-escalation study using dasatinib in patients with Ph"" 
leukaemias who had either IM-resistance or IM-intolerance have recently been
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published (Talpaz et ai., 2006). Dasatinib was administered orally at doses of 15 to
240mg per day in monthly treatment cycles. Thirty seven of 40 patients (92.5%)
with CP CML achieved a CHR, and a major haematologic response (< 5% blasts)
was seen in 31 of 44 patients (70%) with advanced disease (AP, BC or Ph"’ ALL).
The MCR rate was 45% in CP and 25% in advanced disease. These responses
were sustained in 95% of CP patients and 82% of AP patients. However, nearly all
patients with lymphoid BC or Ph"^  ALL relapsed within six months. The main side
effects seen were reversible myelosuppression, pericardial effusion, and oedema.
Dasatinib is currently completing Phase 2 clinical trials (Guilhot et al., 2005;
Hochhaus et al., 2005; Ottmann et al., 2005; Talpaz et al., 2005) and has recently
been licensed for use in the UK and the US.
Another agent also in clinical trials in IM-resistant Ph"" leukaemias is nilotinib 
(Tasigna™; formerly AMN107, manufactured by Novartis). Nilotinib is a rationally 
designed selective inhibitor of BCR-ABL, which was based on the crystal structure 
of the ABL kinase domain in complex with IM (Weisberg et al., 2005). In vitro, 
nilotinib is approximately 20-fold more potent than IM against wild-type BCR-ABL 
and is also effective against the majority of BCR-ABL kinase domain mutations 
(except T315I) (O'Hare et al., 2005). In a phase 1 dose-escalation study, nilotinib 
was active in IM-resistant CML with a reasonable safety profile (Kantarjian et al., 
2006). The commonest side effects were rash, gastrointestinal disturbances, 
hyperbilirubinaemia and reversible myelosuppression.
While dasatinib and nilotinib are effective against the majority of BCR-ABL kinase 
mutations, their major limitation is the inability to target the relatively common 
mutation T315I which is increasingly being seen (Shah et al., 2002), particularly in 
advanced disease. The small molecule aurora kinase inhibitor MK-0457 (VX-680; 
manufactured by Merck and Co., Inc, Blue Bell, PA, USA) has in vitro activity
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against cells expressing wild type and mutant BCR-ABL including T315I (Giles et
al., 2006) and has been shown to block cell cycle progression and inhibit
apoptosis in different human tumours (Harrington et al., 2004). Aurora kinases are
essential for the regulation of mitotic chromosome separation and cytokinesis. In
addition, MK-0457 has been used in three patients with Ph"" leukaemias
associated with the T315I mutation (Giles et al., 2006). All three patients had
clinical responses and no significant adverse events were reported, providing the
first observation of response in patients with T315I mutations. Clinical trials with
MK-0457 in patients with T315I mutations are currently underway.
1.3.2.2 The role of SRC kinases in normal haemopoiesis
The SRC kinases are a family of eight non-receptor protein tyrosine kinases (SRC, 
LYN, HCK, LCK, FYN, BLK, FGR and YES) which are expressed in haemopoietic 
and non-haemopoietic cells (Korade-Mirnics and Corey, 2000). SRC kinases are 
involved in a range of cellular processes including cell migration, adhesion, 
proliferation, survival, DNA synthesis, the cell cycle and phagocytosis. These 
responses are mediated via the Ras, PI3K and focal adhesion kinase (FAK) 
pathways. SRC kinase activity is modulated by post-translational changes in 
phosphorylation status and ubiquitination (Oda et al., 1999). The SHI domain of 
SRC molecules forms the catalytic domain, consisting of -250 amino acids at the 
carboxy terminus. Within the catalytic domain are a positive autophosphorylation 
site (Y416) which becomes phosphorylated during enzyme activation and a 
negative autophosphorylation site (Y527) which negatively regulates tyrosine 
kinase activity (Cooper and Howell, 1993). Dephosphorylation of Y527 results in a 
conformational change, increasing enzyme autophosphorylation and kinase 
activity.
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LYN, HCK and FGR are the SRC kinases which have been shown to be
expressed in myeloid cells (Korade-Mirnics and Corey, 2000). In myeloid cell
development, SRC kinases promote growth factor-dependent cell cycle
progression, and the presence of LYN has been described as being necessary for
induction of DNA synthesis and hence proliferation by G-CSF in haemopoietic
cells (Corey et al., 1998). In addition, SRC kinases may also contribute to the
differentiation of myeloid cells, improve neutrophil adhesion and migration,
increase phagocytosis and prolong survival by preventing apoptosis (Korade-
Mirnics and Corey, 2000).
1.3.2.3 Evidence for abnormal function of SRC kinases in CML
SRC kinases play a major role in the development, growth, progression and 
metastasis of a range of human cancers (Frame, 2002) and increased SRC kinase 
activity and protein expression have been demonstrated in a variety of cancer 
types including colon, breast, pancreas, lung and brain. SRC kinases affect signal 
transduction through a number of oncogenic mechanisms including EGF-R, 
Her2/neu, PDGF-R, FGF-R and VEGF-R. Therefore it would be anticipated that 
inhibiting SRC kinase activity would be effective at blocking the abnormal 
pathways that stimulate oncogenic transformation of cells.
The first evidence for the activation for SRC kinases in leukaemia came from a 
study which showed that LYN was specifically activated in myeloid leukaemia cell 
lines in response to IL-3 (Torigoe et al., 1992), indicating that LYN may be 
important in IL-3 signalling cascades, at least, in some myeloid leukaemias. A later 
study demonstrated that proliferation of the myeloid leukaemia cell line M07e in 
response to GM-CSF was decreased by a LYN antisense oligonucleotide or 
culture in the presence of the TKI PD166285 (Roginskaya et al., 1999). More
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pertinent was a study which showed that the SRC kinases LYN and HCK were
activated in a number of cell lines expressing (Danhauser-RiedI et a!.,
1996).
In normal haemopoiesis, CXCR-4, the G protein-coupled receptor of stromal- 
derived factor (SDF)-I, stimulates LYN and activates the PI3K pathway with 
effects on cell motility and migration. It has been demonstrated that binding of 
phosphorylated BCR-ABL to LYN results in constitutive activation of LYN and 
PI3K. In addition, these kinases become completely unresponsive to SDF-1 in the 
presence of phosphorylated BCR-ABL (Ptasznik et al., 2002). Moreover, inhibition 
of BCR-ABL with IM restored the regulation of LYN by SDF-1. This highlights a 
LYN-dependent mechanism via which BCR-ABL disrupts G protein-coupled 
receptor signalling and function and indicates that BCR-ABL disrupts normal LYN 
function, altering chemokine signalling and chemotaxis, resulting in altered cell 
motility and migration. Further studies have reported that in vitro, the IM-resistant 
cell line, K562-R, displays BCR-ABL independence in association with over­
expression of LYN kinase (Donato et al., 2003). In addition, samples taken from 
patients with advanced phase CML who became IM-resistant showed similar 
levels of LYN kinase expression to the K562-R cell line (Donato et al., 2003). Up- 
regulation of BCL-2 by LYN has also been implicated as a potential mechanism of 
BCR-ABL-independent resistance in CML (Dai et al., 2004), although this study 
was conducted in cell lines only and may have been flawed as the phosphorylated 
LYN antibody used was targeted against the negative regulatory site (Y507) and 
not the activation site (Y411). These studies suggest that, in some cases, acquired 
IM-resistance may be associated with BCR-ABL independence and increased 
expression of additional tyrosine kinases, resulting in up-regulation of downstream 
signal transduction pathways.
Mhairi Copland, 2007 Chapter 1, 69
HCK has also been implicated in the signalling pathways downstream of BCR-
ABL. HCK is activated by BCR-ABL and studies have shown that the growth factor
independence exhibited by BCR-ABL"’ cell lines is suppressed by a kinase-
defective HCK (Lionberger et al., 2000). More recently, HCK has been implicated
in a novel BCR-ABL-HCK-STAT5 signalling pathway, involved in transformation of
myeloid cells by BCR-ABL (Klejman et al., 2002).
Taken together, these results indicate that SRC kinases are likely to be important 
in modulating signal transduction pathways downstream of BCR-ABL. In addition, 
there is evidence that activation of SRC kinases may result in BCR-ABL- 
independent IM-resistance in some patients. Therefore, dasatinib, which is 325 
times more potent than IM at inhibiting BCR-ABL and also has the ability to inhibit 
SRC kinases may be useful for targeting quiescent CML stem cells.
1.3.3 The rationale for combining IM with other chemotherapeutic 
agents
To date, a wide range of conventional and novel agents (e.g. hydroxycarbamide, 
Ara-C, IFN-a, arsenic trioxide and FTIs) have been combined with IM in vitro to 
overcome IM resistance and eliminate CML cells (La Rosee et al., 2002; Topaly et 
al., 2002; Druker, 2003). The majority of in vitro data come from experiments with 
CML cell lines and not primary CML cells. Many of these studies showed 
significant in vitro responses in proliferating cells, however, they did not target the 
IM-insensitive quiescent stem cell population. Although many of these studies 
have been informative, none have addressed cytotoxicity at the stem cell level. A 
recent study (Jorgensen et al., 2005a) showed that many drug combinations 
inducing apoptosis in CML cell lines were ineffective in primary CML cells and, 
indeed, there was a trend towards further accumulation of quiescent stem cells in 
response to combination therapy. Indeed, in this study by Jorgenson et al
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(Jorgensen et al., 2005a), the only combination to show superiority to IM alone on
the quiescent stem cell population was the combination of IM with the FTl
lonafarnib (formerly SCH66336; Schering-Plough, Kenilworth, NJ, USA), however,
the results failed to reach statistical significance. Farnesyltransferase inhibitors
have been used extensively in clinical trials of myeloid leukaemias including CML.
Interestingly, a novel cytotoxic FTl, BMS-214662, has been described which has
activity against non-proliferating cells in vitro (Lee et al., 2001).
1.3.3.1 The mode of action of FTIs
A critical pathway activated by BCR-ABL is the Ras pathway, and although not 
fully specific for Ras, a range of FTIs have been developed which inhibit Ras. The 
FTIs are also potent inhibitors of MDR1 (Wang et al., 2001). The signalling 
functions of both normal and oncogenic Ras are dependent on the membrane 
association of Ras which is achieved by post-translational processing of cytosolic 
Ras and involves three enzymatic steps. Firstly, there is farnesylation of a cysteine 
four residues from the C-terminus; secondly, hydrolysis of the C-terminal 
tripeptide; and, thirdly, methyl estérification of the new C-terminal farnesylcysteine 
(Hunt et al., 2000). The key step in this process is the farnesylation of Ras by the 
enzyme FT and, based on this finding, a number of FTIs have been developed for 
clinical use because, although Ras undergoes a number of post-translational 
modification steps, only farnesylation is necessary for membrane localisation and 
cell-transforming activity (Heimbrook and Oliff, 1998). In addition to Ras, a number 
of other intracellular proteins are substrates for prénylation by FT including RhoB, 
Rac and lamin (Rowinsky et al., 1999). In CML, the importance of Ras is as an 
obligatory signalling molecule downstream of BCR-ABL, and inhibitors of Ras may 
have potent anti-proliferative effects.
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Ras proteins exist in the farnesylated form only in the absence of FTIs. The
isoforms K-Ras and N-Ras, but not H-Ras, undergo geranylgeranylation when
farnesylation is inhibited resulting in failure to completely inhibit Ras processing
and it is hypothesised that the K-Ras resistance to FTIs explains the failure to
inhibit growth or induce significant toxicity in normal cells as well as the relatively
poor responses achieved in solid tumours (Reuter et al., 2000; Daley, 2003).
Treatment of Ras transformed cells with FTIs selectively inhibits Ras-dependent
signalling, including Ras processing resulting in the accumulation of unprenylated
(inactive) Ras and inhibition of the Ras-Raf-MEK-ERK pathway.
However, the observed anti-tumour effects of FTIs are not solely due to Ras 
inhibition as these agents are also effective in Ras'^ "^ and Ras mutant cells 
(Nagasu et al., 1995; Sepp-Lorenzino et al., 1995; End et al., 2001; Rose et al., 
2001); they may also act by inhibiting farnesylation of other proteins (Cox and Der, 
1997; Lebowitz and Prendergast, 1998; Ashar et al., 2000; Prendergast and Rane, 
2001); (Discussion 7.3). In addition, FTIs have also demonstrated preclinical 
activity in the treatment of eukaryotic pathogens such as plasmodium falciparum 
and trypanosomiasis brucei by inhibition of FT (Eastman et al., 2006). They may 
also have a role in the treatment of the Hutchinson-Gilford progeria syndrome 
which has recently been found to be associated with accumulation of an abnormal 
farnesylated form of prelamin A (Young et al., 2006). However, FTIs have yet to 
enter clinical trial for treatment of these conditions.
1.3.3.2 The use of FTis in CML
Research has shown that lonafarnib inhibits the proliferation of IM-sensitive and 
resistant BCR-ABL"" cell lines (Peters et al., 2001a; Hoover et al., 2002), is active 
against BCR-ABL-induced murine leukaemia (Peters et al., 2001a) and
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suppresses haemopoietic colony formation from peripheral blood samples of CML
patients resistant to IM (Hoover et al., 2002). In addition, lonafarnib enhances IM-
induced apoptosis in IM-sensitive cells (Hoover et al., 2002; Nakajima et al., 2003)
and, in patients with IM-resistance due to gene amplification cooperates with IM to
induce apoptosis (Hoover et ai., 2002). Tipifarnib (ZARNESTRA™; formerly
R115777; Johnson and Johnson, Titusville, NJ, USA), another FTl in clinical use,
has also been shown to act synergistically with IM to increase apoptosis and
induce cell cycle arrest in BCR-ABL"* cell lines (Miyoshi et al., 2005). However, in
this study the problem of persistence of Gi arrested leukaemia cells was
highlighted as a potential barrier to the complete eradication of disease. In some
cell lines (KCL22 and KCL22/SR) there was accumulation of cells in Gq/G i ;
however, other cell lines (K562, K562SR, KU812 and KU812SR) showed a
decrease in Gq/Gi cells after treatment with IM plus tipifarnib, and it was
hypothesised that apoptosis of these cells occurred before cell cycle arrest.
Phase 1 clinical trials of tipifarnib as a single agent have been conducted in CML 
(Cortes et al., 2003; Gotlib et al., 2003). In the first study of 22 patients with CML, 
7 (6 CP and 1 AP) achieved a complete or partial haematologic response with 4 of 
these achieving a mCR (Cortes et al., 2003). However, the responses were 
transient with a median duration of 9 weeks. In the second study, of the 12 
patients (11 AP and 1 BC) recruited, only 6 were evaluable at the time of interim 
analysis and of these, 3 had a haematological response (Gotlib et al., 2003). 
Therefore, tipifarnib was well tolerated and demonstrated moderate efficacy in IM- 
resistant patients. A pilot study has also demonstrated the safety and modest 
efficacy of lonafarnib as a single agent in IM-resistant CML (Cortes et al., 2002). 
More recently, studies combining both tipifarnib and lonafarnib with IM after failure 
of IM therapy demonstrated efficacy and a tolerable safety profile (Cortes et al., 
2004a; Cortes et al., 2004c). However, the only data available on these studies
Mhairi Copland, 2007 Chapter 1, 73
are interim analyses and final results remain unpublished. Nonetheless, taken as a
group, these studies provide a rationale for examining other, more potent FTIs to
treat IM-resistant CIVIL and attempt to eradicate the quiescent CIVIL stem cell
population.
1.3.3.3 BMS-214662
BMS-214662 (manufactured by Bristol-Myers Squibb) is an atypical non- 
peptidomimetic FTI with a benzodiazepine core (Hunt et a!., 2000) which inhibits 
H-Ras and K-Ras in the low nM range and is approximately 1000-fold selective for 
FT compared to GGT 1 (Rose et al., 2001). Figure 1-10 details the structure of 
BMS-214662.
Figure 1-10. The structure of BMS-214662.
In preliminary experiments (Rose et at., 2001), BMS-214662 demonstrated 
efficacy against a range of tumour cell lines in vitro including the BC CML cell line 
K562 (ICso 160nM using an in vitro cytotoxicity assay). In vivo studies using a nude 
mouse human tumour xenograft model demonstrated that BMS-214662 had 
curative potential in a range of human tumours including colon, pancreas, lung and 
bladder carcinoma (Hunt et al., 2000; Rose et al., 2001). More recently, BMS- 
214662 has also shown activity in the haemopoietic disorders myeloma, chronic 
lymphocytic leukaemia (CLL) and AML (Marzo et al., 2004; Cortes et al., 2005a;
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Gomez-Benito et al., 2005). Very interestingly and pertinent to this project, BMS-
214662 was also shown to preferentially target non-proliferating (quiescent) cells
in solid tumour models in vitro (Lee et al., 2001). This study demonstrated that
BMS-214662 was 20 times more potent in quiescent compared to proliferating
cells from five different solid tumour cell lines. Based on these results, two
potential therapeutic strategies incorporating BMS-214662 were investigated in
vivo in animal models. In the first of these, BMS-214662 was combined with the
chemotherapeutic agents, paclitaxel and epothilone, that preferentially kill
proliferating cells and in the second, BMS-214662 was combined with manoeuvres
to induce tumour cell quiescence such as tamoxifen in oestrogen-dependent
breast cancer and surgical castration in androgen-dependent prostate cancer (Lee
et al., 2001). Both strategies demonstrated synergy with BMS-214662 and
significantly improved response and based on these findings, BMS-214662 was
entered into clinical trials in solid tumours alone and in combination with other
chemotherapeutic agents.
A number of Phase 1 dose-escalation clinical trials have been conducted in solid 
tumours with BMS-214662 given as a single agent for either 1 hour or 24 hours by 
intravenous infusion (Ryan et al., 2004; Papadimitrakopoulou et al., 2005; 
Tabernero et al., 2005; Eder et al., 2006). The commonest side effects reported in 
these studies were gastrointestinal disturbances, elevated liver transaminases, 
renal toxicity, fatigue, electrolyte imbalances and myelosuppression. However, 
disappointingly, despite reaching the maximum tolerated dose in all four studies, 
only one study demonstrated clinical benefit (Tabernero et al., 2005), and this was 
only in a minority of patients (5 of 31). However, the patients recruited to these 
studies had already failed standard treatments and in many cases had received 
multiple chemotherapy regimens.
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Further Phase 1 studies were undertaken in which BMS-214662 was combined
with either cispiatin or carboplatin and paclitaxel (Mackay et al., 2004; Dy et al.,
2005). In combination with cispiatin, there were no objective responses, however
disease stabilisation was observed in 15 of 29 patients over several cycles of
treatment (Mackay et al., 2004). In combination with carboplatin and paclitaxel, 3
of 30 patients had a partial response and a further 8 had stable disease over
several months therapy (Dy et al., 2005). These combination studies using BMS-
214662 showed more promise than BMS-214662 as a single agent.
The only Phase 1 dose-escalation study undertaken in a bone marrow disorder 
used BMS-214662 as a single agent in patients with relapsed of refractory AML 
(n=19), ALL (n=3) or myelodysplastic syndrome (n=8)(Cortes et al., 2005a). Five 
of 30 patients had evidence of anti-leukaemic activity including 2 CHR (with 
incomplete platelet recovery) and, of these, one had a cytogenetic response. The 
remaining 3 patients that responded had an incomplete response with reduced 
bone marrow blast counts.
Therefore, BMS-214662 has demonstrated activity in HSC disorders (Cortes et at., 
2005a) and appears to be more effective when used in combination with other 
therapies which target proliferating cells in solid tumours (Mackay et al., 2004; Dy 
et al., 2005). With in vitro evidence of activity against quiescent tumour cells (Lee 
et al., 2001), and the efficacy of other FTIs in combination with IM in CML (Cortes 
et al., 2004a; Cortes et al., 2004c; Jorgensen et al., 2005a), BMS-214662 
appeared a logical choice to assess in combination with IM or dasatinib. It was 
hypothesised that IM or dasatinib would target the proliferating CML cells and 
BMS-214662 the deeply quiescent and Gq/Gi arrested CML stem and progenitor 
cells.
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1.4 Aims
Experiments were designed to address the following aims:
1. To determine if pulsed IM is more effective than continuous IM at 
eliminating CD34^ CML stem cells in vitro;
2. To determine if the addition of rHu-G-CSF to either continuous or pulsed 
IM enhances the elimination of CD34^ CML stem cells in vitro;
3. To assess the efficacy of dasatinib compared to IM against CD34  ^CML 
cells and determine if dasatinib would eradicate quiescent CML stem 
cells in vitro;
4. To determine the relevance of SRC kinases and BCL-2 in CP CML;
5. To determine the efficacy of BMS-214662 alone and in combination with 
either IM or dasatinib on the quiescent CML stem cell population in vitro;
6. To assess the efficacy of BMS-214662 in BC CML, cell lines expressing 
BCR-ABL kinase mutations and AML in vitro.
These questions are dealt with sequentially within the relevant Results
Chapters. Each Results Chapter begins with a short introduction relevant to the
proceeding data and finishes with a summary of the findings. The discussion of
all the results and final conclusions is presented in a separate Discussion
Chapter (Chapter 7).
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Materials and Methods
2.1 Materials
2.1.1 Novel small molecule Inhibitors
Imatinib mesylate (MW 590) was provided as a white powder under a Materials 
Transfer Agreement from Novartis Pharma (Basel, Switzerland). It was dissolved 
in sterile H2O and stored as a lOOmM stock solution at 4°C. Dasatinib (MW 489), 
BMS-214662 (MW 488) and BMS-225975 (MW 570) were provided as white 
powders under a Materials Transfer Agreement by Bristol-Myers Squibb 
(Princeton, NJ, USA). Each compound was dissolved in dimethyl sulfoxide 
(DMSO) to give a stock concentration of lOmg/mL and stored in multiple aliquots 
at -20°C prior to use. PP2 in solution™’ (lOmM in DMSO) was purchased from 
Calbiochem, Merck Biosciences Ltd, Nottingham, UK and stored at -20°C. All 
small molecule inhibitors were made up fresh and diluted to the appropriate 
concentration with PBS prior to use.
2.1.2 Tissue culture supplies (including CD34^ selection)
Abbott Diagnostics 
Maidenhead, UK
LSI BCR-ABL Dual Colour FISH probe
Amersham Pharmacia Biotech Ltd 
Buckinghamshire, UK
Tritiated (^H) thymidine
Barloworld-Scientific 
Staffordshire, UK
Iwaki Type 1 Collagen coated 6-well 
plates
Baxter Healthcare 
Nottingham, UK
Sterile water
Becton Dickinson 
Plymouth, UK
Hypodermic needles 
Luer lock syringes
Bio-Rad
Hercules, CA, USA
Triton-X-100
Chugai Pharma 
London, UK
Recombinant human G-CSF (rHu-G- 
CSF)
Fisher Scientific 
Loughborough, UK
Acetic acid 
Methanol
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Greiner bio one 
Gloucestershire, UK
75cm^ tissue culture flasks 
96-well plates 
FACS tubes 
Pipette tips
Hendley 
Essex, UK
Multispot microscope slides
Invitrogen 
Paisley, UK
2-Mercaptoethanol
Colcemid
Foetal calf serum (FCS) 
L-glutamine 200mM (100X) 
PBS
Penicillin-streptomycin solution
5000u/mL
RPMI 1640 medium
Miltenyi Biotech 
Bisley, UK
CliniMACS CD34 reagent 
CliniMACS PBS/EDTA buffer 
CliniMACS tubing set
Nalge Nunc International 
Roskilde, Denmark
35mm non-adherent tissue culture 
dishes
75cm^ non-adherent tissue culture
flasks
Cryotubes
Cryofreezer container 
Vacu bottles
Perkin Elmer 
Turku, Finland
Filter mats 
Wax scintillant
Sartorius
Flannover, Germany
Minisart 0.2pM sterile filters
Scottish National Blood Transfusion
Service
Glasgow, UK
2 0 % human albumin solution 
4.5% human albumin solution (ALBA)
Sigma-Aldrich 
Dorset, UK
Ammonium chloride (NH4CI)
Bovine serum albumin (BSA)
Dimethyl suiphoxide (DMSO) 
Dulbecco's Modified Eagle Medium 
(DMEM)
G418 disulphate salt solution 
Hank's buffered salt solution -  calcium 
and magnesium free (HBSS-CMF) 
Hygromycin B
Iscove’s Modified Dulbecco’s Medium 
(IMDM)
Magnesium chloride (MgCL)
Poly-L-lysine
Potassium chloride (KCI)
Sodium azide 
Trisodium citrate 
Trypan blue 
Trypsin-EDTA
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Stem Cell Technologies 
British Columbia, Canada
Bovine pancreatic deoxyribonuclease 
(DNAse 1) 1mg/mL
Bovine serum albumin/insulin/transferrin 
(BIT) serum substitute 
Flt-3 ligand
Hydrocortisone 21-hemisuccinate 
Interleukin-3 (IL-3)
Interleukin-6 (IL-6)
Methocult™
Myelocult™
Stem cell factor (SCF)
Sterilin Ltd 
Hounslow, UK
Pastettes
5mL, 10mL and 25mL disposable 
pipettes
15 and 50mL sterile plastic falcon tubes 
90mm Petri dishes
2.1.3 Flow Cytometry reagents
Becton Dickinson 
Oxford, UK
7-aminoactinomycin D (7-AAD) 
FACS flow 
FACS clean
Human anti-active caspase-3-PE 
Human anti-BCL-2-FITC kit 
Human anti-CD34-PE 
Human anti-CD34-APC 
Human anti-CD38-PE 
Human anti-Ki-67-FITC kit 
IgG FITC isotype control 
IgG PE isotype control 
IgG PE-Cy5 isotype control 
IgG APC isotype control
Caltag Laboratories 
Silverstone, UK
Fix and Perm A and B
Molecular Probes 
Eugene, OR, USA
Carboxy-fluorescein diacetate 
succinimidyl diester (CFSE)
Sigma-Aldrich 
Dorset, UK
Anti-rabbit IgG-FITC conjugate 
Propidium iodide (PI) 
Formaldehyde
Upstate 
Dundee, UK
Human anti-p-Src family Alexa Fluor® 
488 (Y416)
2.1.4 Molecular biology supplies
Amersham Pharmacia Biotech Ltd 
Buckinghamshire, UK
ECL"^ Plus Western Blotting Detection 
Reagents
Hyperfilm™ ECL™ (Xray film)
Rainbow marker (RPN756)
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Bio-Rad
Hercules, CA, USA
4-15% Tris-HCl gradient gels 
Laemmli sample buffer 
Nitrocellulose membrane 
Tris/Glycine/SDS running buffer 
Tris/glycine transfer buffer 
Triton-X-100 
Tween
Calbiochem, Merck Biosciences Ltd 
Nottingham, UK
Phenoxymethylsulphonylfluoride
(PMSF)
Sodium orthovanadate
Cell Signalling, New England Biolabs 
Hitchin, UK
Anti-rabbit IgG horseradish peroxidase- 
linked secondary antibody 
Human anti-p-CrKL antibody (rabbit) 
Human anti-pan-actin antibody (rabbit) 
Human anti-Mcl-1 antibody (rabbit)
Chemicon International 
Temecula, CA, USA
Re-Blot"^ Plus Strong Antibody 
Stripping Solution
Fisher Scientific 
Loughborough, UK
Methanol
Perbio
Northumerland, UK
BCA kit
Sainsburys Supermarkets Ltd 
London, UK
Non-fat dry milk powder
Sigma-Aldrich 
Dorset, UK
0.1% Ponceau S solution 
Ethylenediaminetetraacetic acid (EDTA) 
NP-40
Protease inhibitor cocktail 
Sodium chloride 
Sodium deoxycholate 
Sodium fluoride
Tris (hydroxymethyl)aminomethane 
hydrochloride (Tris-HCl)
2.2 Preparation of media and solutions
2.2.1 Tissue culture media
2.2.1.1 RPWir
RPMI 1640 500mL
FCS 50mL
L-glutamine 5mL
Penicillin/streptomycin solution 5mL
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2.2.1.2 Serum free medium (SFM)
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BIT 25mL
L-glutamine 1.25mL
Penicillin/streptomycin solution 1.25mL
2-Mercaptoethanol 250pL
IMDM 97.25mL
Make up in a Vacu bottle and filter sterilise
2.2.1.3 Serum free medium supplemented with growth factor cocktail
(SFM + 5GF)
Serum free medium 50mL
IL-3 (50pg/mL) 20pL
IL-6 (50pg/mL) 20pL
G-CSF (50|jg/mL) 20pL
Flt-3 ligand (50pg/mL) 100pL
SCF (50pg/mL) 100pL
Filter sterilise through 0.22pM filter
2.2.1.4 RPMI for maintenance of stromal cell line M2-10B4 for LTC-IC
RPMI 1640 500mL
FCS 50mL
L-glutamine 10mL
Penicillin/streptomycin solution 10mL
2.2.1.5 DMEM for maintenance of genetically modified S I/S I fibroblast 
cell line for LTC-IC
DMEM 500mL
FCS 75mL
L-glutamine lOmL
Penicillin/streptomycin solution lOmL
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2.2.1.6 Myelocult
Chapter 2, 82
Myelocult™ lOOmL
Hydrocortisone hemisuccinate (1x10"^M) 1mL
2.2.1.7 RPMIA/VEHI medium for Ba/F3 cell lines
RPMI 500mL
WEHI-3B conditioned cell medium 50mL
PCS 10mL
L-glutamine 5mL
Penicillin/streptomycin solution 5mL
2.2.2 Tissue culture solutions
2.2.2.1 PBS/2% FCS
PBS 490mL
FCS iOmL
2.22.2 PBS/20% FCS
PBS 80mL
FCS 20mL
2.2 2.3 Ammonium chloride solution (lOx)
Ammonium chloride ( N H 4 C I ) 8.33g
Sterile water (dH2 0 ) lOOmL
Filter sterilise through 0.22pM filter
Dilute stock solution 1:10 with dHaO for lysis to give 1x strength
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22.2.4 ‘DAMP’ solution for thawing cryopreserved CD34^ or
unmanipulated cell aliquots from liquid nitrogen
DNAse 11 solution (1mg/mL) 1 vial
Magnesium chloride (400X; 1M) 625|jL
Trisodium citrate (0.155M) 26.5mL
Human serum albumin (20%) 12.5mL
PBS (magnesium/calcium free) 208mL
2.2.2.S 4.5% human albumin solution/20% DMSO
4.5% human albumin solution (ALBA) 80mL
DMSO 20mL
2.2.2.6 PBS/BSA/Azide
PBS 500mL
BSA 5g
Sodium azide 0.5g
2.2.2.7 IMDM/2% FCS
IMDM 98mL
PCS 2mL
2-2.3 Flow cytometry solutions
2.2.3.1 PBS/0.4% formaldehyde
PBS 48mL
1 0 % formaldehyde solution 2mL
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2.2.3.2 PBS/0.2% Triton-X-100
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PBS 50mL
Triton-X-100 lOOpL
2.2.4 Molecular biology solutions
2.2.4.1 Lysis buffer for protein lysates
CIH2O 7.75mL
1.6M NaCI ImL
1M Tris-HCl 0.5mL
150mM EDTA 333pL
NP-40 50pL
10%(w/v) Sodium deoxycholate 250|jL
Immediately prior to use, protease and phosphatase inhibitors 
below added
Protease inhibitor cocktail 100pL
PMSF 100pL
Sodium fluoride 20pL
Sodium orthovanadate 20pL
2.2.4.2 Running buffer
10X TGS buffer 1 0 0 m l
PBS 900pL
2.2.4.3 Transfer buffer
10X TG buffer 80mL
PBS 720ml
Methanol 2 0 0 m l
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2.2.4.4 Wash buffer
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PBS lOOOmL
Tween lOOjjL
2.2.4.S Blocking buffer
PBS lOOmL
Non-fat dry milk
Tween lOOpL
2.2.4.G Primary antibody buffer
PBS lOOmL
BSA 5g
Tween 1 0 0 |j L
2.3 Methods
2.3.1 Cell culture
2.3.1.1 Collection of primary CML samples
All samples (peripheral blood and leucapheresis material) were collected using 
written informed patient consent with approval from the Local Research and Ethics 
Committee. See Appendix 1 for the biological characteristics of the patients from 
whom the samples were collected.
2.3.1.2 Cell counting and assessment of cell viability
Cell counts and assessment of cell viability were performed using a 
haemocytometer with trypan blue exclusion. Trypan blue was diluted 1:10 with
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PBS and either 40 or 90pL of trypan blue was added to 10pL of cell suspension to
give a 1:5 or 1:10 dilution of cells. Eight microlitres of this mixture was transferred
to a haemocytometer and a minimum of 1 0 0  viable cells were counted with dark
blue-staining cells counted as non-viable. Further assessment of cell viability in
CD34^ CML cells after culture was performed using PI staining and FACS analysis
(Section 2.3.2).
2.3.1.3 Red cell lysis
Peripheral blood samples or, in some instances, leucapheresis collections 
required lysis of red blood cells. Red cell lysis was performed using 0.083% NH4CI 
solution at a ratio of 5mL sample to 45mL NH4CI at 37°C for 10 minutes. This step 
was repeated to ensure complete red cell lysis. After completion of red cell lysis, 
leucocytes were recovered by centrifugation (1000RPM for 10 minutes) and 
resuspended in either PBS/2%FCS or 4.5% ALBA, for cryopreservation or CD34^ 
selection.
2.3.1.4 Cryopreservation of cells
CD34^ selected cells, total MNCs from BC CML and AML samples and leukaemia 
cell lines were cryopreserved in liquid nitrogen until use. Briefly, 4x10® to 10® cells, 
as appropriate, were aliquoted into nunc cryotubes. To this cell suspension, an 
equal volume of 20% DMSO in 4.5% ALBA was added to give a final 
concentration of 10% DMSO. The cryotubes were transferred to a cryofreezer 
container and steadily cooled in isopropyl alcohol at -80°C before transfer to liquid 
nitrogen for long-term storage.
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2.3.1.5 Recovery of frozen samples
Cell vials were removed from liquid nitrogen and thawed immediately at 37°C in a 
water bath until all ice crystals had disappeared. Using a pastette, the cells were 
then placed in a 15mL sterile tube (1 tube per vial of cells) and DAMP solution was 
added dropwise over 20 minutes. This step was performed at room temperature to 
enhance the activity of the DNAse II, with frequent agitation of the tubes to prevent 
clumping of cells. The cells were then centrifuged at 1000RPM for 10 mins, the 
supernatant discarded, and the pellet loosened by flicking the tube. The cells were 
then washed a further twice in DAMP to ensure that all DMSO and cell debris had 
been removed from the sample. Following this, the cells were resuspended in 
PBS/2% FCS, and the cell count and viability were assessed.
2.3.1.6 CLINIMACS CD34^ cell selection
Samples were obtained from CML patients at diagnosis (n=22) who, as part of 
their initial clinical management, underwent leucapheresis to reduce the peripheral 
WCC and obtain CD34^ cells for potential use for an autologous SCT at the time of 
disease progression. Further samples were obtained from patients with normal 
bone marrow (n=5 ) undergoing autologous stem cell collection for either non- 
Hodgkin’s lymphoma or multiple myeloma who had been mobilised with rHu-G- 
CSF following chemotherapy and had excess CD34^ cells remaining after those 
required for clinical use had been processed. All leucapheresis procedures were 
performed using the Cobe Spectra continuous blood flow separator (Cobe 
Laboratories, Quedgeley, UK). Samples were processed using the CliniMACS 
clinical system for CD34^ cell selection within 24 hours of sample collection by 
either Dr Graham Templeton or Miss Ashley Hamilton according to the 
manufacturers’ instructions. Briefly, total MNC were incubated with specific anti-
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CD34 antibodies to which super-paramagnetic particles (~50nM in diameter) had
been conjugated. This cell suspension was then exposed to a high-gradient
magnet separation column and the CD34'" cell-antibody-particle complex was
captured and retained by the column. The CD34" cells which had not bound to the
antibody-particle complex were not retained and were eluted with the waste. The
retained CD34^ cells were then eluted and collected by removing the magnetic
field from around the column. The collected CD34^ cells were then made up to a
concentration of 1x10^/mL to 1x10®/mL with 4.5% ALBA and placed on ice prior to
cryopreservation. After CD34^ selection was completed an aliquot (-5x10'^ cells)
was removed for flow cytometry assessment of CD34 purity and confirmed that,
post-selection, all samples were >95% CD34^. Figure 2-1 shows an example of
CD34 purity of a patient sample before and after CliniMACS CD34^ cell selection.
An additional sample of 1x10® cells was removed for BCR-ABL assessment by
FISH.
OCOCO
1.5%CD34
10^  10
98% CD34+
10^ 1q3 10^
CD34PE
Figure 2-1. An example of flow cytometry dot plots of CD34 purity before (in the left panel, 
with CD34^ population highlighted) and after (right panel) CliniMACS CD34* cell selection. 
SSC-H, side scatter.
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2.3.1.7 CFSE staining
After recovery from liquid nitrogen and assessment of cell count and viability, 
CD34^ CML cells were stained with 1pM CFSE according to previously described 
methods (Nordon et al., 1997; Holyoake et ai., 1999; Graham et al., 2002). Before 
CFSE staining, an aliquot (~10%) of the CD34^ cells was removed and set up in 
culture in SFM + 5GF as an unstained control. Carboxy-fluorescein diacetate 
succinimidyl diester is an intracellular stain fluorescent in FL1 by flow cytometry, 
the fluorescence intensity of which halves with each cell division. This allows high 
resolution tracking of cell division. Carboxy-fluorescein diacetate succinimidyl 
diester was dissolved in DMSO to a concentration of 5mM and stored in aliquots at 
-20°C. Prior to use, the CFSE was diluted to 500pM with PBS/2% FCS. Ten 
microlitres of this was then added to 5mL of cell solution to give a final 
concentration of IpM. The cells were then incubated in a water bath at 37°C for 10 
minutes exactly, after which the cells were removed and the CFSE was quenched 
by adding 10X volume of PBS/20% FCS. The cells were centrifuged at 1000RPM 
for 10 minutes and then washed once in PBS/2% FCS. The cells were then 
cultured overnight in lOmL SFM + 5GF in large non-adherent (75cm®) tissue 
culture flasks (1-2x10^ CD34^ cells/flask) at 37°C, 5% CO2. The following morning 
the CFSE-stained CD34^ cells were removed from the tissue culture flask and 
placed into a sterile tube. The flask was then washed out with PBS/2% FCS and 
this was also added to the tube. The cells were then centrifuged at 1000RPM for 
10 minutes and washed again in PBS/2% FCS. Following this, the CFSE-stained 
cells were resuspended in PBS/2% FCS and the cell count and viability were 
determined. An aliquot of cells (-2x10"^) was removed for flow cytometry to assess 
the position of the undivided (CFSE"^®  ^ CD34^) cell population prior to culture in 
the different treatment conditions and an example of this is shown in Figure 2-2 
For each experiment, a colcemid control was set up using CFSE-stained cells to
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determine the position of the undivided peak after culture. The colcemid
stock (2mg/mL) was diluted 1:100 with PBS and then filter sterilised. Ten 
microlitres of this was added per mL of tissue culture medium in the colcemid 
control to give a final concentration of 200ng/mL.
o
o
CO T-
o -
o
CFSE
Figure 2-2. Representative FACS dot plot showing the position of the baseline undivided 
QPggmax QP3 4 + Q0 || population following overnight culture after staining with CFSE.
2.3.1.8 Culture of cell lines
The BC CML cell line K562 (BCR-ABL^) and the AML cell line HL60 (BCR-ABL ), 
which were both available 'in-house', were cultured in RPMI^^ in tissue culture 
flasks. The cells were counted and medium changed every 48 to 72 hours to 
maintain the cell concentration between 0.4 and 1.2x10^ cells/mL. Ba/F3 cells 
containing wild-type or BCR-ABL with kinase domain mutations (T315I, M351T 
and H396P) were kindly provided under a Materials Transfer Agreement by 
Professor Brian Druker, Oregon Health Sciences University, Portland, Oregon, 
USA and Professor Junia Melo, Imperial College, London, UK. The cells were 
maintained in RPMIAA/EHI medium which contained IL-3 from the WEH1-3B cells. 
The cells were counted and medium changed every 96 hours to maintain the cell 
concentration at -IxlO^/mL.
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2.3.1.9 Culture of CD34^ cells
After either recovery from liquid nitrogen or CFSE staining, cells were cultured in 
SFM + 5GF in 35mm suspension dishes at an initial cell concentration of 
-5x10^/mL for 3 to 12 days at 37°C, 5% CO2. The exception to this were the 
experiments using CD34^ CML cells in Chapter 3, in which the cells were cultured 
in SFM only, to which an appropriate concentration of rHu-G-CSF was added. 
Drugs were added to each experiment as appropriate to the described conditions. 
The cells were harvested every 72 to 96 hours depending on the cycle length in 
each experiment, washed in PBS/2% FCS, and aliquots were removed for 
performing a cell count and FACS analysis. The remaining cells were re-set up in 
culture according to the conditions described in each experiment and drug was 
added as appropriate. At the end of the final cycle of each experiment, as well as 
performing a cell count and FACS analysis, an aliquot of cells was prepared for 
FISH to determine if the cells remaining after culture were BCR-ABL^.
2.3.1.10 Long-term culture-initiating ceii assay (LTC-iC)
Primitive haemopoietic cells with proliferative potential can be maintained in 
culture for extended periods of time, typically several months. These culture 
conditions have been called long-term bone marrow culture (LTBMC; (Coulombel 
et al., 1983a). Briefly, LTBMC requires the formation of a supportive stromal layer 
which supplies the necessary microenvironment to allow the primitive 
haemopoietic cells to proliferate over time. An application of LTBMC is an assay 
that measures the number of LTC-IC (Sutherland et al., 1991; Hogge et al., 1996). 
In this assay, the cells of interest are overlayed on pre-established, irradiated 
stromal layers. After 5 weeks culture the contents of each plate are set up in a 
committed progenitor assay for a further two weeks. At the end of this time, the
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number of colonies formed is counted and this allows the frequency of LTC-IC to
be determined. Figure 2-3 shows a simplified schematic diagram for the method
used in the LTC-IC assay.
 ^ Cells cultured 
with drug for 72h 
SFM + 5GF /
Feeder cells 
established (M2- 
10B4) and then 
Irradiated
Cells remaining 
after 72h Rx 
added to feeder 
layers
Cultures maintained 
with weekly % 
medium changes for 
5 weeks
^  Remaining cells 
 ^ harvested and plated 
Into methylcellulose
Total number of 
colonies counted 
after 14-16 days
Figure 2-3. Simplified schematic diagram for the method used to assess LTC-IC after culture 
of CD34* cells In different conditions.
Two genetically-modified murine fibroblast cell lines, M2-10B4 and 81/81 
fibroblasts (both kindly provided by the Terry Fox Laboratories, Vancouver, BC, 
Canada) were used to provide the stromal support necessary for the LTC-IC. The 
M2-10B4 cells have been genetically modified to express G-C8 F and IL-3, and 
81/81 fibroblasts 8 CF and IL-3. After thawing, these cell lines were maintained in 
culture at 37°C, 5% CO2. The cells were trypsinised and passaged when the 
monolayer was semi-confluent to allow propagation of sufficient cells for LTC-IC. 
To minimise the proliferation of untransduced wild-type cells, the cultures were fed 
on alternate weeks with hygromycin B (final concentration 62.5pg/mL for M2-10B4
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and 125ijg/mL for S1/S1 fibroblasts) and G418 (final concentration 400pg/mL for
M2-10B4 and 800|jg/mL for S1/S1 fibroblasts).
Before the stromal layers were seeded with the test cells, it was necessary to 
irradiate the stromal cells to render then incapable of proliferation. After irradiation, 
equal numbers of the stromal cells (M2-10B4 and S1/S1 fibroblasts) were 
resuspended in Myelocult™ myeloid long-term culture medium and then 
inoculated onto Collagen Type 1 coated 6 -well microtitre plates to facilitate stromal 
adherence. Over the next few days, these cells formed a monolayer onto which 
the test cells could be inoculated.
Prior to irradiation, the stromal layers were trypsinised and counted. A total of 
1.5x10® M2-10B4 and 1.5x10® SI/81 fibroblasts were required for each test well. 
The stromal cell layers were then irradiated at 80Gy. Following this, the M2-10B4 
cells and 81/81 fibroblasts were mixed and resuspended in Myelocult™ 
supplemented with hydrocortisone, to give a final cell concentration of 3x10®/mL. 
Two millilitres of this stromal cell suspension was then aliquoted into the wells of 
the Type 1 Collagen coated 6 -well plate. The plates were then incubated at 37°C, 
5% CO2. After the stromal layers had been incubated for 24 to 48 hours, the test 
cells, which were CD34^ CML cells treated under different drug conditions, were 
inoculated onto the stromal layers. Briefly, equal numbers of CD34^ CML cells 
were treated under the treatment condition described in Section 5.1.4. After 72 
hours culture, the remaining cells were washed in PBS/2% FCS and then 
resuspended in 310pL of PBS/2% FCS. Duplicate LTC-ICs were then set up with 
5, 25 and 125pL of treated CD34^ cell suspension. The cells were then incubated 
for 5 weeks at 37°C, 5% CO2. Every week, ImL of Myelocult™ medium was 
removed from each well and ImL of fresh Myelocult™ medium was added and this 
constituted a half medium change.
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At the end of 5 weeks culture, the LTC-IC were harvested and set up in committed
progenitor assays. For each LTC-IC culture well, the culture supernatant
(containing non-adherent cells) was pipetted into a sterile 15mL centrifuge tube
(harvest tube). Two millilitres of HBSS-CMF was added to remove any serum-
containing Myelocult™ medium and the plate swirled gently before the HBSS-CMF
was transferred to the harvest tube. One millilitre of trypsin-EDTA was then added
to each well and swirled gently at intervals until all the adherent cells had detached
(up to 5 minutes). Detachment was facilitated by repeatedly pipetting the trypsin-
EDTA over the surface of the well and this also helped generate a single cell
suspension. The supernatant was transferred to the harvest tube. Immediately,
2mL of IMDM/2% FCS was added to the LTC-IC well and swirled gently and then
transferred to the harvest tube. A further 2mL of HBSS-CML was added to the well
and swirled gently before being transferred to the harvest tube. The harvest tubes
were then centrifuged at 1000RPM for 10 minutes. Following this, the supernatant
was gently poured off and the cells resuspended in the remaining supernatant.
The volume of remaining cell suspension was recorded and a cell count
performed.
Duplicate committed progenitor assays were set up for each cell volume of each 
treatment condition at two different cell concentrations (1x10"  ^ and 2.5x1 
cells/mL). The appropriate volume of cell suspension for duplicate wells was 
added to 2mL of Methocult™ medium for committed progenitor assays. The cell 
suspension and Methocult™ medium were thoroughly mixed and ImL of this was 
aliquoted into a 35mm culture dish and then gently tapped so that the bottom of 
the dish was completely coated. The culture dishes were then incubated for 14 
days at 37°C, 5% CO2 and, at the end of this time, the number of viable colonies 
was counted in each dish and this allowed a comparison of the LTC-IC present in 
the different treatment conditions.
Mhairi Copland, 2007 Chapter 2, 95
2.3.1.11 Tritiated f  H) thymidine proliferation assays
Tritiated (®H) thymidine proliferation assays were performed to determine the IC50 
for the different small molecule inhibitors in cell lines and CD34^ CML cells. These 
experiments were performed in 96 well plates and each well contained 90pL of cell 
suspension and 10pL of drug (final volume 100pL). There were five replicates of 
each drug concentration per experiment. Cell lines were seeded at a cell 
concentration of 2x10® cells/mL in RPMT^ for K562 and HL60 cells and 
RPMIAA/EHI medium for the Ba/F3 cell lines. CD34^ cells were seeded at a cell 
concentration of 5x10® cel Is/m L in SFM only. Cell lines were cultured for 24 or 48 
hours and CD34^ cells for 72 hours prior to assessment of proliferation. Tritiated 
thymidine (37MBq per mL) was diluted 1:100 in medium and 20pL was added to 
each experimental condition 5 hours prior to reading the plate in the cell line 
experiments and 16 hours prior to reading the plate in the CD34^ cell experiments. 
Beta counting was performed according to the manufacturers' instructions. Briefly, 
the cells were harvested using a FilterMate Harvester (Perkin Elmer, Turku, 
Finland) onto a filter mat, wax scintillant was melted onto the filter mat ready for 
beta counting using the Micro beta TriLux (Perkin Elmer).
2.3.1.12 Dual-colour fluorescence in situ hybridisation (FISH)
Chronic myeloid leukaemia cells, pre- and post-culture, and colonies from LTC-IC 
experiments were assessed for the presence of BCR-ABL by FISH. Aliquots of at 
least 5000 cells were required. The CML cells or pooled colonies were firstly put 
into a 5mL FACS tube and washed in PBS/2%FCS. The cells were then 
resuspended in 500pL of hypotonic solution (0.075M potassium chloride), 
transferred to a 1.5mL eppendorf and incubated at room temperature for 20 
minutes. One hundred microlitres of freshly made fixative was added
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(methanol:acetlc acid [3:1]) and the cells incubated for a further 5 minutes at room
temperature. The cells were then centrifuged at 5000RPM for 5 minutes, the
supernatant removed and a further 500pL fixative added, the cells incubated for a
further 5 minutes and then centrifuged for 5 minutes. This step was repeated a
further twice. The cell pellet was finally resuspended in 50pL of fixative and then
stored at -20°C prior to further preparation for FISH.
Aliquots of 20pL of cell solution were placed in wells of a poly-L-lysine coated 
multispot microscope slide and air-dried overnight. If the cells had been stained 
with CFSE, this was bleached under a bright light prior to performing FISH. The 
prepared slides were stored at -20°C wrapped in parafilm until FISH was 
performed according to the manufacturers’ instructions using the LSI BCR-ABL 
Dual Fusion probe. Interphase nuclei were evaluated using a Leica fluorescent 
microscope with a triple-band pass filter for DAP I, Spectrum Orange and Spectrum 
Green. All FISH slides were prepared and scored by Mrs Elaine Allan.
2.3.2 Flow cytometry
Flow cytometry also called FACS is used to sort cells according to their 
fluorescence. A flow cytometer consists of one or more lasers for supplying 
excitation energy and a series of filters and detectors for measuring the resultant 
fluorescent emissions. A flow cytometer can also measure the size of a cell using 
forward-angle light scatter (FSC) and the granularity of a cell using side-angle light 
scatter (SSC). Thus, flow cytometry allows the characterisation of individual cells 
using fluorochrome-labelled antibodies.
2.3.2.1 Surface antibody staining
All antibodies were titrated so that the minimum concentration which gave reliable 
staining and clear separation of different cell populations was used. This was
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always less than the amount recommended by the manufacturer, thus reducing
cost and facilitating compensation when using multiple channel flow cytometry in
experiments. Prior to surface antibody staining, the cells were washed in PBS/2%
FCS. The cells were then resuspended in 200pL PBS/2% FCS and the
appropriate volume of antibody was used. The cells were then incubated in the
dark for 15 minutes and washed twice in PBS/2% FCS (1200RPM for 5 minutes).
If PI (Ipg/mL) was being used to exclude dead cells, IpL of this was added with
the final wash. The cells were then analysed by FACS immediately. Appropriate
isotype controls were included for all experiments. All FACS analysis was
performed using the FACSCalibur flow cytometer (Becton Dickinson) with
compensation set as required using log-linear scale.
2.3 2.2 Intracellular antibody staining
For cells requiring both surface and intracellular antibody staining, the surface 
staining was performed first. Propidium iodide could not be used in association 
with intracellular antibody staining. After surface staining, if appropriate, at least 
1x10® cells were resuspended in lOOpL of Fix and Perm® Medium A (fixation 
medium) and incubated for 15 minutes (in the dark if also surface antibody 
stained). The cells were then washed with PBS, the supernatant completely 
removed using a graduated pipette and the cell pellet resuspended in 50pL Fix 
and Perm® Medium B (permeabilisation medium). To this the appropriate volume 
of intracellular antibody was added (Bcl-2-FITC, p-Src Alexa Fluor® 488 or anti- 
active-caspase-PE) and the cells incubated for 45 minutes at room temperature in 
the dark. Finally the cells were washed twice in PBS (1200RPM for 5 minutes) 
prior to FACS analysis.
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Intracellular staining for CrKL phosphorylation was performed as above with the
following modifications (Hamilton et al., 2006). All washes were performed using
PBS/BSA/azide. After fixing with 100pL of Fix and Perm® Medium A, the cells
were permeabilised with 25pL of Fix and Perm® Medium B, to which 2.5pL of p-
CrKL antibody was added and the cell/antibody solution mixed by vortexing. The
cells were then incubated at room temperature for 40 minutes. The cells were then
washed twice and resuspended in 100pL PBS/BSA/azide to which 2pL of
secondary antibody (anti-rabbit IgG-FITC conjugate) was added. The cells were
then vortexed and incubated for a further 30 minutes at room temperature in the
dark, washed twice and then analysed immediately by flow cytometry using the
FACSCalibur.
The amount of p-CrKL in an untreated CML sample was assessed as the 
geometric mean fluorescence intensity (MFI) of the untreated CML sample minus 
the geometric MFI for P-CrKL of normal CD34^ cells (negative control). The p- 
CrKL status of drug treated samples was expressed as a percentage of the 
untreated control (100%). To compare the amount of p-SRC or BCL-2 in a CML 
versus normal cells at baseline, the following calculation was used:
p-SRC or BCL-2 = ([CML MFI - isotype MFI] / [normal MFI -  isotype MFI])*100%
As with p-CrKL, the amount of p-SRC or BCL-2 in drug treated samples was 
expressed as a percentage of the untreated control (1 0 0 %).
2.3.2.3 High resolution cell cycle analysis
Different culture and treatment conditions may alter progression of cells through 
the cell cycle. Therefore, it was important to determine the effects of the different 
treatment conditions on progression of CML cells though the cell cycle. High
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resolution cell cycle analysis was performed using the method described by
Jordan et al (Jordan et al., 1996) which combines staining using the nuclear
activation antigen Ki-67 (FITC) with 7-AAD staining of DMA. This method allows
discrimination between Go, G i and S/G2/M.
Approximately 1x10® cells were washed in PBS (1200RPM for 5 minutes), the 
supernatant discarded and then resuspended in SOOpL of PBS/0.4% formaldehyde 
for fixing and incubated for 30 minutes on ice. Following this, 500pL of PBS/0.2% 
Triton-X-100 was added to permeabilise the cells and the cells were then 
incubated overnight at 4°C. The following morning, the cells were washed once in 
PBS and then resuspended in ImL PBS. The cell suspension was then divided 
equally between two FACS tubes (SOOpL each) and either 20pL of Ki-67 FITC- 
labelled antibody or 20pL of FITC isotype control was added to the tubes. The 
cells were then vortexed and incubated for 40 minutes at room temperature in the 
dark. After one further wash, the cells were resuspended in ImL of PBS and 5pL 
of 7-AAD (Ipg/mL) was added and then incubated for at least 6  hours, but 
preferably overnight, at 4°C prior to FACS analysis. Before FACS analysis, the 
cells were washed once in PBS. Log-linear analysis was used in FL1 (Ki-67-FITC) 
and linear analysis on FL3 (7-AAD). To separate cells from debris, the cell 
population was gated on using FSC versus FL3. This gated cell population was 
then analysed in FL1 versus FL3 and this allowed calculation of the relative 
percentages of cells at each stage of the cell cycle. A minimum of 1 0 ,0 0 0  cell 
events were collected.
2.3.2.4 FACS for CFSE experiments
Carboxy-fluorescein diacetate succinimidyl diester stained cells were surface 
stained as described in Section 2.3.2.1. Flow cytometry analysis of CFSE-stained
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cells was performed at baseline to determine the position of the undivided peak
and confirm uniform staining of the cell population (which allowed resolution of the
peaks at subsequent analyses), and again at the time points stated for each set of
experiments. Isotype controls were used to correctly set the detectors so that the
negative isotype population was placed in the first log decade for each flow
cytometry channel. Propidium iodide staining in FL3 was used to identify the viable
cell population. CFSE and CD34 positive controls were then run and the
compensation adjusted. Because CFSE is a very bright fluorescent stain which
has substantial spectral overlap into other FACS channels, considerable levels of
compensation were required. To collect an adequate undivided CFSE^^ CD34^
cell population in each experimental condition, a minimum of 50,000 (and
preferably 1 0 0 ,0 0 0 ) cell events were collected.
Carboxy-fluorescein diacetate succinimidyl diester was also successfully 
combined with anti-active caspase-3-PE and CD34-APC to allow assessment of 
apoptosis in the undivided CD34^ cell population. Surface and intracellular 
antibody staining were carried out as described (Sections 2.3.2.1 and 2.3.2 2, 
respectively). As the cells were fixed and permeabilised, PI could not be used, and 
the viable cell population was gated on FSC versus SSC to exclude debris and cell 
aggregates.
2.3.2.5 Calculation of the undivided (CFSE"^ ^^ ) cell population
To determine the anti-proliferative effect of different treatment conditions and 
assess the size of the non-proliferating primitive progenitor population, the 
percentage recovery of viable CD34^ cells in the undivided population remaining 
after culture was assessed. At each analysis time point, the number of viable cells 
harvested from each culture condition was recorded, as was the percentage of
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CD34"' cells found in the undivided fraction (CFSE^^^ CD34" )^. Percentage
recovery of input cells in the undivided peak could then be calculated by dividing
the absolute number of CFSE^^^ CD34^ cells by the total number of input CD34^
cells and multiplying by 100%. This allowed direct comparison of different
treatment conditions on the non-proliferating primitive progenitor population.
2.3.3 Western blotting
This protein detection technique, which is also known as immunoblotting, is used 
to identify specific proteins. A specific protein can be identified after fractionation 
on either one or two-dimensional gels, by exposing all the proteins present to a 
specific antibody coupled to an easily detectable enzyme such as horseradish 
peroxidase, a radioactive isotope or a fluorescent dye. This is done after the 
proteins separated on the gel have been transferred or ‘blotted’ onto a sheet of 
nitrocellulose paper as this is more robust than the gel.
2.3.3.1 Preparation of protein lysate
The lysis buffer (Section 2.2.4.1) was prepared immediately prior to use. Equal 
cell numbers from different treatment condition were washed twice with ice cold 
PBS (1200RPM for 5 minutes). The cells were then transferred to a 1.5mL 
eppendorf and washed again in ice cold PBS (5000RPM for 5 minutes in a bench- 
top micro-centrifuge). The lysis buffer was added to the cells (1-2x10® cells/50pL 
lysis buffer), mixed by pipetting up and down and incubated for 15 minutes on ice. 
Following this, the cells were gently vortexed and then spun at 14000RPM for 10 
minutes at 4°C to clarify the supernatant which was then saved as a detergent 
lysate and stored at -80°C until use.
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2 3.3.2 Protein quantitation
Protein quantification was performed using the bicinchoninic acid (BCA) method 
for colorimetric detection and quantification of total protein according to the 
manufacturers’ instructions. This method utilises the reduction of Cu^  ^ to Cu^ "^  by 
protein in an alkaline medium (the biuret reaction) with the colorimetric detection of 
the cuprous cation (Cu^^) using a reagent containing BCA (Smith et al., 1985). The 
purple reaction product of this assay is formed by chelation of one cuprous ion 
with two molecules of BCA. The water-soluble complex exhibits a strong 
absorbance at 562nm that is nearly linear over a broad range of protein 
concentrations (20-2,000pg/mL).
Firstly the BSA standards were prepared. BSA was dissolved in 0.9% saline to 
give a concentration of 2mg/mL. Serial dilutions of this stock were then made to 
produce a concentration gradient for the controls. Controls of the following 
concentrations were prepared: 1500; 1000; 750; 500; 250; 125; 50; 25; 5pg/mL; 
and a blank. These controls could be stored at -20°C for use on multiple 
occasions. To prepare the assay, 25pL of each control was pipetted into the well 
of a 96-well plate in duplicate. Protein lysate (2.5pL) was added to 22.5pL of PBS 
in duplicate test wells. BCA solutions A and B were combined (50A:1B) and 200pL 
of BCA solution A plus B was added to each well. The 96-well plate was then 
incubated at 37°C for 25 minutes and then the plate was read using an ELISA 
plate reader according to the manufacturers’ instructions. This allowed accurate 
protein quantification so that equal amounts of protein could be used for Western 
blotting.
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2.33.3 Sodium dodecyl sulphate-polyacrylamide-gel electrophoresis
(SDS-PAGE)
This technique has revolutionised protein analysis. It uses a highly cross-linked gel 
as the inert matrix through which the proteins migrate. The proteins are in a 
solution which includes sodium dodecyl sulphate (SDS), a negatively charged 
detergent which binds to hydrophobic regions of the protein molecules, causing 
them to unfold into long polypeptide chains and become freely soluble in the 
solution. A reducing agent such as p-mercaptoethanol is also added to break any 
disulphide bonds present in the proteins, so that all the constituent polypeptides 
can be analysed separately. Each protein molecule binds many of the negatively 
charged detergent molecules. This masks the protein’s inherent positive charge, 
resulting in migration of the protein towards the positive electrode when a voltage 
is applied. The speed of migration through the gel is dependent on the size of the 
polypeptide, with smaller polypeptides travelling more rapidly through the gel. This 
technique can be used to determine the approximate molecular weight of a 
polypeptide as well as the subunit composition of a protein.
To perform SDS-PAGE, equal volumes of protein lysate and Laemmli 2 X sample 
buffer were mixed together in a 1.5mL eppendorf and then heated to 95°C for 5 
minutes. The samples were then loaded onto a 4 to 15% gradient gel. Ten 
microlitres of rainbow ladder marker was loaded onto a lane of the gel to allow 
determination of protein size. The gel was electrophoresed in IX  TGS running 
buffer for 90 minutes at 130V using the Bio-rad Mini-PROTEAN™ electrophoresis 
system.
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2.3 3.4 Transfer to nitrocellulose membrane
The protein bands were then transferred from the gel to nitrocellulose membrane. 
Sponges, blotting paper and nitrocellulose membrane were soaked in transfer 
buffer. The gel was then removed from its holder, soaked in transfer buffer and the 
transfer sandwich was prepared as shown in Figure 2-4 for wet transfer.
- cathode (black) 
sponge 
blotting paper 
gel
nitrocellulose 
blotting paper 
sponge 
+ anode (red)
Figure 2-4. Preparation of sandwich for wet transfer of protein from gel to nitrocellulose 
membrane.
The sandwich then underwent electrophoresis for 1 hour at room temperature at 
80V.
2.3.3.5 Immunolabelling
After transfer, the nitrocellulose membrane was stained with 0.1% Ponceau S for 
30 to 60 seconds to assess protein transfer. The membrane was then de-stained 
with distilled water and washed in PBS-T for 5 minutes. Following this, the 
membrane was blocked in 5% non-fat dry milk in PBS-T at room temperature for 2 
to 4 hours and then the blocking solution was discarded and the membrane 
incubated with the primary antibody solution (H-Ras, Mcl-1 or Actin in PBS-T/5% 
BSA) overnight at 4°C with gentle agitation. The H-Ras antibody was diluted 
1:200, and the Mcl-1 and actin antibodies 1:1000 in PBS-T for immunolabelling. 
The following morning, the nitrocellulose membrane was washed 4 times (15 
minutes per wash) in PBS-T and then incubated with horseradish peroxidase-
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conjugated secondary antibody (anti-rabbit HRP 1:3000) in blocking solution for 1
hour at room temperature with gentle agitation. The membrane was again washed
4 times (15 minutes per wash) and then developed with the ECL plus™ kit
according to the manufacturers' instructions. Briefly, a solution of ECL plus™ A
and B (40A:1B) was prepared, and the membrane was soaked in this for 5
minutes. Excess ECL plus™ solution was then removed and the nitrocellulose
membrane placed in an X-ray box for exposure onto Hyperfilm™ ECL™. Films
were exposed for increasing lengths of time until satisfactory bands were seen.
The films were developed using the Kodak X-omat™.
2.3.3.G Stripping and re-blotting
The Re-Blot™ Plus Strong stripping solution was diluted 1:10 with distilled water. 
The nitrocellulose membrane was incubated in the stripping solution for 10 to 15 
minutes and then washed twice in PBS-T for 10 minutes. The membrane was then 
re-blocked for 1 hour, prior to being incubated with a different primary antibody. 
This method allowed stripping and re-blotting of membranes 3 to 4 times.
2.3.4 Statistics
All statistical analyses were performed using the Student’s T-test on the Minitab 
statistics software package. A level of P ^ 0.05 was taken to be statistically 
significant.
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3 Results 1
3.1 Priming CD34* CML progenitor ceils with rHu-G-CSF 
improves their eradication by IM in vitro
3.1.1 Introduction
In vitro studies have demonstrated that IM acts by inhibiting the growth of primitive 
CML progenitors through reversal of abnormally increased proliferation (Holtz et 
al., 2002). However, these growth arrested (quiescent) CML cells are not 
eradicated by IM In vitro (Graham et al., 2002; Bhatia et al., 2003) or in vivo as 
demonstrated by persistent detection of low level BCR-ABL transcripts by qRT- 
PCR (Hughes et al., 2003; Branford et al., 2004). In addition, recent case reports 
(Cortes et al., 2004b; Mauro et al., 2004) show that some patients who achieved a 
molecular remission on IM, relapsed rapidly after IM was stopped, but responded 
to re-institution of IM therapy. This disease behaviour is suggestive of an IM- 
insensitive LSC compartment.
In view of these observations, we decided to look for a treatment strategy which 
would promote re-entry of these quiescent CML progenitor cells back into the cell 
cycle, rendering them susceptible to eradication by IM. Two potentially successful 
approaches for eliminating the quiescent CML stem cell population could involve 
(1) interruption of IM therapy - an IM ‘drug holiday’; or (2) priming with rHu-G-CSF. 
These therapeutic approaches could also be combined in vitro and in vivo. It is 
proposed that interruption of IM therapy would reverse the observed anti­
proliferative effect of IM at the G0/G1 boundary, allowing these cells to re-enter the 
cell cycle and priming with rHu-G-CSF would promote re-entry of quiescent CML 
stem cells into the cell cycle, rendering them sensitive to IM.
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Therefore, the aims of this part of the study were two fold. Firstly, to determine if
interrupted (pulsed) IM therapy was more effective than continuous IM at
eradicating CML stem cells in vitro] i.e. would an ‘IM holiday' bring cells back into
cycle? Secondly to assess if priming with rHu-G-CSF alone or in addition to
interrupted or continuous IM therapy could improve eradication of CML stem cells
in vitro] i.e. could exogenous G-CSF induce cell cycle activation?
3.1.2 Assessment of G-CSF-R protein expression in CD34* CML 
progenitor ceiis
Our collaborator, Dr Xiaoyan Jiang, had shown that G-CSF-R gene expression 
was up-regulated in the cycling (G1/S/G2/M) compared to the quiescent (Go) 
fraction of both CML and normal CD34'" progenitor cells by qRT-PCR. 
Furthermore, G-CSF-R gene expression was also significantly higher in both the 
quiescent (-2 fold) and cycling (~4 fold) fractions of CD34'" CML progenitors 
compared to normal CD34^ cells (P<0.02) (Jorgensen et al., 2006). Therefore, the 
aims of this experiment were to determine if G-CSF-R protein expression was 
increased in CML versus normal CD34^ progenitor cells and if this expression was 
further enhanced by the addition of rHu-G-CSF.
Flow cytometry was used to assess G-CSF-R protein expression in CML (n=2) 
and normal (n=2) CD34^ progenitor cells at 0, 24, 48, and 72 hours culture in SFM 
in the presence or absence of rHu-G-CSF at a concentration of 20 ng/mL (Figure 
3-1). At baseline (0 hours), both CML and normal CD34^ cells had low levels of G- 
CSF-R expression (-1% of cells G-CSF-R positive). After 24 hours culture, G- 
CSF-R protein expression had started to increase in the CD34^ CML cells, 
reaching a peak (-12%) at 48 hours and still maintained at a high level at 72 hours 
culture (Figure 3-2). The addition of rHu-G-CSF did not affect G-CSF-R protein 
expression in these cells. In normal CD34^ cells, G-CSF-R protein expression
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remained at a low level (< 2%) at all time points in the presence or absence of
rHu-G-CSF.
24 48
Time (hours)
72
□ Normal; no G-CSF 
M Normal + G-CSF 
0  CML; no G-CSF 
m CML + G-CSF
Figure 3-1. G-CSF-R protein expression (percentage of total cells G-CSF-R positive) in CML 
and normal CD34^ cells after 0, 24, 48 and 72 hours culture in the presence or absence of 
rHu-G-CSF.
24 hoursBaseline 48 hours 72 hours
10.83%1.96% 11.79%0.87%
U_(O9o
10'' ■"lO"
CD38
Figure 3-2. Representative FACS dot plots of G-CSF-R expression in CD34^ CML cells at 
baseline (0 hours), 24,48 and 72 hours culture in SFM only.
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Therefore, G-CSF-R protein expression was low in both CML and normal CD34 '^
cells immediately after thawing (time = 0  hours; baseline) and increased rapidly in
the CML CD34^ cells in culture. This indicates that the high G-CSF-R transcript
levels seen in the cycling CML CD34^ cells does translate into increased G-CSF-R
protein expression. To confirm that the cell cycle profiles were similar in the CML
and normal CD34^ cells, Ki-67/7-AAD high resolution cell cycle analysis was
performed on CML and normal CD34^ cells after 72 hours culture in rHu-G-CSF
(20 ng/mL). This verified that the ratio of cycling to quiescent cells was comparable
in CML and normal CD34^ cells (Figure 3-3). Thus, higher G-CSF-R expression in
the CML cells was not due to a different cell cycle profile, with more cycling cells.
CML Normal
Sd
71%
■ M
28%
-, . ■
1%
200 400 600 600 1000
7-AAD
Figure 3-3. Representative FACS dot plots of Ki-67/7-AAD high resolution cell cycle 
analysis. These confirm that there was no difference in cell cycle status between CML and 
normal CD34^ cells after 72 hours culture in the presence of rHu-G-CSF {20 ng/mL). The 
difference in appearance of the CML and normal FACS dot plots is for two reasons: firstiy, 
the two samples were analysed on separate days and the FACSCalibur settings would have 
been different as the voitages and compensation were set with fresh control samples each 
time the FACSCalibur was used; and secondly, the CML sample was stained overnight with 
7-AAD compared to the normal sample which was only stained for 6  hours.
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Next, we needed to determine if the G-CSF-Rs present on the CD34^ CML cells
were functional. This was done by determining the concentration-dependent ability
of rHu-G-CSF to enhance the growth of CD34^ CML progenitor cells in vitro.
3.1.3 Assessment of the proliferative response of CD34* CML
progenitor ceiis to rHu-G-CSF in vitro
This experiment set out to assess the proliferative response of CD34^ CML cells to 
rHu-G-CSF and establish the optimum rHu-G-CSF concentration for further 
experiments. CD34^ CML cells (n=2) were cultured for 6  days in medium 
containing a range of rHu-G-CSF concentrations (0-200ng/mL) or with 5GF 
(Figure 3-4). In the absence of any exogenous growth factors, the total number of 
cells increased in the first 2 days (~3-fold) and then remained constant for the next 
4 days indicating a constant rate of cell production which balanced but did not 
exceed cell death, as expected from the known autocrine IL-3/G-CSF phenotype 
of these cells (Jiang et al., 1999; Jiang et al., 2000b). The addition of rHu-G-CSF 
did not significantly further enhance cell expansion during the first 2  days, although 
the addition of either rHu-G-CSF 200 ng/mL or 5GF showed a trend towards 
increased total viable cells on day 2. However, over the remaining 4 days, the 
addition of rHu-G-CSF stimulated an increase in total viable cells. At 
concentrations of 2 and 10 ng/mL, rHu-G-CSF produced a sub-optimal 
proliferative response. However, rHu-G-CSF concentrations of 20 to 200 ng/mL 
produced equivalent proliferative responses in CD34’*' CML cells, with no benefit 
gained from rHu-G-CSF concentrations above 20 ng/mL. A further increase in cell 
output could be obtained by using 5GF, a growth factor combination optimised to 
stimulate primitive normal haemopoietic cells (Petzer et al., 1996b; Nordon et al., 
1997). Based on these results, a rHu-G-CSF concentration of 20 ng/mL was 
chosen for all subsequent experiments in this section.
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Figure 3-4. Proliferation of CD34'  ^CML cells in vitro in response to different concentrations 
of rHu-G-CSF. Each well was seeded with 5 x 1 0 *  CD34* CML cells in SFM supplemented 
with 0, 2, 20 or 200 ng/mL rHu-G-CSF or 5GF. Total viable cell numbers were determined 
after 1 , 2 , 3  and 6  days. The rHu-G-CSF concentration of 20 ng/mL, chosen for subsequent 
experiments, has been highlighted (black line with circles).
3,1.4 Determination of totai viabie ceii counts after rHu-G-CSF 
priming in combination with continuous or interrupted iM 
therapy
In this series of experiments (n=6 ), the effect of giving continuous, intermittent or 
no rHu-G-CSF (20 ng/mL) in combination with continuous, interrupted or no IM on 
total viable cell numbers was assessed in CD34^ CML cells. The IM concentration 
used was 5 pM which is clinically achievable with standard doses of IM (Peng et 
al., 2004). Each experiment consisted of 3 cycles of 96 hours. Intermittent rHu-G- 
CSF was given for the first 24 hours of each 96 hour cycle and interrupted IM 
therapy was given for the last 72 hours of each 96 hour cycle. To account for all 
possible combinations of rHu-G-CSF with IM, there were 9 experimental arms 
(Figure 3-5): (1) no rHu-G-CSF, no IM; (2) no rHu-G-CSF, IM 72 hours; (3) no
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rHu-G-CSF, IM 96 hours; (4) rHu-G-CSF 24 hours, no IM; (5) rHu-G-CSF 24
hours, IM 72 hours; (6 ) rHu-G-CSF 24 hours, IM 96 hours; (7) rHu-G-CSF 96 
hours, no IM; (6 ) rHu-G-CSF 96 hours, IM 72 hours; and (9) rHu-G-CSF 96 hours, 
IM 96 hours. So that all conditions were treated equally, after the first 24 hours of 
each cycle, all experimental arms where washed three times in PBS and then re­
set up ± IM and ± rHu-G-CSF for the remaining 72 hours.
No IM IM 72h IM 96h 
&  &  &
No G-CSF
G-CSF 24h
G-CSF 96h
Figure 3-5. Schematic diagram of the nine possible combinations of rHu-G-CSF and IM used 
in the experimental protocol. G-CSF, rHu-G-CSF; h, hours.
Total viable cell counts were performed at the end of each 96 hour cycle (i.e. after 
4, 8  and 12 days culture) and the results are shown in Figure 3.6. Taken as a 
group, the three experimental arms to which no IM was added showed the 
expected higher total viable cell counts relative to the IM containing arms (P<0.001 
compared to both the IM 72 hours and IM 96 hours arms at the end of three 
treatment cycles). There were significantly fewer cells remaining after treatment 
with continuous IM (96 hours) compared to interrupted IM (72 hours; P=0.038) 
when no rHu-G-CSF was added. However, in the presence of either intermittent or 
continuous rHu-G-CSF, there was no significant difference between continuous or 
interrupted IM therapy.
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Figure 3-6. Total viable cell counts after each treatment cycle (4, 8  and 12 days) for all 
experimental conditions. Cells were cultured in SFM. Results are expressed as a percentage 
of the starting cell number (± SEM) which was the same for all experimental arms in an 
individual experiment. G-CSF, rHu-G-CSF.
As a group, the three arms to which continuous rHu-G-CSF (96 hours) was added 
had significantly more cells present at the end of three treatment cycles compared 
to the three arms containing either no rHu-G-CSF (P=0.036) or intermittent rHu-G- 
CSF (24 hours; P=0.007). Unexpectedly, the arms with no rHu-G-CSF had 
significantly more cells present than those to which intermittent rHu-G-CSF was 
added (P=0.019). The effect of IM on total cell numbers was consistently greater 
than that of rHu-G-CSF. This is because, even in the absence of rHu-G-CSF, 
CD34"  ^ CML cells produce G-CSF through an autocrine mechanism (Jiang et al., 
1999), thus G-CSF is always present at a low level. Comparison of total viable 
cells in the individual arms is shown in Figures 3-7A and 3-7B and demonstrates 
significant differences in total viable cells between the different treatment arms. 
Interestingly, the pattern of effect of IM (none, interrupted or continuous IM) on 
total cell numbers was similar regardless of the presence of rHu-G-CSF (none, 
intermittent or continuous) and vice versa. However, the effects were most marked
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in the intermittent rHu-G-CSF arms with a reduction in total viable cells (relative to
input) after 12 days (3 cycles) of ~5 fold and 50 fold in the interrupted and
continuous IM arms, respectively.
Figure 3-7. Comparison of total viable cells (n=6 ) In the Individual experimental arms 
together with P values. (A) Three plots comparing the three arms with (I) no IM, (II) 
Interrupted IM (ill) continuous IM. (B) Three plots comparing the three arms with (I) no rHu- 
G-CSF, (II) Intermittent rHu-G-CSF and (III) continuous rHu-G-CSF. Results are expressed as 
a percentage of the starting cell number and represent the mean (± SEM). G-CSF, rHu-G- 
CSF; h, hours.
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3.1.5 Assessment of non-proliferating CD34^ CML cells after
priming with rHu~G-CSF in combination with continuous or 
interrupted IM therapy
After determination of total viable cell counts, we went on to assess the effects of 
continuous and intermittent rHu-G-CSF and continuous and interrupted IM therapy 
on the non-proliferating (quiescent) CD34^ cell sub-population after 3 cycles (12 
days) culture. These experiments were performed using CFSE to track cell 
division (Figure 3-8). A colcemid control was included to determine the location of 
the non-proliferating CFSE"’®’' CD34^ cells during FACS analysis. CFSE"’®* CD34'" 
cells were assessed at the end of each 4-day cycle. The absolute number of these 
non-proliferating cells was calculated and then expressed as a percentage of non­
proliferating cells present at the end of cycle 1 in the no rHu-G-CSF, no IM arm of 
the experiment. This calculation was performed for all three cycles and the results 
are shown in Figure 3-9. Representative FACS profiles for each of the 
experimental arms are shown in Figure 3-10.
All experimental arms washed after 24 hours 
culture, then re set up ± IM ± rHu-G-CSF as 
appropriate
Day 0
I
Cycle 1 Cycle 2 Cycle 3
CFSE i 1 1
Day 4 data Day 8 data Day 12 data
Figure 3-8. Schematic diagram of the protocoi to detect the non-proiiferating CFSE™* CD34* 
sub-popuiation of CML cells (highlighted in rectangle) at the end of each treatment cycle ± 
rHu-G-CSF ± IM.
Mhairi Copland, 2007 Chapter 3, 118
1000
=
sO)
'jp 1002
i
§.É
g
g
i
# I lni n
SI Cycle 1 
B Cycle 2 
w Cycle 3
No G- No G- No G- G-CSF G-CSF G-CSF G-CSF G-CSF G-CSF
es  F, no CSF, IM CSF, IM 24h, no 24h, IM 24h, IM 96h, no 96h, IM 96h, IM
IM 72h 96h IM 72h 96h IM 72h 96h
Figure 3-9. Relative size of non-proliferating CFSE™* CD34* CML ceil sub-population after 
cycles 1-3 (4, 8  and 12 days) in the described treatment conditions. Results are expressed 
as a percentage of the number of non-proliferating cells present at the end of cycle 1 in the 
no rHu-G-CSF, no IM arm (± SEM). Taken as a group the intermittent rHu-G-CSF arms (*) had 
significantly fewer undivided cells present at the end of 3 cycles compared to the no rHu-G- 
CSF {#; P=0.01) and continuous rHu-G-CSF (t; P=0.003) arms with no significant differences 
between the 3 individual intermittent rHu-G-CSF arms. IM alone had no significant effect on 
the non-proliferating population.
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Figure 3-10. Representative FACS plots of CML cells cultured for 12 days under the 
different conditions of rHu-G-CSF and IM. Each panel shows a plot for the treatment arm 
indicated. The non-proliferating CFSE™* CD34* CML cell population is highlighted In the 
box in each panel and the significant reduction in this population with intermittent rHu-G- 
CSF treatment is demonstrated. G-CSF, rHu-G-CSF; h, hours.
Taken as sets, there were no significant differences between the groups of three 
experimental arms in which either no IM, interrupted or continuous IM were 
present. These findings confirm those of previous experiments (Graham et ai..
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2002) which showed that IM did not target the non-proliferating sub-population of
CD34^ CML cells. In addition, interrupted IM therapy did not improve eradication of
the non-proliferating sub-population compared to continuous IM.
However, the results for rHu-G-CSF treatment were dramatically different. 
Intermittent rHu-G-CSF (24 hours) significantly reduced the non-proliferating sub­
population of CD34^ CML cells compared to the three arms containing no rHu-G- 
CSF (P=0.01) and, perhaps surprisingly, the three continuous rHu-G-CSF (96 
hours) arms (P=0.003). Interestingly, there was no difference between the no rHu- 
G-CSF and continuous rHu-G-CSF arms. The addition of either interrupted or 
continuous IM to rHu-G-CSF did not significantly enhance eradication of the non­
proliferating sub-population. This suggests that intermittent treatment with rHu-G- 
CSF may result in an enhanced initial mitogenic response in primitive CD34^ CML 
cells which is not present in more mature myeloid cells.
In selected experiments, the cells remaining after 12 days culture were FACS 
sorted to isolate the non-proliferating sub-population of CD34^ CML cells by Dr 
Martin Barow. The cells were sorted directly onto a microscope slide, the cells 
fixed, and FISH for the BCR-ABL fusion was kindly performed by Mrs Elaine Allan. 
This confirmed that the vast majority (>95%) of non-proliferating cells present were 
indeed BCR-ABL"^ after 12 days culture (Figure 3-11). Therefore, the insensitivity 
of the non-proliferating cells to rHu-G-CSF and IM was not due to enrichment of 
normal CD34^ cells.
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Figure 3-11. Representative FISH Images of BCR-ABL* cells. As treatment with continuous 
rHu-G-CSF and IM was least effective In reducing non-prollferating CD34* cells relative to 
the no rHu-G-CSF no IM control, this treatment arm was selected for FACS sorting of the 
CFSE™* sub-population to provide sufficient cells for FISH analysis to determine Ph status 
of the non-prollferating cell population. (A) The K562 BC CML cell line which has multiple 
copies of BCR-ABL (positive control for FISH). (B) CML patient total CD34* cells prior to 
treatment. (C) CFSE™* Ph* Interphase nuclei recovered after in vitro treatment with 
continuous rHu-G-CSF and IM. FACS sorting was performed by Dr Martin Barow and FISH 
by Mrs Elaine Allan.
To determine if cells leaving the non-proliferating CFSE"’®* CD34^ sub-population 
did so by apoptosis or cell division, active caspase-3 was assessed in combination 
with CFSE and CD34 by flow cytometry in the different experimental arms at the 
end of cycle 1. The non-proliferating CFSE"’®* CD34'^ cells remaining at the end of 
cycle 1 were almost exclusively active caspase-3 negative, indicating that the cells 
leaving the non-proliferating CFSE"’®* CD34"’ sub-population had done so by cell 
division and not apoptosis (Figure 3-12). The addition of either rHu-G-CSF or IM 
to the cultures did not significantly increase apoptosis.
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Figure 3-12. Representative FACS plots of active caspase-3 to measure apoptosis versus 
CFSE to track cell division in (A) rHu-G-CSF 24 hours , no IM; (B) rHu-G-CSF 24 hours, IM 72 
hours; and (C) rHu-G-CSF 24 hours, IM 96 hours arms which demonstrate that non­
proliferating CFSE"’®’' CD34^ CML cells are not undergoing apoptosis. Active caspase-3 was 
measured after the first cycle (4 days). Apoptosis only occurs once the cells are dividing 
indicating that the cells leave the non-proliferating gate by cell division and neither rHu-G- 
CSF nor IM increases the rate of apoptosis.
3,1,6 Summary and conclusions
Continuous IM was more effective than interrupted IM in reducing total viable CML 
cells in the absence of rHu-G-CSF. In the presence of rHu-G-CSF, there was no 
significant difference between the effects of continuous and interrupted IM on total 
viable cells. IM most effectively reduced total viable cells when combined with 
intermittent rHu-G-CSF. As expected, IM had no significant effect on the non­
proliferating sub-population of CD34^ CML cells. However, intermittent rHu-G-CSF 
significantly reduced the non-proliferating sub-population compared to either no 
rHu-G-CSF or continuous rHu-G-CSF by increasing the number of cells which 
leave this quiescent pool by cell division. The addition of IM did not significantly 
enhance this effect.
These results suggest that the combination of intermittent rHu-G-CSF to stimulate 
cells to divide and reduce the non-proliferating pool, combined with continuous IM
Mhairi Copland, 2007 Chapter 3, 123
to eradicate more mature myeloid cells may be particularly effective in treating
CIVIL and reducing the phenomenon of molecular persistence.
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4 Results 2
4.1 A comparison of the efficacy of dasatinib and iM 
against quiescent primitive CIVIL progenitor cells in 
vitro
4.1.1 Introduction
There is increasing evidence that, even after prolonged treatment, IM does not 
eradicate CML stem cells in vivo. Previous research has shown that patients in 
CCR after IM therapy continue to have detectable BCR-ABL^ CD34^ cells, CFCs 
and LTC-ICs (Bhatia et at., 2003). Therefore, it is unlikely that IM will cure CML 
and patients will require long-term monitoring of BCR-ABL levels by qRT-PCR. 
This is also supported by the observed rapid relapses in a number of patients who 
have stopped IM after a period of negative qRT-PCR results (Cortes et al., 2004b; 
Mauro et al., 2004) and the persistence of IM-insensitive, non-proliferating 
(quiescent) cells in vitro (Graham et al., 2002; Holtz et al., 2002). With continued 
IM therapy, there is also the risk of developing IM resistance through BCR-ABL 
kinase domain mutations (Shah et al., 2002), BCR-ABL amplification (Gorre et al., 
2001), BCR-ABL independence with the acquisition of additional mutations 
(Donato et al., 2004) or reduced intracellular levels of IM (Mahon et al., 2003) as 
previously discussed (Section 1.2.7).
Recent work by our group has aimed to examine the mechanisms of IM resistance 
in non-proliferating (or quiescent) CD34^ CML cells (Copland et al., 2006). These 
studies have shown that, before and after short term culture (72 hours) in the 
presence of IM, the majority of CD34^ and the more primitive CD34^38" cells are 
BCR-ABL^ and have only a single copy of BCR-ABL; i.e. do not show gene
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amplification. This research has also shown that CD34^ CML cells have higher
BCR-ABL transcript levels than the more mature total MNC population when
measured by qRT-PCR. In addition, phosphorylated BCR-ABL, tyrosine and CrKL
protein expression were highest in the most primitive CD34"'38‘ cell fraction, at an
intermediate level in the CD34^ population and expressed at a low level in total
MNCs from CML patients. Furthermore, mutation analysis confirmed that kinase
domain mutations were not detectable in the CD34^ cells taken from early CP
CML patients at diagnosis or in those cells surviving 5pM IM or 150nM dasatinib
(Copland et al,, 2006). Therefore, at present, the only confirmed explanation for
the insensitivity of CML stem cells to IM is increased BCR-ABL gene and protein
expression. Taken together, all these findings highlight the importance of finding a
therapy which targets the primitive CML stem cell population.
Dasatinib is a novel multi-targeted kinase inhibitor of the SRC family and BCR- 
ABL kinases (Shah et al., 2004) which is currently in Phase 3 clinical trials in IM- 
resistant and IM-intolerant CML and Ph"" ALL patients (Talpaz et al., 2006). In 
vitro, dasatinib is more potent (325 fold greater) than IM in cell lines and inhibits 
the majority of BCR-ABL kinase mutations that result in IM resistance (except 
T315I) (O'Flare et al., 2005). It is believed that the improved efficacy of dasatinib 
against CML cells is due to increased potency against BCR-ABL and not directly 
through the additional inhibition of SRC kinases (Donato et al., 2003; Donato et al., 
2004; Flu et al., 2004). Flowever, these studies have been conducted in cell lines 
and mouse models and the importance of SRC kinases in primary CML cells has 
not been directly assessed, in models of advanced phase CML, BCR-ABL has 
been shown to activate LYN and FICK, the SRC kinases most prevalent in myeloid 
cells (Corey and Anderson, 1999), and this contributes to the survival and 
proliferation of BCR-ABL^ cells. Further in vitro studies have also shown that 
increased levels of activated LYN may up-regulate the anti-apoptotic protein BCL-
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2 in IM-resistant BCR-ABL^ cells, contributing to the IM resistance seen (Donato et
a!., 2003; Dai et al., 2004).
Therefore, the aims of this study were, firstly, to determine if dasatinib was more 
effective than IM in CD34'^ CML cells and if it would eradicate quiescent CML stem 
cells in vitro. Secondly, to determine the relevance of SRC kinases and BCL-2 in 
early CP CML.
4.1.2 Assessment of IC50 for dasatinib in the K562 cell line and
primary CD34* CML cells
Concentration finding studies to determine the IC50 for dasatinib in K562 and 
primary CD34^ CML cells were performed using thymidine cell proliferation 
assays and counting of total viable cells. K562 cells were assessed at 24 and 48 
hours and compared to the BCR-ABL negative AML cell line HL60 to show the 
specificity of dasatinib for BCR-ABL. Primary CD34^ CML cells were assessed 
after 72 hours culture in SFM only. Using proliferation assays (n=4), the IC50 for 
dasatinib in K562 cells was approximately 0.8nM at 48 hours culture (Figure 4- 
1A). These results were supported by total viable cell count results which showed 
a reduction in total viable cells to 80% of no drug control at InM and 35% at 5nM 
after 48 hours culture (Figure 4-1B). Dasatinib had no effect on proliferation or 
total viable cell counts in the BCR-ABL negative cell line HL60 at any of the 
concentrations assessed (Figure 4-1A and B). These results demonstrate that 
K562 cells are highly sensitive to dasatinib and that the drug selectively targets 
BCR-ABL expressing cells. Dasatinib had an IC50 of approximately 5nM as 
demonstrated by proliferation assay and confirmed by total viable cell count in 
primary CML cells (n=3; Figure 4-2A and B), indicating the potency of dasatinib in 
primary CML cells.
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Figure 4-1. Determination of ICso for dasatinib by thymidine proliferation assays and total 
viable cell counts in K562 cells (n=4 experiments) and HL60 cells (n=2 experiments). (A) 
thymidine proliferation assays after 24 and 48 hours in K562 and HL60 cell lines 
demonstrate that dasatinib has an ICso of approximately 0.8nM at 48 hours in K562 cells and 
has no effect on HL60 cells. Five replicates of each condition were performed in each 
experiment. (B) Total viable cell counts in K562 and HL60 cells at 48 hours expressed as a 
percentage of the no drug control confirm the results of the proliferation assays. Results 
represent the mean ± SEM. h, hours.
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Figure 4-2. Determination of ICgo for dasatinib by thymidine proliferation assays and total 
viable cell counts in primary CD34^ CML cells (n=3 experiments). (A) thymidine 
proliferation assays were performed after 72 hours and demonstrate that dasatinib has an 
ICso of approximately 5nM in primary CD34* CML cells cultured in SFM only. Five replicates 
of each condition were performed in each experiment. (B) Total viable cell counts after 72 
hours expressed as a percentage of the no drug control confirm the results of the 
proliferation assays. Results represent the mean ± SEM.
In primary CD34^ CML cells, even at doses up to lOOnM, there was no further 
reduction in proliferation or total viable cells compared to the 10nM dose. There 
are two possible explanations for this. Firstly, that there is enrichment of a normal
Mhairi Copland, 2007 Chapter 4, 129
Ph" cell population which is not affected by dasatinib. However, FISH on these and
other patients samples after 6 days culture in the presence of dasatinib confirmed
that >95% of cells remaining after culture were BCR-ABL'*', thus excluding this
explanation. The second potential reason is that there is a population of cells
present which is resistant to dasatinib and, as in the case of IM, this may be the
primitive CML stem cell population.
These results for dasatinib are similar to those of other groups which have 
reported an IC50 of 0.6 to 0.8nM for cell lines expressing wild type BCR-ABL (Shah 
et ai., 2004; O'Hare et al., 2005) and 60 to 80% inhibition of growth of bone 
marrow progenitors isolated from patients with IM-sensitive CML in CFU assays 
(Shah et al., 2004) . However, in Phase 1 clinical trials with CML patients (Talpaz 
et al., 2006), plasma concentrations of up to 180nM dasatinib have been achieved. 
Therefore, a concentration of 150nM dasatinib was chosen for further experiments 
as it more closely represented the clinical situation.
4.1.3 A comparison of IM and dasatinib in CD34* CML progenitor 
cells in short term culture
4.1.3.1 Assessment of total viable cell counts
In this series of experiments (n=8), the effects of IM or dasatinib, dosed either as 
single agents, sequentially or simultaneously on total viable cell counts was 
assessed in CD34'*' CML cells in vitro. As previously, an IM concentration of 5pM 
was chosen for these experiments, and dasatinib was used at 150nM as 
discussed. The cells were cultured in SFM + 5GF for a total of 6 days. After 72 
hours, an aliquot of cells was removed for counting; the remaining cells in all 
treatment arms were washed and then re-set up in culture for a further 72 hours 
under the following conditions: (1) No drug control; (2) IM 5pM; (3) dasatinib
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150nM; (4) IM for 72 hours then dasatinib for 72 hours; (5) dasatinib for 72 hours
then IM for 72 hours; and (6) simultaneous IM and dasatinib. Therefore, at 72
hours, there were only 4 experimental arms (no drug control, IM 5pM, dasatinib
150nM and simultaneous IM and dasatinib). The total viable cell counts for 72
hours and 6 days are shown in Figure 4-3 A and B, respectively.
P < 0.001 for all treatment arms 
compared to no drug control
P=0.006
B
No drug 
control
IM 5pM Dasatinib IM + Dasatinib
150nM
P = 0.001 for all treatment arms 
(except Dasatinib 150nM; P=0.002) 
compared to no drug controi
rP=0.007-i
No drug IM SpM IM then Dasatinib Dasatinib IM + 
control Dasatinib then IM 150nM Dasatinib
Figure 4-3. Total viable cell counts after 72 hours (A) and 6  days (B) for all experimental 
conditions. Cells were cultured in SFM + 5GF. Results are expressed as a percentage of the 
no drug control (± SEM).
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At both time points, there was a significant reduction in total viable cells in all
treatment arms compared to the no drug control (P<0.001 for all treatment arms at
72 hours, and P=0.001 for all treatment arms at 6 days except dasatinib 150nM
which had a significance value of P=0.002). However, as the cells were cultured in
the presence of 5GF, there was marked proliferation and expansion of total viable
cells compared to the starting cell number in all treatment arms (Figure 4-4). The
CD34*  ^ CML cells were cultured in 5GF for these experiments to aid identification
of the quiescent progenitor population which has the greatest resistance to
activation in the CFSE experiments described next (4.1.3.2).
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Figure 4-4. Total viable ceils after 72 hours and 6  days culture of CD34^ CML cells in SFM + 
5GF with the stated treatment conditions. There is expansion of cell numbers due to 
proliferation in all treatment arms relative to the starting cell number at 3 days with further 
expansion evident at 6  days. IM then dasatinib and dasatinib then IM have a 6  day time-point 
only. Results are expressed as percentage starting cell number (± SEM).
There was no significant difference in total cells between the IM and dasatinib 
arms at either time point (P=0.419 and P=0.118 for 72 hours and 6 days, 
respectively), although there was a trend for total viable cells to be lower in the IM
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arm. The experimental arm which consistently had the lowest total viable cell
number was the simultaneous IM and dasatinib arm. At both time points this was
significantly lower than the dasatinib only arm (P=0.006 at 72 hours and P=0.007
at 6 days) and significantly lower than either of the sequential treatment arms (IM
then dasatinib or dasatinib then IM) at 6 days (P=0.002 for both). There was no
significant difference between the IM only and simultaneous IM and dasatinib
arms. These results confirm that IM and dasatinib, at high therapeutically
achievable concentrations, have equivalent efficacy on primary CD34^ CML cells
in vitro.
4.1,3.2 The effect of IM versus dasatinib on non-proliferating CD34* CML 
progenitor cells
Having assessed total viable cell counts, the effects of IM and dasatinib, either as 
single agents, as sequential therapy or given simultaneously on the non­
proliferating (quiescent) CD34^ cell sub-population after 72 hours and 6 days was 
studied. As in Chapter 3 (3.1.5), these experiments were performed using CFSE to 
track cell division and, again, a colcemid control was included to identify the 
position of the non-proliferating CFSE*^ ®^  CD34^ cells during FACS analysis. The 
absolute number of these non-proliferating cells was calculated and then 
expressed as a percentage of the starting cell number for each treatment condition 
at 72 hours and 6 days. The results are shown in Figure 4-5A and B. 
Representative FACS profiles for the no drug control, IM and dasatinib arms are 
shown in Figure 4-6.
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Figure 4-5. Absolute number of non-proliferating CFSE"'®* CD34* cells remaining after 72 
hours (A) and 6  days (B) for all experimental conditions. Cells were cultured In SFM + 5GF. 
Results are expressed as a percentage of the starting cell number (± SEM).
Compared to the no drug control, there was a significant increase in non­
proliferating CFSE"^®^  CD34^ CML cells in the IM and IM plus dasatinib arms at 72 
hours (P=0.04 and P=0.05, respectively). However, this increase was not present 
in the dasatinib arm (P=0.27). After 6 days culture, all treatment arms had 
increased CFSE*^ ®^  CD34"' cells compared to the no drug control. There were no
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significant differences between the different treatment arms, although there was a
trend for the arms containing continuous IM (IM 5pM and simultaneous IM plus
dasatinib arms) to have the largest non-proliferating cell populations (P=0.22).
IllQ.
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No drug control imatinib 5pM Dasatinib 150nM
CFSE
Figure 4-6. Representative FACS dot plots of CML cells after 72 hours culture In the 
presence of no drug control, IM 5pM or dasatinib ISOnM as indicated. The non-proliferating 
CFSE"’®* CD34^ CML cell population is highlighted in the box in each panei. The piots 
demonstrate the very iow number of undivided ceils remaining in the no drug controi 
compared to the relatively large population remaining in the iM arm. The intermediate sized 
CFSE"”®* CD34^ population remaining after treatment with dasatinib is also shown.
The relatively large population of non-proliferating CFSE*^^  ^ CD34'*' CML cells 
remaining after exposure to IM is due to the accumulation of cells arrested in 
Gq/Gi phase of the cell cycle. The intermediate sized non-proliferating CFSE"^^  ^
CD34^ CML cell population remaining after dasatinib treatment likely reflects the 
less profound anti-proliferative effect of dasatinib, resulting in fewer cells 
accumulating in the CFSE**^ ®’^  gate due to reversible Gq/Gi arrest. This anti­
proliferative effect is further demonstrated in Figure 4-7.
FISH was performed by Mrs Elaine Allan at baseline and again after 6 days culture 
in the presence of IM or dasatinib and confirmed that, at both baseline and again
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at the end of treatment, >95% of the cells were BCR-ABL* with only single copy
BCR-ABL being detected.
No drug control v. IM 5pM
10^
No drug control v. Dasatinib 150nM
IM 5pM V. Dasatinib 150nM IM 5pM V. IM + Dasatinib
—  No drug control —  IM 5pM —  Dasatinib 150nM —  IM + Dasatinib
Figure 4-7. Representative FACS histogram plots which demonstrate the anti-proliferative 
effects of IM and dasatinib. In the upper panels, IM and dasatinib treated cells have 
progressed through fewer divisions (right shift) compared to the no drug control. In the 
lower panels, the less anti-proliferative effect of dasatinib compared to IM is seen (left) and 
the identical profiles for IM and simultaneous IM plus dasatinib administration are 
demonstrated (right).
As clearly demonstrated here, none of the treatment conditions, including the 
combined administration of IM and dasatinib, reduced the non-proliferating 
CFSE'"®’' CD34^ CML cell population compared to the no drug control. This 
suggests that neither IM nor dasatinib targets the most primitive quiescent CML 
stem cells.
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4.1.3.3 Assessment of apoptosîs in CD34^ CML cells after exposure to IM or
dasatinib
Previous work has shown that the most primitive CML cells do not readily undergo 
apoptosis after treatment with IM (Graham et al., 2002; Holtz et al., 2002; Bhatia at 
al., 2003; Jorgensen et al., 2005a), it is the more mature cells which apoptose. 
Therefore, apoptosis was assessed in CD34^ CML cells (n=4) after treatment with 
IM 5pM, dasatinib 150nM or a no drug control using an anti-active caspase-3-PE 
FACS antibody. To enable assessment of apoptosis in the non-proliferating 
fraction, the cells were stained with CFSE prior to culture as previously. In 
preliminary experiments, caspase-3 activity was assessed at 48, 72 and 96 hours 
culture in the presence of different treatment arms. Apoptosis was found to be 
greatest at 72 hours, therefore in all subsequent experiments, caspase-3 activity 
was assessed after 72 hours and the results are shown in Figure 4-8.
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Figure 4-8. Representative FACS dot plots which demonstrate increased caspase-3 activity 
in the presence of either IM 5pM or dasatinib ISOnM compared to no drug control after 72 
hours culture. Apoptosis was assessed using anti-active caspase-3 antibody (PE) in CD34^ 
CML cells. The cells were stained with CFSE prior to culture to allow assessment of 
apoptosis in the non-proliferating (quiescent; boxed area) fraction. The dot plots Illustrate 
that the majority of apoptosis occurs in the more mature progenitors which have already
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undergone several divisions, with the non-proliferating compartment being relatively 
resistant to apoptosis.
Compared to the no drug control, there was a trend towards increased apoptosis 
in both the IM and dasatinib arms (5.5% versus 7.9% for both IM and dasatinib) for 
total cells remaining after 72 hours culture, but these results did not reach 
statistical significance (P=0.067 and P=0.069 for IM and dasatinib, respectively), 
due, in part, to inter-patient variability. In the non-proliferating population, there 
were no significant differences in apoptosis between the 3 arms with very few 
caspase-3 positive cell events (Figure 4-8). Therefore, dasatinib was no more 
effective than IM at inducing apoptosis in primary CD34^ CML cells, and most 
particularly, compared to IM, did not increase apoptosis in the non-proliferating 
CFSE"^®^  CD34^ CML cell population. This result also confirms that the trend to 
fewer cells remaining in the non-proliferating CFSE"^®^  CD34^ CML cell gate after 
treatment with dasatinib, compared to IM, is due to the cells leaving this gate 
through cell division and not apoptosis.
4.1.3.4 Assessment of CrKL phosphorytation as a marker of BCR-ABL 
activity in primary CD34^ and more primitive CD34^38‘ CML cells after 
treatment with IM or dasatinib
To further define the effects of IM and dasatinib on primary CML cells, a flow 
cytometry method for measuring CrKL phosphorylation has been developed and 
validated in our lab (Hamilton et ai., 2006). This FACS method allows 
determination of CrKL phosphorylation status on relatively small cell numbers (< 
1x10®) from which there would have been insufficient protein to perform Western 
blotting. Our first finding was that CrKL phosphorylation was significantly increased 
in the more primitive CD34^38" population compared to the total CD34^ population 
(P=0.002; Figure 4-9A). Further experiments assessed the effect of IM at a dose
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of 5|jM on CrKL phosphorylation in total CD34^ and more primitive CD34'*'38‘ cell
populations (Figure 4-9B). Results showed that IM inhibited CrKL phosphorylation
at 16 hours but not 72 hours in total CD34^ cells, consistent with enrichment of an
IM-insensitive population (P=0.01 for 16 hours versus 72 hours). However, at both
time-points, in the more primitive CD34^38" cell population, IM failed to inhibit CrKL
phosphorylation, confirming the inherent insensitivity of these primitive cells to IM.
We then went on to compare the effects of either IM 5pM or dasatinib ISOnM on
the primitive CD34^38' cell population at 16 hour and 72 hour time-points (Figure
4-9C). At both time points, there was significant inhibition of CrKL phosphorylation
compared to IM (P=0.004 for 16 hours and P<Q.001 for 72 hours).
These results provide evidence that dasatinib is a more potent inhibitor of BCR- 
ABL than IM. However, they also suggest that BCR-ABL may be irrelevant in the 
stem cell compartment as both IM and dasatinib have equivalent potency at 
clinically achievable concentrations against CD34^ CML cells in vitro, despite the 
superior inhibition of CrKL phosphorylation in the primitive CD34^38’ compartment 
demonstrated here. This further suggests that either inhibition of BCR-ABL does 
not lead to cell death or the enhanced inhibition CrKL phosphorylation 
demonstrated here with dasatinib is mediated via SRC and not BCR-ABL. An 
alternative explanation, although unlikely, is that CML cells require more than 72 
hours after inhibition of CrKL phosphorylation before undergoing apoptosis.
Mhairi Copland, 2007
A
T " « - I I I T |
10'
Chapter 4, 139
Kssa CD34+ 
I  CD34+38
- I -------------------------- ■ I - r  1
10' 10
120
100
iO 80 
Q.sP ^  60
# 4 0
20
CD34'
— p-0.004-
p= 0.4 —Ip= 0.01
GD34+38
I—p<0.001"
mi6h
072h
H IM 5pM
O Dasatinib 150 nM
16h 72h
Figure 4-9. Assessment of CrKL phosphorylation (p-CrKL) In total 0034^ and the more 
primitive 0034*38' cell populations before and after treatment with IM or dasatinib. (A) 
Comparison of p-CrKL In total CD34* and CD34 38 cells at baseline. CD34*38 cells exhibit
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significantly greater p-CrKL than total CD34* cells (P=0.002). (B) p-CrKL In total CD34* and 
CD34*38‘ cells after treatment with IM 5pM for 16 and 72 hours. IM Inhibited p-CrKL at 16 
hours (P=0.01) but not 72 hours in the total CD34* cell population, suggesting enrichment of 
an IM-lnsensitlve population. (C) Comparison of p-CrKL after treatment with IM 5pM or 
dasatinib 150nM In CD34*38 cells after 16 and 72 hours. There was significant Inhibition of 
p-CrKL at both time-points with dasatinib (P=0.004 at 16 hours and P<0.001 at 72 hours) 
compared to IM. h, hours
4.1.4 Determination of the reievance of SRC kinases in CML
Recent research has shown that the SRC kinase LYN is over-expressed and 
activated in the K562-R cell line (Donato et al., 2003) which is resistant to IM. This 
cell line was developed by culturing K562 cells with increasing concentrations of 
IM and then cloning the cells which were resistant to IM by limiting dilution. The 
surviving cells were then cultured in the absence of IM and then re-assessed for 
IM sensitivity. The cells which remained IM-resistant were termed K562-R cells. 
Further experiments showed that inhibition of LYN with the SRC family-specific 
inhibitor CGP76030 (Novartis) resulted in reduced proliferation and survival of 
K562-R cells. Samples taken from patients with BC CML who had progressed on 
IM also showed increased expression of activated LYN similar to the K562-R cell 
line (Donato et al., 2003). In addition, specimens taken from BC CML patients 
before and after IM failure suggested that expression of activated LYN and/or HCK 
occurred during disease progression. The authors concluded from this research 
that SRC kinases were highly expressed in BC CML and that this increased 
expression correlated with disease progression or IM resistance. Further studies 
using a mouse model have also shown that BCR-ABL activated the SRC kinases 
LYN, HCK and FGR in B-lymphoid cells (Hu et al., 2004) and induced CML, but 
not ALL, in LYN' HCK'-FGR-'- mice. The SRC inhibitor CGP76030 impaired 
proliferation of B-lymphoid cells expressing BCR-ABL in vitro and prolonged 
survival of mice with B-ALL, but not CML. In addition, in B-ALL, the combination of
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CGP76030 with IM was superior to IM alone (Hu et al., 2004). These studies
suggest that SRC kinases are not required for CML induction but are necessary
for Ph^ ALL and that SRC activation does not contribute to the proliferation or
survival of CML cells. Further research in the cell lines K562-R and LAMA-R which
exhibit BCR-ABL independent IM resistance has shown that activation of LYN
plays a functional role in the up-regulation of the anti-apoptotic protein BCL-2 (Dai
et al., 2004). Figure 4-10 shows the signalling pathways between BCR-ABL, the
SRC kinases and BCL-2.
SRC kinases
Ras
Raf
MEK
CM ERK
Figure 4-10. Simplified schematic diagram of the signalling pathways showing the Indirect 
relationship between the SRC kinases and the anti-apoptotic protein BCL-2.
In view of the results of these studies which have concentrated on SRC kinase 
expression in CML cell lines and BC CML, I undertook further research to assess 
levels of BCL-2, LYN and HCK in primary CML cells before and after treatment
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with IM or dasatinib in vitro to determine if SRC family kinases are a relevant
target in CP CML. I was assisted in some of these experiments by Miss Emma
Hamill. The aims of this research section were to answer the following questions:
1. Is p-SRC (used to measure active LYN and HCK) and BCL-2 protein 
expression increased in CD34^ CML cells at the different disease stages 
(CP, AP, BC) compared to normal CD34^ cells?
2. Does treatment with TKIs (IM, dasatinib or the SRC kinase inhibitor PP2) 
alter expression of p-SRC or BCL-2?
3. Is there a difference in p-SRC and BCL-2 expression in the different phases 
of CML?
4.1.4.1 Expression of p-SRC and BCL-2 in CD34^ cells from the different 
phases of CML compared to normal CD34* cells
Protein expression of p-SRC and BCL-2 was assessed in primary CD34^ CML 
cells from patients in different phases of the disease using intracellular flow 
cytometry techniques. A p-SRC antibody was used as this was capable of 
measuring phosphorylation status of all members of the SRC kinase family (SRC, 
LYN, HCK, FGR etc.) which are all phosphorylated on the same tyrosine residue 
(Y416). Phosphorylated SRC and BCL-2 were measured in normal CD34^ cells 
(n=3), CP (n=5) AP (n=2) and BC CML (n=5) CD34^ cells (Figure 4-11A and B).
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Figure 4-11. Assessment of p-SRC and BCL-2 protein expression in CD34^ ceiis from normal 
donors and patients with CP, AP and BC CML. (A) p-SRC expression is increased in CD34^ 
CML ceiis compared to normai CD34^ ceiis (P=0.002 for CML versus normal). (B) BCL-2 
expression is increased in the different phases of CML compared to normal CD34^ ceils 
(P=0.029 for CML versus normai). Results are expressed as a percentage of p-SRC or BCL-2 
expression in the normai CD34* ceils (average of 3 normai samples).
Compared to normal CD34^ cells, CP and BC CD34^ CML cells showed 
significantly increased levels of p-SRC (P=0.02 and P=0.022, respectively: Figure
4-11 A). There was also a trend towards higher p-SRC levels in the BC compared
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to CP samples. Due to low sample numbers (n=2), AP 0034^ CML cells failed to
show statistical significance, but demonstrated a trend towards increased p-SRC
compared to normal CD34^ cells. There was a trend towards increased BCL-2
expression in each of the three phases of CML compared to normal CD34^ cells,
however results failed to reach statistical significance. As a group CD34'^ CML
cells showed increased BCL-2 expression compared to normal CD34'" cells
(P=0.029). There was marked inter-patient variability in expression of both p-SRC
and BCL-2. Figure 4-12A and B show FACS histograms for the different phases
of CML for p-SRC and BCL-2, respectively.
p-SRC
Isotype control 
Normal 002 
CP CML 166 
APCML 185 
BC CML 002
BCL-2
Figure 4-12. Representative FACS histogram plots of (A) p-SRC and (B) BCL-2 in CD34^ cells 
from normal donors and patients with different phases of CML.
Using three-colour flow cytometry, I went on to assess the expression of p-SRC 
and BCL-2 in the more primitive CD34^38 sub-population from CP, AP and BC
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CML cells compared to normal CD34‘^ 38‘ cells. The results are shown in Figure 4-
13A and B.
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Figure 4-13. Assessment of p-SRC and BCL-2 protein expression in CD34^38‘ cells from 
normal donors and patients with CP, AP and BC CML. (A) p-SRC expression is increased in 
CD34*38 CML cells compared to normal CD34^38 cells (P=0.001 for CML versus normal).
(B) BCL-2 expression is increased in CD34^38 CML cells compared to normal CD34^38‘ cells 
(P=0.004 for CML versus normal). Results are expressed as a percentage of p-SRC or BCL-2 
expression in the normal CD34*38 cells (average of 3 normal samples).
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As with total CD34^ celle, CP and BC CD34^38“ celle CML celle showed
significantly increased levels of p-SRC (P=0.032 and P=0.013, respectively;
Figure 4-13A) in comparison to normal CD34‘*'38‘ cells. Again, there was also a
trend towards higher p-SRC levels in the BC compared to CP samples. Due to low
sample numbers (n=2), AP CD34'"38“ CML cells failed to show statistical
significance, but demonstrated a trend towards increased p-SRC compared to
normal CD34^38‘ cells. In the primitive CD34^38‘ sub-population BCL-2 expression
was also significantly increased in CP and BC compared to normal CD34^38' cells
(P=0.012 for both; Figure 4-138). Once more, there was marked inter-patient
variability in expression of both p-SRC and BCL-2 in the CD34'^38' sub-population.
These results show, for the first time, that p-SRC expression is increased in CP 
CML and may be a relevant target for therapy. However, it is unclear whether this 
increase in activated SRC is BCR-ABL-dependent or independent because, as 
well as acting as downstream modulators of BCR-ABL signalling, SRC family 
kinases can also be directly activated by haemopoietic growth factors via cell 
surface receptors (Corey and Anderson, 1999). In addition, these results indicate 
that BCL-2 is up-regulated in CML cells and may be contributing to the anti- 
apoptotic phenotype of CML.
Interestingly, compared to the total CD34^ cell population, absolute expression 
levels were lower in the more primitive CD34'^38" sub-population in all sample 
groupings (Figure 4-14A-C). However, both p-SRC and BCL-2 expression were 
proportionately much higher in CD34'"38' CML cells compared to normal CD34^38' 
cells (Figure 4-13 A and B). Overall, p-SRC was 3-fold and 6.4-fold increased and 
BCL-2 was 1.7-fold and 2.8-fold increased in CD34^ and CD34^38" populations, 
respectively, compared to normal CD34^ and CD34^38‘ CML populations. A 
possible explanation for this is that p-SRC and BCL-2 are increased as a direct
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result of higher BCR-ABL levels in the primitive CD34*38' sub-population (Figure
4.9). This relative over-expression of p-SRC and BCL-2 in CD34‘^ 38* CML cells
compared to normal CD34^38" cells may contribute to their relative IM resistance.
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Normal
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N=5 CD34* cells 
CD34*38-cells
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Figure 4-14. Comparison of p-SRC and BCL-2 expression in total CD34^ cells and more 
primitive CD34*38 cells. (A) Representative FACS dot plot highlighting the primitive 
CD34*38 sub-population. (B) and (C) Histograms showing the higher p-SRC (B) and BCL-2
(C) expression in total CD34^ compared to the more primitive CD34*38 sub-population. MFI, 
mean fluorescence intensity.
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4.1.4.2 Assessment of the effects of IM, dasatinib or PP2 on p-SRC and BCL-
2 expression in CD34^ CML cells in CP and BO CIVIL
Having established that the expression of p-SRC kinases was increased in CML, I 
went on to determine the effects of IM, dasatinib and the SRC specific kinase 
inhibitor PP2 on the expression of p-SRC and BCL-2 in CP (n=4) and BC (n=2) 
CML
4.1.4.2.1 Assessment of tCso for the SRC kinase inhibitor PP2 in CD34* CML 
ceiis
PP2 has been described as a potent pyrrolo-pyrimidine inhibitor of the SRC family 
of tyrosine kinases (Hanke et al., 1996). Concentration finding studies to 
determine the IC50 for PP2 in primary CD34^ CML cells (n=3) were performed 
using thymidine cell proliferation assays and total viable cell counts with 
assessment after 72 hours in culture in SFM only. PP2 had an I C 5 0  of 
approximately 7pM as demonstrated by thymidine proliferation assay and 
confirmed by total viable cell counts in primary CD34^ CML cells (Figure 4-15). 
These results are similar to those obtained by another group (Wilson et al., 2002) 
who reported an I C 5 0  of lOpM in the K562 cell line, but did not undertake 
experiments in primary CML cells.
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Figure 4-15. Determination of IC50 for PP2 using H thymidine proliferation assays and total 
viable cell counts in primary CD34^ CP CML cells cultured in SFM only (n=3 experiments).
(A) 72 hour proliferation assays demonstrate that PP2 has an IC50 of approximately 7pM 
in primary CD34* CML cells. Five replicates of each condition were performed in each 
experiment. (B) 72 hour total viable cell counts confirm the proliferation assay results. 
Results represent the mean ± SEM.
Based on these results, PP2 was used at a concentration of 10|jM in subsequent 
experiments.
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4.1.4.2.2 Effect of IM, dasatinib and PP2 on p-SRC and BCL-2
expression in CD34* and CD34^38' CML cells
The effects of IM, dasatinib and PP2 on p-SRC and BCL-2 protein expression 
were assessed by intracellular flow cytometry after 16 hours and 72 hours culture. 
Compared to the no drug control (n=6), at 16 hours, both IM and dasatinib 
significantly reduced p-SRC expression in CD34^ and the more primitive CD34''38' 
CML cells (P=0.001 for no drug control versus IM in both CD34^ and CD34‘'38“ 
populations; and P<0.001 and P=0.003 for no drug control versus dasatinib in 
CD34^ and CD34^38" cells, respectively; Figure 4-16A). At 72 hours, there was a 
trend towards reduced p-SRC in the total CD34^ cells with both IM and dasatinib, 
however this did not reach statistical significance. In the CD34^38' cells at 72 
hours, only dasatinib significantly reduced p-SRC compared to no drug control 
(P=0.001; Figure 4-16B). In CD34^ and CD34^38" CML cells at both 16 and 72 
hours, PP2 had no significant effect on SRC phosphorylation status. This suggests 
that the majority of activated SRC kinase expression in CML is being mediated via 
BCR-ABL and is not BCR-ABL-independent. A possible explanation for the 
inability of the SRC inhibitor PP2 to significantly reduce p-SRC Is that, if BCR-ABL 
is stimulating p-SRC, then in the presence of high levels of BCR-ABL there may 
simply be too much p-SRC being produced to be inhibited by PP2. In the future it 
would be important to combine IM and PP2 to determine if the effect of this 
combination is equivalent to that of the dual SRC/BCR-ABL inhibitor dasatinib on 
p-SRC and BCL-2 expression in primary CML cells.
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Figure 4-16. The effect of IM, dasatinib and PP2 on p-SRC expression in (A) total CD34* and
(B) more primitive CD34*38 CML cells at 16 hours and 72 hours (n=6; 4 CP, 2 BC). Results 
are expressed as a percentage of the no drug control (± SEM). There was no difference 
between CP and BC CML in the samples assessed.
At both 16 and 72 hours, compared to no drug control, IM, dasatinib or PP2 did not 
significantly inhibit expression of BCL-2 in CD34'^ CML cells (Figure 4-17A). 
However, in the primitive CD34'"38' cells, there was a modest reduction in BCL-2 
with all treatment arms compared to no drug control (Figure 4-17B). This was only 
significant with dasatinib at 16 hours (P=0.021) but not 72 hours (P=0.061) and
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suggests that BCL-2 may be more relevant in the more primitive CD34^38‘ CML
cell population in keeping with the higher BCL-2 expression in these cells relative
to normal CD34^38' cells.
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16 hours 
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No drug control IM SpM Dasatinib ISOnM PP2 lOpM
Figure 4-17. The effect of IM, dasatinib and PP2 on BCL-2 expression in (A) total CD34* and 
(B) more primitive CD34*38 CML cells at 16 hours and 72 hours (n=6; 4 chronic phase, 2 
blast crisis). Results are expressed as a percentage of the no drug control (± SEM). In total 
CD34* cells, there were no significant differences between the experimental arms at either 
16 or 72 hours. However in the CD34*38 cells, at 16 hours, any treatment (IM, dasatinib, 
PP2) versus no treatment significantly reduced BCL-2 expression (P=0.002). No significant 
differences in BCL-2 expression were present at 72 hours in the CD34*38 popuiation. There 
was no difference between CP and BC CML in the samples assessed.
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The discrepancy between p-SRC and BCL-2 expression after treatment with IM or
dasatinib may suggest that, in CML, BCL-2 expression is not mediated by LYN as
previously proposed (Dai et ai., 2004). Alternatively, BCL-2 is known to have a
long half-life (Merino et al., 1994) and may be more stable and not degraded over
the culture period compared to p-SRC, which, because of its phosphorylated state
has a short half-life. Furthermore, In this study, total BCL-2 and not
phosphorylated BCL-2 was assessed. Recent evidence suggests that the anti-
apoptotic functions of BCL-2 may be controlled by its phosphorylation
(Blagosklonny, 2001), with phosphorylation of BCL-2 appearing to inhibit its anti-
apoptotic function (Haidar et al., 1995) The phosphorylation status of BCL-2 can
be altered by chemotherapeutic agents and cytokines, but was not assessed here.
4.1.5 Summary and conclusions
The multi-targeted kinase inhibitor, dasatinib has an IC50 of ~5nM in CD34^ CML 
cells in vitro. Cell line studies confirm that dasatinib selectively targets BCR-ABL^ 
haemopoietic cells.
In vitro, IM and dasatinib have equivalent cytotoxicity on primary CD34^ CML cells 
at high therapeutically achievable concentrations (5pM versus ISOnM, 
respectively). The simultaneous administration of IM and dasatinib further 
enhances the cytotoxic effect. However, there is no advantage to sequential 
treatment with these agents.
Neither IM nor dasatinib, alone or in combination, reduced the non-proliferating 
CFSE^^: CD34^ CML cell population compared to the no drug control. However, 
there was a trend for IM to be more anti-proliferative than dasatinib. Apoptosis 
studies using caspase-3 activity demonstrated that those cells leaving the 
undivided CFSE*^ ®^  CD34^ gate did so by cell division and not apoptosis. Further
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studies using p-CrKL expression to measure BCR-ABL activity demonstrated that
dasatinib was a more potent inhibitor of BCR-ABL than IM.
Activated SRC kinases as measured by p-SRC and BCL-2 expression were 
significantly increased in CD34^ and CD34^38" CML cells compared to normal 
CD34^ and CD34^38' cells. There was a tendency for p-SRC, but not BCL-2 to be 
higher in BC than CP CML. Imatinib mesylate or dasatinib, but not PP2, reduced 
p-SRC in CML; however as with p-CrKL expression, the effect was only transient 
with IM, suggesting that p-SRC expression is mediated by BCR-ABL. Imatinib 
mesylate, dasatinib and PP2 had only modest effects on BCL-2 expression, 
suggesting that either BCL-2 expression may be independent of both BCR-ABL 
and SRC kinases or BCL-2 is a more stable molecule and changes in BCL-2 
expression take longer to become evident. In addition, in future studies, it would 
be useful to assess BCL-2 phosphorylation as well as total BCL-2 levels to 
determine the amount of active BCL-2 present and the importance of BCL-2 
phosphorylation in CML.
However, as shown in Section 4.1.3.2, the most important finding of this study was 
that, although dasatinib treatment resulted in a smaller non-proliferating CFSE'^^’^ 
CD34^ CML cell population than IM, it did not eradicate this population. Therefore, 
in overall conclusion, these results suggest that neither BCR-ABL nor SRC 
kinases are relevant targets in the most primitive stem cell populations in CP CML.
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5 Results 3
5.1 The novel FT! BMS-214662 targets quiescent CML 
stem and progenitor cells and synergises with 
imatinib or dasatinib in vitro
5.1.1 Introduction
Two main strategies to overcome IM resistance have emerged. The first is the 
development of second generation TKIs such as dasatinib and nilotinib (Shah et 
al., 2004; O'Hare et al., 2005; Weisberg et al., 2005; Kantarjian et al., 2006; Talpaz 
et al., 2006) and the second, the use of IM in novel drug combinations (Holtz et al., 
2005; Jorgensen et al., 2005a).
The results of Chapter 4 demonstrated that, although dasatinib induced durable 
inhibition of BCR-ABL tyrosine kinase activity in primitive CML cells as compared 
to either IM or nilotinib which were significantly less effective (Copland et al., 2006; 
Jorgensen et al., 2007), neither of these agents targeted the most primitive, 
quiescent CML stem cell population. A wide range of drug combinations with IM, 
including arsenic, Ara-C, the heat-shock protein-90 antagonist 17AAG, and the 
PI3K inhibitor LY294002, have been investigated (Holtz et al., 2005; Jorgensen et 
al., 2005a) in CD34^ CML progenitor cells. However, the only agent to enhance 
the activity of IM against the quiescent CML stem cell fraction was the cytostatic 
FTI lonafarnib (Jorgensen et al., 2005a), but the results failed to reach statistical 
significance.
As discussed in the introduction (1.3.3.1), FTIs are a novel class of small 
molecules developed to inhibit oncogenic Ras and have entered clinical trials in
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both solid tumours and acute leukaemias (Adjei et al., 2000; Cortes et al., 2003;
Cortes et al., 2005a; Tabernero et al., 2005). BMS-214662 is a cytotoxic FTI (Hunt
et al., 2000; Rose et al., 2001; Manne et al., 2004) that has produced potent
tumour regression and curative responses in selected human tumour xenografts
and transgenic tumour models, and differs from other cytostatic FTIs such as
lonafarnib and R115777 which had non-curative activity (Liu et al., 1998; End et
al., 2001). In addition, BMS-214662 has been shown to preferentially kill non-
proliferating cells (Lee et al., 2001) and has anti-leukaemic activity in AML (Cortes
et al., 2005a).
In view of the cytotoxic effect of BMS-214662 on non-proliferating cells in tumour 
models (Lee et al., 2001), and the promising results obtained previously with 
lonafarnib (Peters et al., 2001a; Hoover et al., 2002; Nakajima et al., 2003; 
Jorgensen et al., 2005a) and tipifarnib (Miyoshi et al., 2005), it was hypothesised 
that this small molecule inhibitor might target the quiescent CML stem cell 
population which has been shown to be resistant to IM, dasatinib and nilotinib 
(Copland et al., 2006; Jorgensen et al., 2007) and, indeed, may synergise with 
these drugs which induce potent anti-proliferative effects within the stem cell 
compartment in CML. Therefore, the aims of this study were to determine the 
effects of BMS-214662 alone and in combination with IM or dasatinib on the 
primitive quiescent CML stem cell population in vitro. In addition, the cytotoxic 
effects of BMS-214662 in BC CML and cell lines expressing BCR-ABL kinase 
domain mutations were assessed.
5.1.2 Assessment of IC5 0 for BMS-214662 in primary CD34* CML 
cells
Concentration finding studies to determine the IC50 for BMS-214662 in primary 
CD34^ CML cells were performed using ^H thymidine cell proliferation assays and
^  ,f..„ L  ^ ■ - A " / y ' - . r.:-.
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counting of total viable cells. Results were assessed after 72 hours culture in SFM
alone. BMS-214662 had an IC50 of approximately 375nM after 72 hours culture in
CD34^ CML cells as determined by thymidine proliferation assays (n=3; Figure
5-1 A). Interestingly, cell counting showed a 50% reduction in total viable cells at
the lower BMS-214662 concentration of 250nM (Figure 6.1 B). These results show
that BMS-214662, when used as a single agent, is extremely potent against
CD34^ CML cells. Based on these results, a dose of 250nM BMS-214662 was
chosen for all further experiments in this study. Previous in vivo studies have
shown that a BMS-214662 plasma concentration of 250nM is readily achievable in
patients (Tabernero et al., 2005; Eder et al., 2006).
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Figure 5-1. Determination of iCso for BIVIS-214662 by (A) thymidine proliferation assay 
(n=3) and (B) total viable cell counts performed after 72 hours culture in SFM. thymidine 
proliferation assays show an IC50 of approximately 375nM and total viable cell counts 
250nM. Five replicates of each condition were performed in each experiment. Results 
represent the mean (± SEM).
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5.1.3 Determination of the efficacy of BMS-214662 alone or in 
combination with IM or dasatinib in CD34^ CML cells after 
short-term culture
5.1.3.1 Assessment of total viable cell counts
To assess the cytotoxic effect of BMS-214662 atone and in combination with IM or 
dasatinib, primary CD34^ CML cells (n=4) were cultured for 6 days in SFM + 5GF. 
Once again, the GD34^ CML cells for these experiments were cultured in 5GF to 
aid identification of the quiescent progenitor population in the CFSE experiments 
described next (5.1.3.2). After 72 hours, an aliquot of cells was removed for 
counting; the remaining cells were then washed and set up again in culture for a 
further 72 hours. The conditions studied were: (1) No drug control; (2) BMS- 
214662 250nM; (3) IM 5pM; (4) BMS-214662 250nM + IM 5pM; (5) dasatinib 
ISOnM and (6) BMS-214662 250nM + dasatinib 150nM. The drug concentrations 
for BMS-214662, IM and dasatinib were chosen on the basis that these were 
concentrations which were clinically achievable.
After 3 days culture, there was a significant reduction in total viable cells in the 
treatment arms compared to the no drug control (P=0.04; Figure 5-2A). Also, the 
combination of BMS-214662 + dasatinib showed a significantly greater cytotoxic 
effect than dasatinib alone (P=0.026) and the combination of BMS-214662 + IM 
showed a trend towards increased cytotoxic effect (P=0.055) compared to IM 
alone. After a total of 6 days in culture, there was a further significant reduction in 
total viable cells in the treatment arms relative to the no drug control (P=0.001; 
Figure 5-2B). Importantly, in addition, the combinations of BMS-214662 + IM and 
BMS-214662 + dasatinib showed increased cytotoxic effect over either IM or 
dasatinib alone (P=0.024 and P=0.034, respectively). Therefore, the addition of
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BMS-214662 to either IM or dasatinib significantly enhanced the effect of these
drugs in vitro by increasing overall cytotoxicity.
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Figure 5-2. Total viable cell counts after (A) 72 hours and (B) 6 days for all experimental
conditions (n=4). CD34^ CML cells were cultured in SFM + 5GF. Resuits are expressed as a
percentage of the no drug control (mean ± SEM).
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5.1.3.2 The effect of BMS-214662 alone and in combination with IM or
dasatinib on non-proliferating CD34* CML progenitor cells after
short-term culture
Previous studies (including those in Chapter 4) have shown that both IM and 
dasatinib result in increased numbers of non-proliferating CD34^ CML cells 
remaining after culture (Graham et al., 2002; Copland et al., 2006), in part due to 
failure to induce apoptosis of CML stem cells and also as a result of their potent 
anti-proliferative effects leading to reversible Gi arrest. Therefore, we assessed 
the efficacy of BMS-214662 alone and in combination with IM or dasatinib in 
primary CD34‘" CML cells in vitro, again using CFSE-based flow cytometry to track 
cell division. After 3 days, there were no significant differences between the arms 
(Figure 5-3A). However, by 6 days, while the IM and dasatinib arms showed 
significant accumulation of non-proliferating CFSE"^^  ^CD34^ CML cells over the no 
drug control (P=0.04 and P=0.023, respectively), the arms containing BMS- 
214662 with either IM or dasatinib showed a significant reduction in these primitive 
cells to 40% and 27% of the no drug control (Figure 5-3B; P=0.023 and P=Q.005) 
respectively. Despite reducing the non-proliferating CFSE^^'^ CD34^ cell population 
to 48% of the no drug control, results with BMS-214662 alone just failed to reach 
statistical significance (P=0.06). In addition, the reduction in non-proliferating 
CFSE*^^  ^ CD3 4 + Q|\/|L cells was highly statistically significant when either IM or 
dasatinib alone was compared to the combination with BMS-214662 (P=0.01 and 
P=0.043, respectively). Representative FACS plots for each of the experimental 
arms are shown in Figure 5-4.
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Figure 5-3. Non-prollferating CFSE"’ *^ CD34* cells remaining after (A) 72 hours and (B) 6 
days culture for all experimental conditions. Cells were cultured in SFM + 5GF. (A) There 
were no significant differences in non-proliferating cell numbers after 72 hours. However, by 
6 days (B), compared to either IM or dasatinib alone, the combinations with BMS-214662 
showed a significant reduction in non-proliferating cells (P=0.01 and P=0.043, respectively). 
In addition, compared to no drug control, BMS-214662 + IM and BMS-214662 + dasatinib 
showed a significant reduction in non-proliferating cells (P=0.023 and P=0.005, 
respectively). In these experiments, due to inter-patient variability in the size of the non- 
proiiferating CFSE"’^ ’' GD34^ cell population, the cells remaining after the culture period 
were expressed as a percentage of the starting cell number normalised to the no drug 
control. The absolute number of non-proliferating cell decreased over time; non-
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proliferating cells in no drug control = 1.1% at 72 hours and 0.17% at 6 days. Results are 
expressed as a percentage of the no drug control (mean ± SEM).
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Figure 5-4. Representative FACS dot plots after 6 days culture for each of the experimental 
conditions. The non-proliferating CFSE"’®* CD34* CML cell population is highlighted in the 
box in each panel. The plots demonstrate the very low number of undivided cells remaining 
in the no drug control and BMS-214662-containing arms compared to the relatively large 
populations remaining in the IM and dasatinib only arms.
The marked anti-proliferative effect of IM or dasatinib due to reversible Gi arrest is 
demonstrated in Figures 5-5A and B, respectively. BMS-214662 had minimal anti­
proliferative effect compared to no drug control (Figure 5-5A and B) and did not 
overcome the anti-proliferative effect of either IM or dasatinib, indicating that BMS- 
214662 is able to exert its cytotoxic effect on non-proliferating cells. There were no 
significant differences in non-proliferating CFSE'^®  ^CD34^ CML cells between the 
BMS-214662-containing arms. Very significantly, these are the first drug 
combinations tested using this CFSE-based method, which show a significant 
reduction in non-proliferating cells remaining after culture to a level below that of 
the no drug control (Jorgensen et al., 2005a).
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Figure 5-5. Representative overlay flow cytometry histograms demonstrating anti­
proliferative effects of IM and dasatinib. (A) No drug control, BMS-214662, IM and BMS- 
214662 + IM, and (B) no drug control, BMS-214662, dasatinib and BMS-214662 + dasatinib. 
Compared to the no drug control, the cells treated with IM, BMS-214662 + IM, dasatinib and 
BMS-214662 + dasatinib have progressed though fewer divisions (right shift) highlighting 
the anti proliferative effects of both IM and dasatinib. This anti proliferative effect was not 
overcome when either IM or dasatinib was combined with BMS-214662, demonstrating that 
BMS-214662 exerts Its cytotoxic effect on non-prollferating cells. BMS-214662 alone had 
minimal anti-proliferative effect compared to the no drug control.
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5.1.4 Determination of the efficacy of BMS-214662 aione or in
combination with iM or dasatinib in CD34* CML ceiis after 
iong-term cuiture using LTC-iC assays
To further investigate the efficacy of BMS-214662 on functional CML stem cells, 
LTC-IG assays were performed with both CP CML (n=3) and normal (n=3) CD34^ 
cells to determine drug selectivity. The CD34^ cells were treated for 72 hours 
under the following conditions: (1) No drug control; (2) BMS-214662 250nM; (3) IM 
5jjM; (4) BMS-214662 + IM; (5) dasatinib 150nM; (6) BMS-214662 + dasatinib, 
before LTC-IC assay. Compared to the no drug control, CD34^ CML cells showed 
increased Ph^ colony formation in the IM and dasatinib arms (191 and 175%, 
respectively; Figure 5-6A; P-0.033 for IM and dasatinib arms versus no drug 
control), indicating that these drugs exert a protective effect on CML stem cells in 
culture via their anti-proliferative effect described previously (Graham et al., 2002; 
Copland et al., 2006). The addition of BMS-214662 to either IM or dasatinib 
significantly reduced the number of Ph^ colonies compared to either agent alone 
(P=0.032 and P=0.027, respectively). Furthermore, the BMS-214662 only arm 
showed a significant reduction in Ph"" colonies compared to either IM or dasatinib 
atone (P=0.032 and P=0.028, respectively). All three BMS-214662-containing 
arms showed a virtual elimination of colonies to <1% of the number in the no drug 
control (P=0.033), with no significant difference between the arms. Figure 5-7 
shows examples of the CFU-GM colonies produced in the committed progenitor 
cell assays following LTC-IC.
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Figure 5-6. Results of LTC-IC assay for (A) CD34^ CML cells and (B) normal donor CD34^ 
cells treated under the experimental conditions described. (A) The addition of BMS-214662 
to either IM or dasatinib significantly reduced the number of Ph  ^ colonies produced from 
CD34^ CML cells compared to either drug alone (P=0.032 and P=0.027, respectively), BMS- 
214662 alone also significantly reduced the Ph  ^ colonies compared to the no drug control 
(P=0.033) and to either IM or dasatinib alone (P=0.032 and P=0.028, respectively). There were 
no significant differences between the BMS-214662-containing arms. (B) Compared to the 
no drug control, there was a non significant reduction in colonies produced from the normal 
donor CD34"^  cells in the BMS-214662-containing arms.
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In normal CD34^ cells from healthy donors (n=3), there was a non-significant
reduction in LTC-IC in the BIVIS-214662-containing arms compared to the no drug
control (P=0.079-0.29; Figure 5-6B), with LTC-IC survival significantly higher for
normal compared to Ph"" CD34^ cells (P=0.001). Neither IM nor dasatinib alone
had a significant effect on colony formation from normal CD34^ cells compared to
the no drug control. These results confirm that BMS-214662 is targeting primitive
CML stem cells and provide evidence of selectivity for CML stem cells over normal
HSCs.
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Figure 5-7. Examples of CFU-GM colonies produced in the colony forming assays after LTC- 
IC.
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5.1.5 Fluorescence in situ hybridization results for short-term
cuiture and LTC-iC experiments for ceiis treated with
BMS-214662 alone or in combination with IM or dasatinib
FISH was performed at baseline and again after 6  days culture on the cells 
remaining in selected arms at the end of the CFSE experiments and on the 
colonies produced following the LTC-IC experiments. In the CFSE experiments, 
FISH was carried out on selected treatment arms at the end of 6  days culture 
(Table 5-1). All samples tested at either baseline or following culture were >90% 
Ph^ by FISH confirming that the cells present were from the leukaemic clone, and 
there was no evident enrichment for normal (Ph ) cells immediately after short term 
drug treatment.
UPN
BCR-ABL^ / total cells (%)
Baseline Dasatinib
BMS-
214662
BMS- 
214662 + 
Dasatinib
170 211/218
(97)
70/70
(100)
ND 58/58
(100)
189 932/1003
(93)
217/217
(100)
187/196
(95)
102/104
(98)
215 104/109
(95)
81/83
(98)
115/118
(97)
92/93 
(99) _
218 233/236
(99)
92/92
(100)
111/111
(100)
131/131
(100)
Table 5-1. FISH results for CFSE experiments with CD34* CML samples. FISH was performed 
on the cells remaining after after 6 days culture in selected treatment arms. UPN; unique 
patient number, ND; not determined.
In the LTC-IC experiments (Table 5-2), all samples were >90% Ph"" at baseline. 
However, after LTC-IC, only 1 of 3 samples (CML 166) remained Ph  ^ in the BMS- 
214662-containing arms. This case illustrates the 10-15% of CP CML patients in 
whom, even at diagnosis, LTC-IC are already exclusively Ph^ (Coulombel et al.. 
1983b; Petzeretal., 1996a).
-.1- — —  : —
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UPN
BCR-A BL* / total cells (%)
Baseline
No drug 
control IM Dasatinib
BMS-
214662
BMS- 
214662 
+ IM
BMS- 
214662 + 
Dasatinib
166 439/463
(95)
111/111
(100)
ND 74/74
(100)
97/99
(98)
ND 62/62
(100)
189 932/1003
(93)
51/78
(65)
85/120
(71)
181/291
(62)
12/145
(8)
8/88
(9)
0/335
(0)
215 104/109
(95)
67/71
(94)
40/40
(100)
63/66
(95)
6/134
(4)
ND ND
Table 5-2. FISH results for LTC-IC experiments with CD34^ CML samples. Colonies were 
harvested after LTC-IC experiments, pooled for each treatment condition and then FISH was 
performed on the cells from these colonies. UPN, unique patient number; ND, not 
determined.
In the remaining samples (CML 189 and 215), following treatment with BMS- 
214662, more than 90% of cells surviving LTC-IC were Ph', indicating that these 
patients had residual normal Ph' haemopoiesis at the time of leucapheresis (Goto 
et al., 1982; Coulombel et al., 1983b; Petzer et al., 1996a) and that these Ph' cells 
had selectively survived exposure to BMS-214662 in vitro as compared to their 
Ph^ counterparts which were eradicated. This further illustrates the degree of Ph^ 
versus Ph" selectivity for BMS-214662, suggesting quiescent cancer stem cells are 
more susceptible than normal cells to BMS-214662.
5.1.6 Assessment of apoptosis in both proliferating and non- 
proliferating populations of CD34* CML progenitor cells in 
the presence of BMS-214662 alone or in combination with IM 
or dasatinib
In order to determine the apoptotic effect of BMS-214662, active caspase-3 
activity was assessed at 48, 72 and 96 hours culture in CD34^ CML cells (n=4). 
Compared to the no drug control, apoptosis was increased in all treatment arms at 
48, 72 and 96 hours, with maximal apoptosis seen at 72 hours (Figure 5-8). The
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greatest apoptosis was seen in the BMS-214662-containing arms with the BMS-
214662, BMS-214662 + IM and BMS-214662 + dasatinib arms having 14.6, 18.4
and 12.4% caspase-3 positive cells, respectively, compared to 5.5% in the no drug
control arm and 7.9% in both the IM and dasatinib only arms. Due to large
variations in levels of apoptosis between different primary CD34^ CML samples,
the results did not achieve statistical significance.
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Figure 5-8. Assessment of apoptosis In total CD34* CML cells (n=4) after 72 hours culture 
under the experimental conditions shown. Although there was a trend for Increased 
apoptosis In the BMS-214662-containing arms, due to wide variations In the percentage of 
caspase-3 positive cells between different primary CML samples, the results failed to reach 
statistical significance (P=0.17). Results are expressed as the percentage of total cells 
which were caspase-3 positive (mean + SEM).
Using CFSE stained cells allowed assessment of apoptosis in the quiescent 
CFSE’^ ax fraction (<5% of total CD34^ cells). At 48 and 72 hours there was an 
increase in caspase-3 positive cells in the quiescent CFSE^^^x population. With IM 
or dasatinib alone, a modest increase in apoptosis was seen (12.2 and 10.9% 
CFSE"^ax CD3 4 + cells caspase-3 positive, respectively) compared to 8.3% in the 
no drug control; however, the apoptotic effect was increased by the addition of 
BMS-214662 (Figure 5-9A and B) with 22.0, 30.8 and 24.0% caspase-3 positive
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cells in the BMS-214662, BMS-214662 + IM and BMS-214662 + dasatinib arms,
respectively (P=0.045 for BMS-214662 containing versus non-containing arms).
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Figure 5-9. Assessment of apoptosis in non-proliferating CFSE"’“* CD34* CML cells (n=4) 
after 72 hours culture under the experimental conditions shown. (A) Representative FACS 
dot plots demonstrating the increased caspase-3 activity In the non-prollferating fraction of 
cells treated with BMS-214662 + dasatinib compared to dasatinib only. (B) Apoptosis was 
significantly Increased in the BMS-214662-contalning arms compared to the IM and 
dasatinib only arms (P=0.045). Results are expressed as the percentage of total cells which 
were caspase-3 positive (mean ± SEM).
These results demonstrate that BMS-214662 is causing apoptosis in CD34^ CML 
cells, in particular in the non-proliferating sub-population, and show that in the
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presence of BMS-214662, although cells continue to leave the undivided gate
through cell division, increased numbers of non-proliferating cells leave the
undivided gate by apoptosis. The data presented here provide further evidence for
the selectivity of BMS-214662 for quiescent versus proliferating cancer cells.
5.1.7 Cell cycle analysis of CD34* CML cells treated with BMS-
214662 alone or in combination with IM or dasatinib
To assess the effect of BMS-214662 on the cell cycle in CD34^ CML cells, high 
resolution cell cycle analysis was performed using Ki-67 and 7-AAD (n=5). After 72 
hours culture in the presence of the different treatment conditions, there was a 
trend towards reduced Go cells in the BMS-214662-containing arms (BMS-214662 
alone, BMS-214662 + IM and BMS-214662 + dasatinib) compared to the IM and 
dasatinib only arms (P=0.08). Go cells represented 0.65% of total cells in the BMS- 
214662-containing arms compared to 1.38% in the IM and dasatinib only arms 
(Figure 5-10). Go cells represented 1.13% of total cells in the no drug control. 
These results provide further evidence for the efficacy of BMS-214662 against 
non-proliferating cells in CML.
No drug control
1.13%
BMS-214662 Dasatinib
7-AAD
Figure 5-10. Representative FACS plots for high resolution cell cycle analysis In CD34* CML 
cells after 72 hours treatment In the stated conditions. There was a trend towards reduced 
Go cells In the BMS-214662-contalnlng arms.
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5.1.8 Assessment of CrKL phosphorylation status to determine
the effect of BMS-214662 alone or in combination with IM or 
dasatinib on BCR-ABL activity
To determine the effect of BMS-214662 on BCR-ABL kinase activity in CD34^ 
CIVIL cells, the CrKL phosphorylation FACS assay described in Section 2.3.2.2 
and used in Section 4.1.3.4 (Hamilton et al., 2006) was performed after 16 and 72 
hours culture under the following experimental conditions (n=6): (1) No drug 
control; (2) BMS-214662 250nM; (3) dasatinib 150nM; (4) BMS-214662 + 
dasatinib. As previously, dasatinib inhibited CrKL phosphorylation at both 16 and 
72 hours compared to the no drug control (Figure 5-11). BMS-214662 alone had 
no effect on CrKL phosphorylation status and, when used in combination with 
dasatinib, did not significantly enhance the inhibitory effect of dasatinib on CrKL 
phosphorylation. Therefore, these results demonstrate that BMS-214662 is not 
acting through inhibition of BCR-ABL.
No drug 
control
BMS-214662
250nM
Dasatinib
ISOnM
BMS-214662 + 
Dasatinib
16 hours 
72 hours
Figure 5 11. Assessment of CrKL phosphorylation status in total CD34* CIVIL cells after 16 
and 72 hours treatment under the described conditions. BMS-214662 alone had no effect on 
CrKL phosphorylation and did not enhance the effect of dasatinib when the two were used 
in combination. Results are expressed as a percentage of CrKL phosphorylation in the no 
drug control (mean ± SEM).
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5.1.9 Assessment of efficacy of pulsed BMS-214662 regimens in
combination with continuous dasatinib
BIVIS-214662 has already entered Phase 1 clinical trials in solid tumours and AML 
(Mackay et al., 2004; Ryan et al., 2004; Cortes et al., 2005a; Dy et al., 2005; 
Papadimitrakopoulou et al., 2005; Tabernero et al., 2005). In clinical trials, BMS- 
214662 was given as an intravenous infusion over either 1 hour or 24 hours, which 
resulted in a plasma concentration of >250nM for at least 8 or 24 hours 
respectively (Tabernero et al., 2005). In order to mimic the clinical scenario, we set 
up a multi-armed experiment to look at the effect of treating primary CD34^ CML 
cells with pulsed BMS-214662 for either 8 or 24 hours (equivalent to a 1 or 24 hour 
infusion in patients respectively) combined with continuous dasatinib. The test 
arms assessed in these experiments (n=4) were: (1) No drug control; (2) BMS- 
214662 250nM for 8 hours; (3) BMS-214662 250nM for 24 hours; (4) dasatinib 
150nM; (5) BMS-214662 for 8 hours + dasatinib 150nM; and (6) BMS-214662 for 
24 hours + dasatinib 150nM. These experiments consisted of two 96 hour cycles. 
In the arms containing BMS-214662 for 8 hours, the BMS-214662 was added after 
24 hours in culture and in the arms containing BMS-214662 for 24 hours, the 
BMS-214662 was added after 8 hours. All experimental arms were washed three 
times in PBS after 32 hours in culture and re-set up in fresh culture medium. 
Dasatinib was re-added to the dasatinib-containing experimental arms. After 8 
days, total viable cells were significantly reduced in all the dasatinib-containing 
arms compared to the no drug control (P=0.019, P=0.003 and P=0.002 for the 
dasatinib, BMS-214662 for 8 hours + dasatinib and BMS-214662 for 24 hours + 
dasatinib arms, respectively; Figure 5-12A). There was no significant difference in 
total viable cells between no drug control and the pulsed BMS-214662 only arms. 
Undivided CFSE'^®  ^CD34^ CML cells were significantly increased in the dasatinib 
arm compared to no drug control (P=0.037; Figure 5-12B). There was a trend
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towards reduced undivided CD34^ CML cells in the pulsed BMS-214662
only arms, but this did not reach statistical significance (P=0.1). The addition of
pulsed BMS-214662 to dasatinib reduced the undivided CFSE^^ CD34^ CML cell
population compared to dasatinib alone, but again, this did not reach statistical
significance (P=0.1). These results provide useful information for design of a
clinical trial for the combination of BMS-214662 with dasatinib in CML.
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Figure 5-12. Effect of pulsed BMS-214662 with dasatinib on (A) total and (B) non- 
proliferating CD34^ CML cells (n=4). (A) Total viable cells present after 8 days (two 96 hour 
cycles) in the presence of different pulsed treatment regimens. There is a significant 
reduction in total cells in the dasatinib-containing arms. Pulsed BMS-214662 alone had no 
effect on total viable cells. (B) Non-proliferating CD34^ CML cells present after 8 days 
culture. As previously, dasatinib alone significantly increased the non-proliferating fraction 
remaining after culture compared to no drug control. The addition of pulsed BMS-214662 
demonstrated a trend towards reducing this non-proliferating fraction, but was less 
effective than continuous BMS-214662 in vitro. Only pulsed BMS-214662 alone reduced the 
non-proliferating cell fraction to below the level seen in the no drug control, but again was 
less effective than continuous BMS-214662. Results are expressed as a percentage of the 
no drug control (mean ± SEM). h, hours.
Mhairi Copland, 2007 Chapter 5, 177
5.1.10 Comparison of the effects of BMS-214662 and BMS-
225975 on CD34" CML cells
Previous studies have shown that the cytostatic FTI lonafarnib does not 
significantly reduce the number of quiescent CML stem cells relative to no drug 
control (Jorgensen et al., 2005a). BMS-225975 is another cytostatic FTI, which is 
structurally very similar to BMS-214662, the only difference being substitution of a 
hydrogen ion for a methyl group at position 1. Both these compounds have similar 
inhibitory effects on FT with BMS-214662 having an IC50 of 0.7nM and BMS- 
225975 0.8nM in HGT-116 tumour xenografts (Frank Lee, personal
communication). Therefore, for the following experiments, like BMS-214662, a 
concentration of 250nM BMS-225975 was chosen.
To determine if the effects of BMS-214662 in CML were due to inhibition of Ras, 
we directly compared its activity with that of BMS-225975 in primary CD34^ CML 
cells. CFSE-based flow cytometry was used to track cell division, and caspase-3 
activity to measure apoptosis. The treatment conditions studied were: (1) No drug 
control; (2) BMS-214662 250nM; (3) BMS-225975 250nM; (4) dasatinib 150nM; 
(5) BMS-214662 + dasatinib; (6) BMS-225975 + dasatinib. After 6 days, total 
viable cells were significantly reduced in all the treatment arms compared to the no 
drug control (P<0.001; Figure 5-13A). BMS-214662 significantly reduced total 
viable cells compared to BMS-225975 (P=0.028). There was no significant 
difference between the combinations of BMS-214662 + dasatinib and BMS- 
225975 + dasatinib on total viable cells. As previously, after 6 days culture, not 
only had BMS-214662 significantly reduced undivided CFSE*^®^  CD34‘" CML cells 
compared to the no drug control (P=0.018), but also compared to BMS-225975 
containing arms (P=0.024). Undivided CFSE"^ ®^  CD34'*' CML cell numbers were not 
significantly different in the no drug control and BMS-225975 arms (Figure 5-13B).
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Figure 5-13, Comparison of the effects of BMS-214662 with the cytostatic FTI BMS-225975 
on (A) total viable cells and (B) non-proliferating CD34^ CML cells after 6 days culture (n=4). 
(A) Although BMS-225975 significantly reduced total viable cells compared to no drug 
control (P=0.001), BMS-214662 had a superior effect (P=0.028 compared to BMS-225975 and 
P<0.001 compared to no drug control). (B) Once again, BMS-214662 significantly reduced 
non-proliferating cells compared to no drug control (P=0.018). BMS-225975 did not 
significantly alter the number of non-proliferating cells remaining after culture compared to 
the no drug control. However, BMS-214662 significantly reduced non-proliferating cells 
compared to BMS-225975 (P=0.024). Results are expressed as a percentage of the no drug 
control (mean ± SEM).
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BMS-225975 did not increase caspase-3 activity compared to no drug control in
either the BMS-225975 or BMS-225975 + dasatinib arms in total CML cells or the
non-proliferating CD34^ fraction (Figure 5-14A and B). The dissimilar effects of
BMS-214662 and BMS-225975 suggest that the efficacy of BMS-214662 in CML
may not be via inhibition of the Ras pathway.
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Figure 5-14. Assessment of apoptosis by measuring caspase-3 activity in (A) total cells and 
(B) non-proliferating CFSE"’ ’^* CD34* CML cells after 72 hours culture with BMS-214662 or 
BMS-225975 alone or in combination with dasatinib. BMS-225975 alone or in combination 
with dasatinib failed to increase apoptosis above the level seen in the no drug control. 
Results expressed as percentage of cells which were caspase-3 positive (mean ± SEM).
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To further confirm that the effects of BMS-214662 are not through inhibition of
Ras, H-Ras activity was assessed using Western blotting (n=3) after 72 hours
culture in the presence of no drug control, BMS-214662, BMS-225975, IM or
dasatinib. The blots showed that there was equivalent inhibition of H-Ras with both
BMS-214662 and BMS-225975 with the appearance of an unprenylated band.
Imatinib mesylate or dasatinib had no effect on H-Ras activity. A representative
blot is shown in Figure 5-15. This result further implies that the activity of BMS-
214662 in CML is not mediated via Ras.
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Figure 5-15. Representative Western blot showing that BMS-214662 and BMS-225975 have 
equivalent activity against H-Ras with similar sized unprenylated Ras bands (arrowhead) 
appearing after treatment with these compounds in CD&F CML cells. IM and dasatinib have 
no direct effect on Ras activity as illustrated here. A pan-actin control confirms equal 
protein loading.
5.1.11 Assessment of Mcl-1 activity in CD34* CML cells
Recent in vitro studies in B-CLL (Marzo et al., 2004) and myeloma (Aichberger et 
al., 2005) have identified inhibition of Mcl-1 in association with Bax or Bak 
activation as potential modes of action for BMS-214662 in these haematological 
malignancies. However, these conditions have not yet been shown to be stem cell 
disorders and the mechanism of action may be different in CML. Western blotting
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was undertaken after 72 hours culture in the presence of: (1) No drug control; (2)
BMS-214662 250nM; (3) BMS-225975 250nM; (4) IM 5pM; (5) Dasatinib 150nM
(n=3). The resulting blots showed no evidence for inhibition of Mcl-1 in any of the
treatment arms indicating that, in CML, BMS-214662 is not acting via inhibition of
Mcl-1 (Figure 5-16).
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Figure 5-16. Representative Western blot demonstrating that BMS-214662 has no effect on 
Mcl-1 activity in CD34^ CML cells. A pan-actin control confirms equal protein loading.
5.1.12 Assessment of BMS-214662 activity in BC CML and 
ceils expressing BCR-ABL kinase mutations
Much of this study has focussed on CD34^ CML cells taken from patients with CP 
CML and the role of the CML stem cell in molecular persistence after treatment 
with IM or dasatinib. However, it is also very important to assess the effects of 
novel agents such as BMS-214662 in advanced CML and in cells expressing 
BCR-ABL kinase domain mutations as it will be those patients with advanced 
disease or BCR-ABL kinase mutations, who are most likely, in the short-term to 
benefit from novel therapies. In addition, these are the patients most likely to be 
recruited to a Phase 1 clinical trial of BMS-214662 in CML.
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5.1.12.1 BMS-214662 activity in BC CML
Using CFSE to track cell division, BMS-214662 was assessed alone and in 
combination with IM or dasatinib in BC CML (n=2; 1 lymphoid and 1 myeloid BC). 
BMS-214662 had little effect on total viable cells (Figure 5-17A) in BC CML when 
used alone, but when used in combination with either IM or dasatinib, overall 
cytotoxicity was enhanced. BMS-214662 acted to reduce the number of non­
proliferating CFSE"^^  ^ CD34^ CML cells (Figure 5-17B) compared to the no drug 
control and acted synergistically with IM or dasatinib to reduce undivided CFSE^^^ 
CD34^ CML cells. These results show than BMS-214662 when used in 
combination with IM or dasatinib may prolong remission and may prove useful as 
a single agent if inhibition of tyrosine kinase activity with IM or dasatinib has failed.
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Figure 5-17. Assessment of BMS-214662 activity alone or in combination with IM or 
dasatinib on BC CML (n=2). (A) Total viable cell counts were performed after 6 days culture. 
(B) Determination of non-proliferating CFSE"’®’^ CD34* cells remaining after 6 days culture. 
Blast crisis CML cells were cultured in SFM + 5QF, The absolute number of non-proliferating 
cells decreased over time and were 1.62% at 72 hours and 0.7% at 6 days in no drug control. 
Results are expressed as a percentage of the no drug control (mean ± SEM).
5.1.12.2 BMS-214662 activity In cells expressing BCR-ABL kinase
mutations
The efficacy of BMS-214662 in Ba/F3 cells expressing different BCR-ABL kinase 
mutations (WT BCR-ABL, T315I, M351T and H396P) was assessed using total
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viable cell counts and thymidine proliferation assays. It was not possible to use 
primary CD34'*' CML cells with kinase domain mutations as a bank of these cells 
was not available. After 48 hours culture, BMS-214662 was equipotent in both WT 
BCR-ABL and mutant BCR-ABL kinase expressing cells (Figure 5-18A and B), 
indicating that BMS-214662 may be a useful therapeutic option in patients with 
BCR-ABL kinase domain mutations.
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Figure 5-18. Assessment of efficacy of BMS-214662 in Ba/F3 ceils expressing different 
kinase domain mutations (n=3 experiments) by (A) thymidine proliferation assay and (B) 
total viable cell count after 48 hours culture. Results show that BMS-214662 is equally 
effective in Ba/F3 ceils expressing either wild type or mutant BCR-ABL. Five replicates of 
each condition were performed in each experiment. Results represent the mean ± SEM.
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5.1.13 Summary and conclusions
The novel cytotoxic FTI, BMS-214662 has an IC50 of approximately 375nM when 
assessed by thymidine proliferation assay in CD34^ CML cells. However it had 
a greater inhibitory effect on total viable cell counts with a 50% reduction in total 
viable cells at a concentration of 250nM. BMS-214662 is very potent against 
CD34^ CML cells at clinically achievable concentrations. When used in 
combination with IM or dasatinib, BMS-214662 enhances overall cytotoxicity 
compared to either IM or dasatinib alone, with no significant difference between 
the combinations of BMS-214662 + IM or BMS-214662 + dasatinib.
BMS-214662 targets non-proliferating cells in short-term culture experiments. In 
addition, it has minimal anti-proliferative effect and apoptosis studies demonstrate 
that BMS-214662 increases caspase-3 activity in proliferating and, more 
importantly, non-proliferating (quiescent) CD34^ CML cells. This is the first drug 
tested using the CFSE method, either alone or in combination, to show a 
significant reduction in non-proliferating cells compared to the no drug control. In 
addition, when used in combination with either IM or dasatinib, BMS-214662 
overcomes the anti-proliferative effects of these agents to significantly reduce non­
proliferating cells remaining after culture. These results are further supported by 
cell cycle analyses which also shown that non-proliferating cells (Go) are reduced 
after treatment with BMS-214662.
Studies using LTC-IC assay of CD34^ CML cells confirm that BMS-214662 is 
targeting primitive CML stem cells and provide evidence of selectivity for CML 
stem cells versus normal HSCs. These data are further supported by FISH results 
from the colonies remaining at the end of LTC-IC assay which showed that in 2 of 
3 patients, more than 90% of the cells surviving LTC-IC were Ph". This is further 
evidence for the selectivity of BMS-214662 for Ph^ versus Ph" cells.
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The mode of action of BMS-214662 remains elusive. BMS-214662 is not acting via
inhibition of BCR-ABL as evidenced by failure to inhibit CrKL phosphorylation. It is
unlikely that BMS-214662 is acting solely via inhibition of Ras in CML cells as
another FTI, BMS-225975 which is cytostatic and not cytotoxic, inhibits Ras to the
same extent, but lacks the efficacy of BMS-214662 against primitive quiescent
CML cells. Future studies will be directed at attempting to elucidate a mode of
action for BMS-214662 in CML.
Finally, preliminary studies presented here indicate that BMS-214662 is likely to be 
effective in BC CML and also in patients with BCR-ABL kinase domain mutations, 
who are resistant to BCR-ABL-directed TKIs. The activity of BMS-214662 against 
the T315I mutation may prove to be particularly important.
Overall, the results presented here show very promising evidence for the utility of 
BMS-214662 in CML. Further studies are ongoing to determine its mode of action 
and design of a Phase 1 clinical trial in CML is underway (see discussion 7.3).
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6 Results 4
6.1 Assessment of BMS-214662 activity in AML cells in 
vitro
6.1.1 Introduction
The results presented in Chapter 5 demonstrate that BMS-214662 is highly 
effective against CML stem and progenitor cells in vitro. The mode of action for 
BMS-214662 is not via inhibition of BCR-ABL kinase activity, therefore, BMS- 
214662 may be effective in other forms of leukaemia, particularly those which 
have been shown to be stem cell disorders. Thus, the next logical step is to 
assess BMS-214662 activity in AML. There are a number of reasons for this. 
Firstly, like CML, AML is a myeloid neoplasm. Secondly, the only Phase 1 clinical 
trial to date using BMS-214662 in leukaemia was undertaken in patients with AML 
and myelodysplastic syndrome (Cortes et al., 2005a) and, despite being a Phase 1 
study, this trial demonstrated efficacy for BMS-214662 in AML, although the mode 
of action was uncertain. Thirdly, as with solid malignancies in vivo (Mackay et al., 
2004; Dy et al., 2005) and as shown here in CML in vitro, there is the possibility of 
combining BMS-214662 with chemotherapeutic agents such as Ara-C in novel 
therapeutic regimens for AML.
6.1.2 BMS“214662 activity in AML ceii line HL60
Concentration finding studies were undertaken to determine the IC50 for BMS- 
214662 in the AML cell line HL60 using thymidine cell proliferation assays and 
total viable cell counts which were performed after 48 hours culture in the 
presence of increasing concentrations of BMS-214662 (n=3; Figure 6-1 and B).
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Figure 6-1. Determination of IC50 for BMS-214662 In the AML cell line HL60. (A) thymidine 
proliferation assays (n=3) performed after 48 hours culture showed an ICgo of approximately 
450nM and (B) total viable cell counts approximately 375nM. Five replicates of each 
condition were performed in each experiment. Results represent the mean ± SEM.
The I C 5 0  for BMS-214662 in HL60 cells was approximately 450nM by proliferation 
assay. Like CML, BMS-214662 showed a greater reduction in total viable cells 
than inhibition of proliferation with a 50% reduction in total viable cells at a 
concentration of 375nM. These results demonstrate that BMS-214662 is effective 
in the AML cell line HL60 with a similar I C 5 0  to that seen in CML cells. Based on 
these similar results, BMS-214662 was used at a concentration of 250nM in 
further experiments with primary AML cells.
-  __
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6.1.3 Assessment of activity of BMS-214662 in primary AML ceiis
in vitro
6.1.3.1 Assessment of total viable cell counts in AML
In these experiments (n=2), the effect of BMS-214662 either given as a single 
agent or in combination with Ara-C on total viable cells counts was assessed in 
primary AML cells. Ara-C was used at a concentration of 0.5pM as this is a 
concentration which is achievable in patients (Fleming et al., 1995) and has also 
been used in similar in vitro experiments in CML in our laboratory (Jorgensen et 
al., 2005a). The cells were cultured in SFM + 5GF (as for CD34^ CML cells) for 72 
hours under the following conditions: (1) No drug control; (2) BMS-214662 250nM; 
(3) Ara-C 0.5pM and (4) BMS-214662 250nM + Ara-C O.SpM. The total viable cell 
counts are shown in Figure 6-2.
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Figure 6-2. Total viable cell counts after 3 days culture for all experimental conditions. Cells 
were cultured in SFM + 5GF. Results are expressed as a percentage of the no drug control 
(mean ± SEM).
There was a reduction in total viable cells in all treatment arms compared to the no 
drug control, with the combination of BMS-214662 + Ara-C having the greatest
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effect. However, due to the low number of experiments (n=2) and variation
between the two patient samples used, the results did not reach statistical
significance. These results suggest that BMS-214662 has a cytotoxic effect in
AML and enhances the cytotoxic effect of Ara-C.
6.1.3.2 Effect of BMS-214662 on non-proliferating CFSE"’®’^ AML progenitor 
cells
After assessment of total viable cell counts, the effect of BMS-214662 either alone 
or in combination with Ara-C was assessed on the non-proliferating (quiescent) 
AML cell sub-population after 72 hours in culture (n=2). Once again, these 
experiments were performed using CFSE to track cell division, with a colcemid 
control included to identify the non-proliferating CFSE"^®  ^ AML cell population 
using flow cytometry. As for the CML experiments, the absolute number of non­
proliferating cells was calculated and expressed as a percentage of those present 
in the no drug control. The results are shown in Figure 6-3A with representative 
FACS profiles for each experimental condition in Figure 6-3B. The potency of Ara- 
C on proliferating AML cells is clearly demonstrated with the majority of cells 
remaining after culture in the presence of Ara-C being in the non-proliferating 
population. This population is substantially reduced with the addition of BMS- 
214662.
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Figure 6-3. Non-proliferating CFSE"’ ’^‘ primary AML ceils (n=2) remaining after 72 hours 
culture for all experimental conditions in SFM + 5GF. (A) The absolute number of non­
proliferating cells is expressed as a percentage of the no drug control (mean ± SEM). There 
is a substantial reduction in the absolute number of non-proliferating CFSE"’®’^  cells in the 
BMS-214662-containing arms compared to the no drug control and Ara-C only arms. (B) 
Representative FACS histogram plots after 72 hours culture for each of the experimental 
conditions. The plots demonstrate the very low number of undivided cells remaining (boxed 
area) in the no drug control and BMS-214662 arms relative to the total cell numbers. The 
non-proliferating CFSE""®* AML cell population is the only cell population remaining in the 
Ara-C arms, with a very much reduced number in the BMS-214662 + Ara-C arm. Any dividing 
AML cells have been eradicated by Ara-C, however, the majority of CFSE""®* AML cells
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remain undivided in the presence of Ara-C, clearly demonstrating its marked anti­
proliferative effect. The addition of BMS-214662 to Ara-C eliminates the majority of these 
undivided cells.
Non-proliferating CFSE"^^  ^AML cells were reduced in the arms containing BMS- 
214662 compared to the arms without BMS-214662 (P=0.039). However, due to 
the low number of experiments, differences between individual experimental arms 
did not reach statistical significance. Nonetheless, there was a trend towards 
reduced non-proliferating cells in the BMS-214662 + Ara-C arm compared to the 
Ara-C only arm (P=0.062). Despite the limited number of experiments due to 
sample availability, these results suggest that BMS-214662 targets quiescent AML 
cells and may be a useful addition to chemotherapy protocols in AML. Further 
experiments are required to fully explore the potential of BMS-214662 in AML.
6.1 A  Summary and conclusions
BMS-214662 has an IC50 of approximately 450nM in the HL60 AML cell line by 
assessment of ^H thymidine proliferation assays, although, as with CML, this 
agent had a greater effect on total viable cells. The results presented here indicate 
that BMS-214662 is cytotoxic to primary AML cells in vitro, and enhances the 
effect of Ara-C. Importantly, BMS-214662 appears to target quiescent AML stem 
and progenitor cells, resulting in an enhanced effect when BMS-214662 and Ara-C 
are combined. Overall, these results suggest that BMS-214662 may be a very 
effective therapy for AML and further investigation of its therapeutic potential in 
AML is required.
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7 Discussion
7.1 Priming primitive CML progenitor cells with rHu-G- 
CSF improves their eradication by IM in vitro
The aims of this chapter were to determine if using an ‘IM holiday’ (interrupted IM 
therapy), or priming primitive CML progenitors with rHu-G-CSF would overcome 
the inherent insensitivity of the most quiescent CML progenitors to IM (Graham et 
al., 2002). The first experiments in this chapter set out to characterise G-CSF-R 
protein expression and functionality in CD34^ CML progenitor cells in response to 
rHu-G-CSF in vitro. Previous studies have shown that CD34^ cells from CP CML 
patients can be maintained in culture in the absence of exogenous growth factors 
via autocrine production of IL-3 and G-CSF (Jiang et al., 1999). This suggests that 
proliferating CD34^ cells possess functional G-CSF-Rs. Here, we have shown that 
G-CSF-R protein expression is increased in proliferating CD34^ CML cells 
compared to normal CD34’*’ cells and that this increase is not further augmented 
by the addition of rHu-G-CSF to culture (3.1.2). We then went on to confirm the 
presence of functional G-CSF-Rs on CD34^ CML cells by demonstrating a 
concentration-dependent response to rHu-G-CSF in these cells (Figure 3.4) which 
was saturated at a rHu-G-CSF concentration of ~20ng/mL. This G-CSF 
concentration is readily achievable in vivo and equates to a rHu-G-CSF dose of 
approximately 5pg/kg in the patient (Stute et al., 1992). This is the standard dose 
of rHu-G-CSF given for peripheral blood stem cell mobilisation (Drummond et al., 
2003; Hui et al., 2003), IM-induced neutropenia (Marin et al., 2003b; Sneed et al., 
2004) and growth factor priming in combination with cytotoxic chemotherapy in 
AML (Cannistra et al., 1989; Bhalla et al., 1991; te Boekhorst et al., 1993). We 
further demonstrated, indirectly, that the quiescent sub-population of CD34^ CML
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cells express functional G-CSF-Rs by showing that, in the presence of intermittent
rHu-G-CSF (first 24 hours of each 96 hour cycle), this population is significantly
reduced due to increased numbers of these cells leaving the undivided (quiescent)
gate through cell division.
In the absence of rHu-G-CSF, an ‘IM holiday' was less effective than continuous 
IM therapy at reducing the total viable cell number. However, in the presence of 
rHu-G-CSF, there was no significant difference between the two strategies, with 
the combination of intermittent rHu-G-CSF with either interrupted or continuous IM 
being most effective at reducing total viable cells. Furthermore, in the quiescent 
sub-population, there was no significant difference in the size of the remaining 
sub-population between continuous and interrupted IM therapy after 12 days in 
culture. This suggests that in vivo, an ‘IM holiday’ alone is unlikely to reduce the 
molecular persistence which occurs with continuous IM therapy. Conversely, the 
addition of intermittent rHu-G-CSF (G-CSF priming) to either continuous or 
interrupted IM therapy may be more effective.
The diverging results seen here with intermittent and continuous rHu-G-CSF 
exposure in the quiescent sub-population suggests that treatment of these 
primitive cells with intermittent rHu-G-CSF may activate a unique mechanism 
which is not maintained in later progeny. One possible explanation is that, in the 
quiescent fraction, initial exposure to rHu-G-CSF up-regulates G-CSF-R protein 
expression. However, continuous exposure to supra-physiological doses of rHu-G- 
CSF in this population serves to down-regulate functional G-CSF-R expression 
removing the drive for these cells to proliferate. Each intermittent exposure to rHu- 
G-CSF up-regulates the functional G-CSF-Rs and stimulates a proportion of the 
quiescent cells to proliferate, but because high G-CSF levels are not present
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continuously, the cells do not become unresponsive or ‘resistant’ to the effects of
rHu-G-CSF.
The effect of combining different chemotherapeutic agents such as 
hydroxycarbamide or Ara-C with rHu-G-CSF was not assessed in this study, and 
these combinations could be equally effective at reducing total viable CML cells as 
well as the quiescent CD34^ sub-population. However, to date, IM is the only 
agent which has been shown to prevent progression to more advanced phases of 
CML (Druker et al., 2006). BCR-ABL increases the production of ROS, inhibits 
protein tyrosine phosphatases (PTPases) (Battler et al., 2000), and causes 
inappropriate regulation of DNA repair pathways which results in unfaithful repair 
of ROS-dependent DNA double strand breaks (Nowicki et al., 2004). These effects 
may add to the mutator phenotype shown by BCR-ABL^ cells and are inhibited by 
IM in vitro (Battler et al., 2000; Nowicki et al., 2004). It has recently been reported 
that the production of ROB stimulated by BCR-ABL results in oxidative DNA 
damage and increases the acquisition of BCR-ABL kinase domain mutations 
associated with IM resistance in vitro (Koptyra 2006). Genotoxic stress such as 
that induced by agents like Ara-C may further increase ROB and result in 
additional kinase domain mutations which have previously been shown to exist 
prior to IM therapy (Roche-Lestienne et al., 2002; Kreuzer et al., 2003). Therefore, 
these agents may be less suitable than BCR-ABL TKIs for combination therapy in 
CML. In addition, genomic instability may be related to BCR-ABL expression 
levels. Therefore, in the primitive CD34^38‘ CML progenitor cells with high levels 
of BCR-ABL expression (Copland et al., 2006), it is possible that mutations 
resulting in IM-resistance will occur at the highest frequency. Caution should also 
be taken if combining haemopoietic growth factors with IM as growth factors 
including GM-CBF and IL-3 have been shown to increase ROB in vitro in 
haemopoietic cell lines by increasing tyrosine phosphorylation (Battler et al..
Mhairi Copland, 2007 Chapter 7, 196
1999). Thus it would be important to monitor patients for BCR-ABL kinase domain
mutations if the BCR-ABL level is rising in a trial combining rHu-G-CSF with IM.
The treatment of BCR-ABL^ cells with antioxidants such as N-acetylcysteine or
vitamin E reduced accumulation of ROS, reactivated PTPases and resulted in
fewer BCR-ABL kinase domain mutations developing in both in vitro and in vivo
models (Battler et al., 2000; Koptyra et al., 2006). Very interestingly, the addition of
IM to an antioxidant had a superior anti-mutagenic effect compared to antioxidant
alone (Koptyra et al., 2006) and it will be important to determine if the addition of
an antioxidant to IM therapy reduces the incidence of IM-resistant BCR-ABL
kinase domain mutations in vivo.
As discussed, a further aim of this study was to determine if rHu-G-CBF priming of 
CD34^ CML cells combined with IM therapy would reverse the anti-proliferative 
effect of IM alone at the Gq/Gi interface, allowing these quiescent cells to re-enter 
the cell cycle. These results confirm that intermittent exposure to rHu-G-CSF does 
enhance the eradication of quiescent CD34^ CML cells, however, a sub-population 
of deeply quiescent CML cells does persist, even after combined therapy with 
intermittent rHu-G-CBF and either continuous or interrupted IM. In agreement with 
the results of this study, Holtz et al have also recently shown that IM in 
combination with a high concentration growth factor cocktail enhances elimination 
of quiescent CD34^ CML cells (Holtz et al., 2004).
A number of observational case series have reported that patients with IM-induced 
neutropenia obtain improved cytogenetic responses when also treated with rHu-G- 
CSF (Heim et ai., 2003; Marin et al., 2003b; Quintas-Cardama et al., 2004). It has 
been presumed that this is due increased and maintained continuous IM dosing 
being achieved in the face of a rHu-G-CBF-supported neutrophil count. However, 
while this may still be true, the results here would also support the alternative
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mechanism of action proposed in 3.1.1 -  that intermittent exposure to rHu-G-CSF
promotes re-entry of quiescent CML cells into the cell cycle, which results in cell
division and renders the cells susceptible to the effects of IM in later divisions
(Jorgensen et al., 2005b).
We also demonstrated that when non-proliferating CD34^ CML cells treated with 
IM ± G-CSF leave the undivided gate, they do so by cell division and not 
apoptosis. This suggests that, in this quiescent CML sub-population, the anti- 
apoptotic pathways which are activated and maintained by BCR-ABL and, in part, 
responsible for the dys-regulated cell turnover seen in CML (Bedi et al., 1994), are 
not inhibited by IM. Conversely, in dividing CML cells, our results and others (Holtz 
et al., 2005), demonstrate that IM does induce apoptosis, resulting in reduced 
numbers of total viable cells.
The results of this study have provided a powerful rationale for the design and 
implementation of a National Cancer Research Network (NCRN; 
www.ukcrn.orq.uk) randomised clinical trial called G-CSF with Imatinib Mesylate 
Intermittently (GIMI) which compares continuous IM, interrupted IM (21 of every 28 
days) and pulsed rHu-G-CSF with interrupted IM (G-CSF on Monday, Wednesday 
and Friday of the no IM week; Figure 7.1). The primary end points of this study 
are to determine the safety of interrupting IM therapy and giving intermittent rHu- 
G-CSF in combination with interrupted IM (Mitchell et al., 2006). Secondary 
endpoints are to compare molecular response using qRT-PCR for BCR-ABL and 
proportion of patients progressing in each of the 3 arms. The interventions 
(intermittent IM or pulsed rHu-G-CSF plus intermittent IM) will be deemed 
successful if these arms show no rise in BCR-ABL levels at the end of the study 
compared to the continuous IM control arm. Patients are required to have 
achieved a CCR for a minimum of 6 months on IM therapy as demonstrated by
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<2% BCR-ABL by qRT-PCR prior to study entry. Recruitment has recently been
completed in this multi-centre trial based in the UK and France. A total of 45
patients have been recruited, with 15 in each arm. Patients are receiving the
randomised intervention for one year with monthly monitoring of qRT-PCR levels
for BCR-ABL.
Three way randomisation 
15 patients per arm
Interrupted IIW + 
rHu-G-CSF
CIVIL 
Start IM1
OCR
I Minimum of 6 months in OCR on IM (<2% BCR-ABL by qRT-PCR)
Randomisation1
Interrupted IM alone Continuous IM monotherapy
Figure 7-1. Schematic diagram of the protocol for the GIMi trial.
In conclusion, intermittent exposure to rHu-G-CSF enhances the effect of IM on 
quiescent CD34'*' CML cells. However, an ‘IM holiday’ alone does not reduce the 
quiescent CD34^ CML cell sub-population, but in combination with intermittent 
rHu-G-CSF is as effective as continuous IM. This strategy, which is currently in 
clinical trial, may offer a unique opportunity for improving molecular responses in 
patients with CP CML by improving eradication of IM-insensitive quiescent CML 
cells.
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7.2 A comparison of the efficacy of dasatinib and IM 
against quiescent primitive CML progenitor cells in 
vitro
As highlighted in the introduction (1.2.8), CML stem cells are relatively resistant to 
IM (Graham et al., 2002; Holtz et al., 2002; Bhatia et al., 2003; Holtz et al., 2005; 
Jorgensen et al., 2005a), and it is postulated that this CML stem cell insensitivity to 
IM results in the molecular persistence seen even in patients responding well to 
IM (Holtz et al., 2002). The mechanisms underlying the IM resistance seen in CML 
stem cells, including whether this resistance is BCR-ABL-dependent or 
independent remain to be determined. Our group has recently demonstrated that 
primitive IM-resistant CML cells have only single-copy, non-mutated BCR-ABL, but 
express significantly higher levels of BCR-ABL transcripts and protein than mature 
CML cells (Copland et al., 2006), however, like other studies, we were unable to 
determine whether BCR-ABL was a relevant target in these IM-resistant cells. 
These results highlight the importance of investigating more potent BCR-ABL 
kinase inhibitors and determining their effect on the quiescent CML stem cell 
population. The multi-targeted kinase inhibitor, dasatinib, is one such inhibitor 
which has been shown to be 325 times more potent than IM at inhibiting wild-type 
BCR-ABL in cell line studies and also targets mutant BCR-ABL with the exception 
of the T315I mutation (Shah et al., 2004; O'Hare et al., 2005). Therefore, the aims 
of this chapter were to determine if dasatinib was more effective than IM in 
primitive CML progenitor cells and whether dasatinib would eradicate quiescent 
CML cells in vitro. A further aim was to investigate the relevance of SRC kinases 
and BCL-2 in early CP CML as dasatinib is also a potent inhibitor of SRC kinases 
(Lombardo et al., 2004) one of which, LYN, is believed to mediate the activity of 
BCL-2 in CML (Dai et al., 2004).
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The data presented in this study demonstrate that, at high therapeutically
achievable concentrations (IM 5pM and dasatinib 150nM), IM and dasatinib had
equal cytotoxicity in primitive CML progenitor cells. Further studies to assess BCR-
ABL kinase activity, using a novel intracellular flow cytometry assay which
determined CrKL phosphorylation status after treatment with either IM or dasatinib
showed that, after 72 hours treatment with IM, the surviving CD34^ CML cells had
fully phosphorylated CrKL, indicating that we had failed to inhibit BCR-ABL.
However, after 72 hours culture in the presence of dasatinib, both CD34^ and
more primitive CD34^38" CML cells had significant inhibition of CrKL
phosphorylation, indicating that dasatinib was a more effective inhibitor of BCR-
ABL than IM. However, these results do not provide evidence for the relevance of
BCR-ABL in the IM-resistant cells.
There are a number of possible explanations for the IM-resistance demonstrated 
here and also, the superior effect of dasatinib in CML. Firstly, there may be 
insufficient IM levels within the stem cell population to inhibit BCR-ABL kinase 
activity. This may be related to gene amplification (Gorre et al., 2001), high 
transcript levels (Jiang et al., 2003; Jiang et al., 2004), increased kinase activity 
(Chu et al., 2004) or the balance between drug influx and efflux (Burger et al., 
2004; Thomas et al., 2004; Clark et al., 2005) within this primitive quiescent 
population. The increased potency of dasatinib may overcome the increased 
transcript levels and kinase activity demonstrated in the stem cell population here. 
In addition, unlike IM, dasatinib is not a substrate for p-Glycoprotein, and this may 
be another reason why it reaches further into the stem cell compartment (Lee et 
al., 2005). A second possible explanation is that cells expressing kinase domain 
mutations are enriched within the stem cell population (Shah et al., 2002). If this is 
the case, then the majority of these would be inhibited by dasatinib. However, in 
this study, mutation analysis demonstrated wild-type BCR-ABL only, although
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other studies have detected BCR-ABL kinase mutations at a low level in CD34^
cells from patients both pre- (Jiang et al., 2005) and post treatment with IM (Chu et
al., 2005). In this study, if the resistance to IM was due to BCR-ABL kinase domain
mutations, then the mutation would need to be present in the majority of the cells
to explain the resistance to IM in the CD34^38" population. We did not exclude a
low level of mutated BCR-ABL in these populations in this study as the sensitivity
of direct sequencing is insufficient to detect this. Other groups have shown that
BCR-ABL kinase domain mutations can be detected at low level using sensitive
techniques in stem cells such as bi-directional sequencing of individually cloned
complementary DNA from patient samples (Chu et al., 2005; Jiang et al., 2005). A
third explanation is that, in the stem cell compartment, BCR-ABL may tend to
remain in its active conformation to which IM cannot bind, thereby reducing the
affinity of IM for the ATP binding site of BCR-ABL (Nagar et al., 2002; Burgess et
al., 2005). This would also explain the superior inhibition of CrKL phosphorylation
seen with dasatinib as this drug is able to bind BCR-ABL in both active and
inactive conformations.
Assessment of CrKL phosphorylation status has been accepted as a robust 
method to determine BCR-ABL activity as it is thought to be a specific marker for 
BCR-ABL signalling and the CrKL phosphoprotein complex is relatively stable 
(Hochhaus et al., 2001; White et al., 2005). However, a very recent study indicates 
that the adaptor molecule CrKL may be a substrate of the SRC kinases (Qiao et 
al., 2006). If this is the case, then CrKL phosphorylation status is likely to be 
affected by a SRC kinase inhibitor (i.e. dasatinib). Therefore, the superior inhibition 
of CrKL phosphorylation seen with dasatinib in CD34^ and CD34^38" CML cells 
may be due to enhanced inhibition of SRC kinases and not BCR-ABL and, thus, 
IM-resistance in the CML stem cell population may not be BCR-ABL-dependent. In
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addition, other BCR-ABL-independent mechanisms of IM resistance may be
present in CML stem cells.
It has been postulated that the increased efficacy of dasatinib compared to IM in 
CML is mediated via BCR-ABL and not SRC kinases. Indeed, previous studies in 
cell lines and animal models, but not primary CML cells, have failed to 
demonstrate a role for the SRC kinases, LYN, HCK and FGR, which are most 
commonly expressed on myeloid cells, in CP CML (Donato et al., 2003; Hu et al., 
2004). In this study, I have shown that the expression of activated SRC kinases (p- 
SRC), is increased in all phases of CML compared to normal CD34  ^and CD34^38" 
cells. Of particular interest is the finding that, in the more primitive CD34’^ 38" CML 
sub-population, compared to normal CD34^38" cells, expression of p-SRC was 
relatively higher. However, the action of IM or dasatinib on p-SRC was very similar 
to that seen with p-CrKL, suggesting that the effect is most likely mediated via 
BCR-ABL and not direct SRC kinase activation. This was also supported by the 
fact that the SRC-specific kinase inhibitor PP2 had no significant effect on p-SRC 
compared to no drug control in CD34^ CML cells. In addition, BCL-2 expression 
was also significantly increased in all phases of CML. However, I was unable to 
demonstrate a direct link between p-SRC and BCL-2 expression as IM, dasatinib 
and PP2 had only modest effects on BCL-2 levels in CD34^ CML cells. This would 
tend to suggest that expression of BCL-2 may be independent of both BCR-ABL 
and SRC kinases in CML. Alternatively, because BCL-2 has a longer half-life than 
activated BCR-ABL or SRC, it may take longer for changes in BCL-2 expression 
following drug treatment to become apparent.
The use of molecularly targeted therapies such as IM and dasatinib is rapidly 
increasing in the treatment of malignant disease. As more cancers are being 
identified as stem cell diseases, researchers are focussing their attention on the
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elimination of cancer stem cells as a potentially curative strategy. The importance
of LSCs and their resistance to IM has long been recognised in CML (Holyoake et
al., 1999; Graham et al., 2002). Therefore, in this study, I used a CFSE-based
assay which allows high resolution tracking of cell division and identification of the
quiescent (non-proliferating) primitive progenitor population in CML (Nordon et al.,
1997; Graham et al., 2002). These experiments demonstrated that, within the stem
cell compartment, there was a trend for dasatinib to be less anti-proliferative than
IM. Therefore, dasatinib is less likely to induce the reversible Gi arrest seen in
vitro and in vivo with IM. This is particularly important when combining cytotoxic
and/or cytostatic agents, the majority of which tend to cause cell cycle arrest.
However, despite its increased potency, dasatinib failed to eradicate the quiescent
stem cell population in vitro. Although compared to IM, dasatinib showed a trend
towards reducing the CFSE'^^’^  population, it still remained substantially higher
than the no drug control and failed to show a statistically significant reduction
compared to IM (Figures 4-5 and 4-6). This implies that, although dasatinib was
able to inhibit CrKL phosphorylation in the primitive CD34^38" population, like IM, it
failed to target the truly quiescent CML stem cells in culture.
Overall, these results indicate that dasatinib is a much more potent inhibitor of 
BCR-ABL than IM and is able to target BCR-ABL^ cells deeper into the stem cell 
compartment (Figure 7-2). Therefore, dasatinib would be expected to produce 
lower levels of MRD in vivo in CML patients. However, it has been demonstrated 
that quiescent CML stem cells appear intrinsically resistant to IM and dasatinib 
and thus, dasatinib is unlikely to be curative in CML. The possibility that, in 
quiescent CML stem cells, neither BCR-ABL nor SRC kinases are relevant targets 
should be considered. This highlights the need to identify and develop new cancer 
stem-cell directed therapies to effectively eradicate these primitive cancer initiating 
cells in patients while sparing the normal stem cell compartment.
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Figure 7-2. Schematic diagram to show the effects of IM and dasatinib on the different 
progenitor cell populations in CML. Although mature haemopoietic cells and the majority of 
progenitor cells are sensitive to both IM and dasatinib, primitive CML progenitors (CD34^38 ) 
are resistant to IM, and the leukaemia stem cell compartment is resistant to both IM and 
dasatinib through mechanisms which have still to be fully elucidated.
7.3 Assessment of the efficacy of the novel FT! BMS- 
214662 against stem and progenitor ceils in myeloid 
leukaemias in vitro
There is mounting evidence that strategies to target both quiescent stem cells and 
proliferating cells are required to eradicate CML (Graham et al., 2002; Holtz et al., 
2002; Bhatia et al., 2003; Holtz and Bhatia, 2004; Holtz et al., 2005; Copland et al., 
2006). The combination of BMS-214662 with either IM or dasatinib may be one 
such strategy. The data presented in Chapter 5 show that BMS-214662 is 
cytotoxic to both quiescent and proliferating primary cells in CP as well as BC
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CML, and induces apoptosis, as evidenced by increased caspase-3 activity. Used
as a single agent, it has minimal anti-proliferative effect on CML progenitors. In 
combination with either IM or dasatinib, BMS-214662 does not overcome the anti­
proliferative effects of these agents, but kills the quiescent CML stem cells while 
they remain either in Go or arrested in early Gi phase of the cell cycle. This is 
demonstrated by greater caspase-3 activity in the undivided CFSE^^ CD34"' 
progenitor fraction. LTC-IC assays showed that culture in the presence of BMS- 
214662 virtually eliminated the ability of CML stem cells to form colonies. This 
provides further evidence for efficacy of BMS-214662 against quiescent CML stem 
cells by inhibiting their repopulating activity. BMS-214662 also demonstrated 
preferential cytotoxicity for leukaemic versus normal stem cells as evidenced by 
superior inhibition of colony formation in the CML LTC-IC assays compared to 
normal donor cell LTC-IC assays. In addition, in 2 of 3 CML LTC-IC assays, in 
which the CD34^ cells used to seed the assay were pre-treated with BMS-214662 
for 72 hours, FISH performed on the colonies present at the end of 7 weeks 
culture showed that the majority of these colonies were BCR-ABL'. These colonies 
have come from residual normal haemopoiesis which was present in these 
patients with early CP CML at the time of leukapheresis (Goto et al., 1982; 
Coulombel et al., 1983b). In the third patient sample, in which FISH remained 
BCR-ABL^ at the end of LTC-IC, it is likely that there was little normal 
haemopoiesis remaining at the time of leukapheresis. Indeed, after commencing 
IM, this patient required growth factor support and a reduced dose of IM to 
manage the cytopenias resulting from IM therapy.
These results demonstrate that, in vitro, BMS-214662 is superior to cytostatic FTIs 
such as lonafarnib (Jorgensen et al., 2005a) and BMS-225975 in eliminating 
quiescent CML stem cells. The concentration of BMS-214662 used in these 
experiments (250nM) is a clinically achievable plasma concentration (Tabernero et
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al., 2005). Although BMS-214662 has yet to enter clinical trial in CML, phase 1
trials in AML using BMS-214662 as a single agent have shown promising activity
(Cortes et al., 2005a). In a future clinical trial, which is currently under
development with Bristol-Myers Squibb and the National Cancer Institute (NCI), it
is likely that BMS-214662 would be given as a single weekly infusion in
combination with continuous therapy with dasatinib. Monitoring of these patients is
likely to include qRT-PCR to assess BCR-ABL levels and LTC-IC on bone marrow
samples taken pre-treatment and at regular intervals throughout therapy, with
FISH on the colonies produced to assess the effect of this combination therapy on
the stem cell compartment. In clinical trials in advanced solid tumours, intermittent
infusions of BMS-214662 have been successfully combined with cisplatin,
carboplatin and paclitaxel (Mackay et al., 2004; Dy et al., 2005). Preliminary
experiments done in this study show that, in vitro, intermittent exposure to BMS-
214662, in combination with either continuous IM or dasatinib, tended to enhance
the efficacy of these TKIs in CML with increased caspase-3 activity and a
reduction in primitive progenitor cells.
The activity of BMS-214662 in BC CML and cell lines expressing BCR-ABL kinase 
mutations is also important. Patients with BC CML initially respond to IM but then 
relapse (Druker et al., 2001a). A proportion of these IM-resistant patients will 
respond to dasatinib or nilotinib but nearly all relapse within 6 months (Kantarjian 
et al., 2006; Talpaz et al., 2006). Therefore, BMS-214662 in combination with a 
TKI may increase the number of patients with BC CML who respond and also the 
length of remission, possibly allowing time for other therapeutic strategies such as 
alloSCT to be instituted. For those patients with BCR-ABL kinase mutations, the 
majority will respond to either dasatinib or nilotinib (Kantarjian et al., 2006; Talpaz 
et al., 2006), however, patients with the T315I mutation are resistant to these 
drugs. These patients may benefit from single agent therapy with BMS-214662
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which we have shown to be equipotent in both wild type and mutant BCR-ABL
expressing cell lines including T315I.
The effect of BMS-214662 on non-proliferating cells was first identified in in vitro 
models of solid tumours (Lee et al., 2001). However, despite extensive 
investigation, to date, the mode of action of BMS-214662 remains elusive (Rose et 
al., 2001; Manne et al., 2004). Multiple in vitro studies, including this one, have 
demonstrated its pro-apoptotic action (Rose et al., 2001; Manne et al., 2004; 
Marzo et al., 2004; Aichberger et al., 2005), but the pathway(s) leading to this has 
yet to be elucidated. It is unlikely that BMS-214662 is acting via the Ras pathway 
as it has been shown to be effective in Ras""" and Ras mutant cell lines (Rose et 
al., 2001). In addition, this study demonstrates that the structurally similar 
cytostatic FTI, BMS-225975, did not induce apoptosis and failed to eliminate CML 
stem cells. Recent in vitro studies in B-cell CLL (Marzo et al., 2004) and myeloma 
(Aichberger et al., 2005) have identified inhibition of Mcl-1 and activation of Bax 
and Bak as potential modes of action in these haematological malignancies. 
However, these conditions have not yet been shown to be stem cell disorders and 
the mechanism of action may be different. Western blotting showed no evidence of 
alterations in Mcl-1 levels in CD34^ CML cells after treatment with BMS-214662 
either alone or in combination with IM or dasatinib.
Further work has investigated the role of the centromere-associated proteins 
CENP-E and CENP-F in the activity of FTIs (Ashar et al., 2000). These proteins, 
which are involved in the mitotic process, stabilise microtubule capture by 
kinetochores required for complete chromosomal capture during metaphase and 
are believed to be mediators of the G2/M checkpoint. FarnesyItransferase 
inhibitors alter the association between CENP-E and the microtubules resulting in 
cell cycle arrest with accumulation of cells prior to metaphase. However, this is an
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unlikely mode of action in CML as cell cycle analyses performed for this project
after treatment with BMS-214662 did not show cell cycle arrest.
Another study (Du and Prendergast, 1999) has focussed on the 21 kD G-protein 
RhoB which regulates receptor trafficking and is believed to be a prénylation target 
of FTIs. This study demonstrated that RhoB GTPase activity was increased in 
some human cancer cell lines (predominantly epithelial) and that the accumulation 
of RhoB GGT increased apoptosis, inhibited tumour cell proliferation, and resulted 
in cell cycle arrest via multiple mechanisms, including alterations in cell adhesion. 
In addition, in cancer cells which over-express AKT, FTIs induce apoptosis and 
inhibit P13K/AKT-mediated adhesion and growth factor-dependent survival 
pathways (Jiang et al., 2000a). It is possible that one of these proposed 
mechanisms of action that alters cell adhesion could explain the dramatic results 
seen in the LTC-IC assay experiments. The hypothesis would be that after 
treatment with BMS-214662, the CML stem cells are unable to adhere to the 
stromal layer, resulting in failure to form colonies. Again, these potential modes of 
action need further investigation in CML.
An alternative recent study has shown that FTIs directly induce production of ROS 
resulting in DNA damage in neoplastic cells (Pan et al., 2005; She et al., 2005). 
However, the pathway by which FTIs induce ROS is not yet fully elucidated, 
although it has been postulated that ROS are increased primarily by greater 
generation (Pan and Yeung, 2005). Interestingly, additional recent research has 
shown that FTIs increase inducible nitric oxide synthase (iNOS), resulting in higher 
nitric oxide (NO) production and apoptosis in CD34^ CML cells (Selleri et al.,
2003). Furthermore, in this study, the Rho inhibitor C3 exoenzyme, significantly 
increased iNOS expression in CML cells, indicating that FTIs may increase NO 
production at least partly through FTI-mediated inhibition of Rho. These exciting
Mhairi Copland, 2007 Chapter 7, 209
studies provide further insights into the potential mechanisms of action through off-
target activities of BMS-214662 and highlight the importance of determining a
mode of action for BMS-214662 in CML. In future studies, it would be important to
measure RhoB and iNOS activity before and after treatment with BMS-214662 in
CD34+ CML cells.
A further recent study using a chemical genetics approach in the nemotode 
Caenorhabditis elegans showed that several pro-apoptotic FTIs induced p-53- 
independent apoptosis (Lackner et al., 2005). In addition, these FTIs also inhibited 
the eukaryotic protein prenylase RabGGT in mammalian cancer cell lines. 
Geranylgeranylation by RabGGT is responsible for the membrane localisation of 
the Rab family of small GTPases which are involved in endosomal to lysosomal 
trafficking. This study also showed that RabGGT was over-expressed in a sub-set 
of human solid tumours (ovarian tumours, adenocarcimoma of colon, large cell 
lung carcinoma and melanoma) and that short interfering RNA (siRNA) against 
RabGGT induced apoptosis in 3 human cancer cell lines (the lung 
adenocarcinoma cell line A549, the ovarian cancer cell line A2780, and the p-53 
null prostate cancer cell line PC3). This is the first study to suggest a potential role 
for RabGGT in apoptosis and cancer initiation or progression and identifies a novel 
pathway for p-53-independent apoptosis and a potential post-translational mode of 
action for FTIs, including BMS-214662. However, this study did not assess 
RabGGT in any haematological malignancies, and in further work I would propose 
determining if RabGGT is over-expressed in myeloid leukaemias. If it is, then I 
would go on to assess whether RabGGT was inhibited by BMS-214662 in CD34^ 
CML or AML cells and, if so, whether inhibition of RabGGT with siRNA resulted in 
increased apoptosis in order to determine if RabGGT is a relevant target in 
myeloid leukaemias.
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Further studies, including gene expression profiling, a kinase screen and detailed
investigation of the Ras pathway have been undertaken by us in an attempt to
determine the mode of action of BMS-214662 in CML. At present, it is
hypothesised that BMS-214662 acts post-translationaiiy on CML cells. In support
of this post-translational role for BMS-214662, a comprehensive transcriptional
profiling experiment utilising the Affymetrix microarray platform and analysed by Dr
Francesca Pellicano showed no evidence for significant up- or down-regulation (by
greater than 1.3-fold) of genes in CML CD34^ cells following treatment with BMS-
214662 as compared with either BMS-225975 or no drug control. In addition,
Bristol Myers Squibb have performed a detailed kinase screen on the CML cell line
K562 which was entirely negative and excluded kinase inhibitory activity against
BCR-ABL and other kinases. However, one positive finding which is currently
under further investigation is that, in association with induction of apoptosis, BMS-
214662 resulted in near complete inhibition of phosphorylation of ERK and down-
regulation of the inhibitor of apoptosis protein (lAP), whereas BMS-225975 neither
induced apoptosis nor inhibited ERK phosphorylation or down-regulated lAP,
strongly suggesting that BMS-214662 acts post-translationally.
In addition to its potent effect on CML stem and progenitor cells, very preliminary 
data, presented here in Chapter 6 indicate that BMS-214662 shows some efficacy 
when used either alone or in combination with Ara-C in primary AML cells. This is 
an important finding which requires further investigation. To this end, we are in the 
process of developing a bank of primary samples taken from AML patients at 
diagnosis which will allow us to undertake experiments similar to those performed 
in CD34^ CML cells in this study. A Phase 1 trial of BMS-214662 has already been 
performed in AML (Cortes et al., 2005a) and demonstrated some efficacy. Further 
laboratory studies, in particular examining the effect of BMS-214662 alone and in 
combination with other chemotherapeutic agents on AML stem cells, may provide
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a rationale for the development of a Phase 2 trial in AML as have already taken
place with tipifarnib (Harousseau et al., 2003; Lancet et al., 2003).
Finally, it will be important to investigate the activity of BMS-214662 on stem cell 
malignancies such as breast, prostate and brain (Al-Flajj et al., 2003; Singh et al., 
2003; Collins et al., 2005). Previous studies in solid tumours have failed to show a 
significant effect for BMS-214662, but these trials were undertaken in patients with 
a range of malignancies, not all of which have been demonstrated to be of stem 
cell origin, who had already received multiple chemotherapy regimens. In addition, 
in these heavily pre-treated patients, side effects at higher doses of BMS-214662 
proved to be a problem with haematological, renal, gastrointestinal and hepatic 
toxicities being dose-limiting (Mackay et al., 2004; Dy et al., 2005; 
Papadimitrakopoulou et al., 2005; Eder et al., 2006). These Phase 1 studies were 
powered to assess safety and tolerability and not efficacy with only one study 
showing significant clinical benefit from treatment, and in this study (Tabernero et 
al., 2005), only 5 out of 31 patients had a response. This apparent lack of efficacy 
led to further trials with BMS-214662 in solid tumours being abandoned. It is only 
in recent months, based on the results presented here, that further clinical grade 
BMS-214662 has been manufactured and there has been a resurgence in interest 
in the potential use of BMS-214662 in stem cell malignancies. It is likely that 
further research into the use of BMS-214662 in solid tumours will be much more 
selectively focussed on tumours shown to be derived from stem cells such as 
breast, prostate and brain.
It is only by understanding the mechanism of action of BMS-214662 that advances 
can be made in using BMS-214662 in the clinic, resulting in increased efficacy and 
reduced toxicity. In addition, by using BMS-214662 as a laboratory tool, it may be 
possible to Identify new molecular targets in the treatment of myeloid leukaemias
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and other stem cell neoplasms leading to the development of novel therapeutic
agents.
7.4 Final discussion and conclusions
The importance of developing targeted cancer therapies is related to the toxicity of 
conventional chemotherapy regimens to normal cells and the failure of these non­
specific agents to target cancer stem cells, resulting in an inability to cure many 
cancers. The development of molecularly targeted therapies allows specific 
targeting of cancer cells without affecting normal cells, reducing toxicity and, in 
most cases, improving patient quality of life. Although the introduction of IM for the 
treatment of BCR-ABL^ malignancies is widely heralded as the first successful 
molecularly targeted cancer therapy (Druker et al., 2001b), it was preceded by 
others. Perhaps the first real targeted approach to cancer therapy was the use of 
hormonal manipulation in the form of tamoxifen in breast cancer (Early Breast 
Cancer Tria lists' Collaborative Group, 1998). Another was the use of monoclonal 
antibodies such as the anti-CD20 agent rituximab (Mabthera™) in B cell disorders 
(Coiffier et al., 2002). Currently, targeting signal transduction pathways is a major 
strategy in the development of novel anti-neoplastic agents.
CML represents an excellent model for the study of cancer stem cells because it 
results from a single genetic mutation {BCR-ABL) and is measurable by standard 
laboratory techniques such as FISH and PCR (Kaeda et al., 2002). This also 
makes CML an ideal disease in which to identify novel agents which target cancer 
stem cells.
There have been major advances in the treatment of CML in recent years with the 
development of IM (Druker et al., 1996; O'Brien et al., 2003) and, more recently.
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the oral, multi-targeted kinase inhibitor dasatinib (Talpaz et al., 2006) and the
second generation BCR-ABL kinase inhibitor, nilotinib (Kantarjian et al., 2006).
These newer compounds target IM-resistant mutations and, in the case of
dasatinib, reach further into the stem cell compartment (Copland et al., 2006).
However, despite inhibition of BCR-ABL, quiescent CML stem cells remain
insensitive to these compounds. Further, as shown here for the first time, in LTC-
IC experiments, IM and dasatinib would appear to exert a protective effect on the
CML stem cell compartment through their anti-proliferative action, although this
may be an in vitro culture artefact and has yet to be confirmed in vivo. Therefore,
strategies are required to target both quiescent and proliferating BCR-ABL^ cells.
The importance of cancer stem cells is a rapidly emerging area of research and 
the ability of BMS-214662 to selectively target quiescent LSCs is shared by a very 
few novel anti-cancer agents (Guzman et al., 2002; Guzman et al., 2005). Studies 
are planned to determine if this property is applicable to other malignancies with 
quiescent stem cells (breast, brain and prostate cancer etc). However, the study of 
quiescent primary cancer stem cells is complex as it is difficult to separate this 
small sub-population of cells from the proliferating majority, making 
characterisation of these cells difficult. Studies in fibroblasts (Coller et al., 2006), 
which artificially induced quiescence by different mechanisms (mitogen 
withdrawal, contact inhibition and loss of adhesion), showed that although there 
was a cohort of genes universally expressed in quiescent states, the expression of 
many other genes varied depending on the mechanism inducing quiescence. In 
addition, it is unclear which of these mechanisms are active in primary cells.
If differences in gene and protein expression between quiescent normal and 
cancer stem cells can be found, then it is possible that these differences could be 
exploited to develop cancer-specific therapies which avoid damage to normal
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tissues. Although BMS-214662 exhibits some toxicity to normal primitive
progenitor cells, it is far more toxic to leukaemia progenitor cells. Thus BMS-
214662 may prove to be such a cancer-specific therapy or perhaps a tool for
developing other approaches to targeting the cancer stem cell.
Recently, two different dynamic models of CML have been proposed (Michor et 
al., 2005; Roeder et al., 2006) which arrive at different conclusions. The first model 
suggests that although IM is a potent inhibitor of differentiated CML cells, it does 
not reduce the CML stem cell population (Michor et al., 2005). In CML, BCR-ABL 
transcripts exhibit a biphasic decline in patients responding to IM, but even after 
years of therapy, the majority of patients have persistent disease at the molecular 
level (Hughes et al., 2003; Branford et al., 2004). The biphasic decline in BCR- 
ABL transcripts consists of an initial rapid decline which represents the death of 
differentiated CML cells followed by a much slower decrease representing the 
death of more primitive CML progenitors in response to IM. In support of this first 
hypothesis, in a proportion of patients that discontinued IM after prolonged 
treatment and had achieved a CMoIR, the number of BCR-ABL transcripts rapidly 
increased over the following three months to at least pre-treatment levels (Cortes 
et al., 2004b; Mauro et al., 2004). This indicates that IM does not deplete the CML 
stem cell population which is driving the disease, and supports the hypothesis that 
CML stem cells are resistant to IM and other agents (Graham et al., 2002; Holtz et 
al., 2005; Jorgensen et al,, 2005a; Copland et al,, 2006). This model further 
proposes that, as CML progresses, the number of LSCs rises and the probability 
of a patient having a resistance mutation also increases as a result of this larger 
population of CML stem cells (Michor et al., 2005). In addition, it is suggested that 
the time to treatment failure as a result of acquired resistance is dependent on the 
growth rate of the CML stem cells. Therefore, based on the theories put forward in 
this study, IM is extremely unlikely to cure CML patients, and over time, the
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majority of patients will develop acquired resistance as the stem cell population
gradually expands. Thus, the development of strategies, such as BIVIS-214662, to
target the LSC population will be vital for the eventual eradication of CML.
The hypothesis proposed in the second study is rather more positive for CML 
patients (Roeder et al., 2006). It suggests that the clinically observed biphasic 
pattern of BCR-ABL transcript dynamics may be explained by a selective effect of 
IM on proliferating CML stem cells. This model makes two main assumptions. 
Firstly, it assumes that IM inhibits proliferative activity and induces death of 
proliferating CML stem cells and secondly, it assumes that there is a large 
population of quiescent CML stem cells which are resistant to IM due to their 
quiescent state as previously demonstrated (Graham et al., 2002). However, these 
quiescent CML stem cells retain the potential for proliferation and are responsible 
for the rapid relapses seen after stopping IM (Cortes et al., 2004b; Mauro et al.,
2004). This model predicts that, over time, as quiescent CML stem cells gradually 
enter the cell cycle, they will proliferate and become sensitive to IM. Therefore, 
levels of MRD will continue to fall over prolonged periods of IM treatment as 
suggested by clinical data (Branford et al., 2004), and complete disease 
eradication may be possible if patients do not develop resistance mutations. The 
model also proposes that promoting quiescent CML stem cells to enter the cell 
cycle by using additional agents in combination with IM may enhance the 
eradication of MRD in CML. This hypothesis was tested in Chapter 3 of this thesis 
which used priming with intermittent exposure to rHu-G-CSF in an attempt to force 
the quiescent CML stem cells to proliferate with promising results. As discussed, a 
clinical trial (GIMI trial) to test this potential therapeutic strategy in vivo is currently 
underway (Mitchell et al., 2006).
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Although these two different hypothetical models of CML dynamics arrive at
different conclusions, they both highlight the importance of developing drug
combination strategies with IM or the newer agents (dasatinib, nilotinib and others)
to eliminate the quiescent CML stem cell population.
Another hypothesis leading to much debate at present is the concept that CML 
stem cells may not be dependent on BCR-ABL; therefore BCR-ABL kinase 
inhibitors may not be appropriate therapy for CML stem cell eradication. There is 
evidence that CML is a stem cell disorder (Eaves et al., 1998). In addition, there is 
support for a normal HSC hierarchy in LSCs (Bonnet and Dick, 1997), suggesting 
that LSCs may retain many of the properties of HSCs. Furthermore, there is 
increasing evidence that BCR-ABL-targeted therapies such as IM, dasatinib or 
nilotinib fail to eradicate CML stem cells in vitro (Graham et al., 2002; Holtz et al., 
2005; Copland et al., 2006; Jorgensen et al., 2007).
Further support for this hypothesis comes from studies which have shown that 
transduction with either M0Z-TIF2 or MLL-ENL resulted in the development of the 
capacity for self-renewal in committed non self-renewing myeloid progenitors in 
vitro and rapid induction of leukaemia in murine transplantation models (Cozzio et 
al., 2003; Huntly et al., 2004), whereas transduction of these same non self- 
renewing myeloid progenitors by BCR-ABL did not (Huntly et al., 2004). The 
mechanisms underlying this difference in the ability of oncogenes to bestow self­
renewal properties on a leukaemia cell remain to be elucidated. Another recent 
study has shown that, despite inactivation of plOO®^ '^^^*" in a murine model of 
ALL, there was failure to rescue the malignant phenotype, implying that pi 90 '^^ '^ " 
is not required for disease maintenance in mice (Perez-Caro et al., 2006). It 
was further hypothesised that p i90^^" '^^^  ^ induced epigenetic changes or 
additional mutations, rendering the LSCs insensitive to inactivation of plOO®^ *^ "^ ®^ .
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However, this is controversial as a number of other studies have demonstrated the
necessity of BCR-ABL for disease maintenance (Szczylik et al., 1991; Skorski et
al., 1994; Zhao et al., 1997; Huettner et al., 2000). In addition, in this murine model
(Perez-Caro et al., 2006), the disease did not behave as an acute leukaemia as
survival was longer than other acute leukaemia models and also the mice were
unresponsive to IM which is not typical of BCR-ABL^ ALL, in which the majority of
patients do achieve a remission, albeit short-lived (Druker et al., 2001a).
Furthermore, another recent study demonstrated that dasatinib resulted in
complete remission of B-ALL with prolonged survival in a murine model (Hu et al.,
2006), providing additional evidence of dependence on BCR-ABL for disease
maintenance.
In some cells, the ability to self-renew may be due to the acquisition of secondary 
mutations in committed progenitor cells which allow these cells to take on the 
properties of a LSC. This has recently been demonstrated in BC CML by 
Jamieson et a! (Jamieson et al., 2004) who showed that there was an increased 
granulocyte-macrophage progenitor population in BC CML compared to earlier 
stages of disease, and this population had the ability to self-renew in vitro in 
association with activation of p-catenin, a protein of the WNT signalling pathway 
which is associated with cell differentiation, proliferation and death. Very 
interestingly, two inhibitors of the WNT signalling pathway have recently been 
described which show efficacy in myeloid leukaemias (Guzman et al., 2006; 
Kavalerchik et al., 2006). The first of these, MCC-001, a marine sponge-derived P- 
catenin antagonist was demonstrated to inhibit the re-plating capacity of CML stem 
cells, derived from patients with advanced phase CML, at doses which were non­
toxic to normal HSCs (Kavalerchik et al., 2006). The second compound, 4-benzyl, 
2-methyl 1,2,4-thiadiazolidine 3,5-dione (TDZD-8), a GSK-3p inhibitor, induced 
rapid cell death in both primary AML and BC CML cells (Guzman et al., 2006).
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Further studies in a NOD/SCID mouse xenotransplantation model showed a 93%
reduction in engraftment with TDZD-8 for AML samples compared with an 11%
reduction for normal cell engraftment. Further studies are currently underway to
fully elucidate the mechanisms of action of these two novel compounds and further
assess their effect on the LSC compartment.
It should also be considered that BCR-ABL may be an oncogenic mutation which 
is tolerated by HSCs because it has little or no effect on the stem cell in which it 
arises; rather its effects are expressed in the progeny of the mutated stem cell. It is 
possible that mutations which increase self-renewal or impair differentiation may 
be toxic to the HSC and/or trigger apoptotic pathways. BCR-ABL may not induce 
these changes in the stem cell and, therefore may be tolerated. However, there is 
evidence against this hypothesis from Huntly et al, who demonstrated that HSC 
transduction with M0Z-TIF2 resulted in a form of AML indistinguishable from other 
M0Z-TIF2 associated leukaemias (Huntly et al., 2004). Therefore, in HSCs, this 
oncogenic mutation was not only tolerated, but was capable of inducing leukaemia 
without HSC toxicity or apoptosis.
The models of CML disease response dynamics and the hypothesis that BCR-ABL 
may not be a target in CML stem cells highlight the importance of developing 
therapies which target the LSC specifically and identifying differences between 
normal HSCs and LSCs which can be targeted for therapy. A recent study has 
shown that dependence on the tumour suppressor gene PTEN separates HSCs 
from LSCs (Yilmaz et al., 2006). In an in vivo mouse model, conditional deletion of 
PTEN resulted in a myeloproliferative disorder which progressed to acute 
leukaemia over a number of weeks and also induced acute leukaemia in recipient 
mice in a mouse transplantation model. In addition, HSCs were not maintained in 
the absence of PTEN, as PTEN deletion increased HSC proliferation which
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resulted in HSC depletion and the cells were unable to reconstitute irradiated
mice, i.e. there was loss of self-renewal capacity. It is likely that these effects were
modulated by mTOR as rapamycin not only depleted LSCs but also restored
normal HSC function. Further studies in AML have demonstrated that proteasome
inhibitors induce apoptosis in AML stem cells in association with inhibition of NF-
kB and activation of p-53-related genes (Guzman et al., 2002). Furthermore, the
naturally-occurring small molecule inhibitor parthenolide also causes apoptosis in
LSC in AML and BC CML, again through inhibition of NF-kB and activation of p-53
and also increased production of ROS (Guzman et al., 2005).
The data presented in this thesis for BMS-214662 in CP CML represents an 
important step forward in targeting quiescent CML stem cells as this is the first 
study to demonstrate an agent which selectively kills quiescent CML stem cells, 
although the mode of action has yet to be elucidated. All these examples highlight 
the importance of finding agents which specifically target cancer stem cells. It is 
only by understanding the biology of cancer stem cells and developing novel stem 
cell-directed therapies that progress will be made in eradicating these diseases.
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Appendix 1
Patient characteristics for CML samples obtained
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UPN Sex
Disease
Stage
WCCat 
leucapheresis 
(x10®/ L)
Pre­
selection 
% CD34
Post 
selection 
% CD34
Type of 
CD34 
selection
%Ph  ^in CD34^ 
(D-FISH)
23 M CP 276 16.9 51.2 Stemsep 69.1
31 M CP 350 14.4 85.3 Isolex 100
81 F CP 157 17.6 89 Isolex 100
85 M CP N/A 42 N/A Unmanip 88
101 F CP 67 4.4 49.2 Stemsep 90.9
144 F CP 234 33.6 98 Isolex 99.7
151 F CP 270 13.2 98.3 CilnlMACS 100
155 F CP 78 3.6 98.3 CilnlMACS 99
160 M CP 300 1.6 97 CilnlMACS 87.4
162 M CP 173 1.7 98 CilnlMACS 97
164 F CP 147 5.8 99 CilnlMACS 100
166 M CP 206 6.0 99 CilnlMACS 94.8
170 M CP N/A N/A 97 CilnlMACS 96.8
174 F CP 221 5.0 98 CilnlMACS 99.6
189 F CP 133 6.0 97 CilnlMACS 92.9
198 M CP 240 4.2 87.3 CilnlMACS 98.5
215 M CP 165 7.7 96 CilnlMACS 95.4
217 F CP 106 0.6 91.1 CilnlMACS 92
218 M CP 68 6.5 97.8 CilnlMACS 98.7
219 M CP 307 4.2 98.7 CilnlMACS 98.2
222 M CP 124 12.7 99.2 CilnlMACS 85.8
168 M AP 330 11.5 98 CilnlMACS 100
185 M AP 139 12.0 95 CilnlMACS 100
001 F LBC N/A 17.2 N/A Unmanip N/A
002 F MBC 19.1 48.2 N/A RBC Lysis N/A
003 F MBC N/A 4.1 N/A RBC Lysis N/A
004 M MBC 12.5 3 N/A Unmanip N/A
005 M LBC N/A 16.8 N/A RBC Lysis N/A
URN, unique patient number; LBC, lymphoid blast crisis; MBC, myeloid blast 
crisis; Unmanip, unmanipulated sample; RBC Lysis, red blood cell lysis; N/A, not 
applicable or not available.
n
